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Abstract
Image Guided Intensity Modulated Radiotherapy (IG-IMRT) has the potential to 
improve accuracy of treatment delivery, which in turn may improve the therapeutic 
ratio. This is particularly relevant for prostate cancer because the prostate moves 
independently to pelvic bony anatomy due to variations in rectal and bladder filling. 
Radiotherapy is associated with a rare risk of late second malignancy and 
biological and physical parameters can be measured to estimate this risk.
The purpose of this thesis was to evaluate the dosimetric and radiobiological 
effects of IG-IMRT for patients receiving radiotherapy to prostate +/- nodes, and to 
evaluate second cancer risk in this group using a biological marker of DMA 
damage, gammaH2AX (yH2AX), in addition to physical measurements.
A clinical study compared IG RT with online and offline matching with 2-dimensional 
(2D) kilovoltage (kV) matching to fiducial markers and 3-dimensional (3D) cone 
beam computed tomography (CBCT) matching to bone.
There was variation in bladder and rectal volumes between planning CT and 
treatment which resulted in higher doses calculated on CBCT compared to plan 
and this also impacted on rectal normal tissue complication probability (NTCP). 
There was a significantly lower prostate tumour control probability (TCP) calculated 
from CBCT in patients with a larger initial rectal volume. There was satisfactory 
planning target volume (PTV) coverage and TCP for prostate and nodes when 
matching to bone and markers.
There was no evidence of increased gammaH2AX levels with higher photon energy 
or larger treatment volume. There was a higher effective dose with prostate and 
node treatment compared to prostate only treatment, but this did not translate into a 
higher age specific risk of second cancer.
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Section 1: Image Guided Intensity Modulated Radiotherapy In prostate cancer
Chapter 1 Introduction
1.1 General aspects
Radiotherapy (RT) is a curative modality of treatment in patients with localised 
prostate cancer. Recent advances in RT delivery, from 3 Dimensional 
Conformai Radiotherapy (3D-CRT) to Intensity Modulated Radiotherapy (IMRT), 
have focused on increasing the conformality of the delivered dose distributions 
in order to improve target coverage and reduce normal tissue complications. 
IMRT achieves complex dose distributions and allows different dose levels to be 
delivered to different target volumes, often with steep dose gradients close to 
organs at risk (OARs), such as the rectum in the case of patients having 
radiotherapy to the prostate. Ensuring the accurate delivery of such complex 
dose distributions is the next challenge in RT delivery.
Geometric treatment verification is an important (and mandatory) component of 
RT (RCR 2008). This is a process that allows us to ensure that the geometric 
accuracy of the RT delivered is within the limits set in the treatment plan. A 
recent document from the Royal College of Radiologists jointly with the Institute 
of Physics and Engineering in Medicine and the Society and College of 
Radiographers states that “each department should determine the verification 
protocols and planning margins required for their own practice" and that 
“additional exposures must be justified within the Ionising Radiation (Medical 
Exposure) Regulations (IR(ME)R)”(RCR 2008). During a course of treatment, 
errors may arise from equipment misalignment, set-up inaccuracies, and patient 
and organ movement. Rigorous programs of equipment quality control are in
19
place to minimise potential problems. As part of the planning process, and in 
order to account for set-up inaccuracies, and patient and target movement, a 
margin is added to the clinical target volume (CTV) to obtain a planning target 
volume (PTV)(ICRU 1993; ICRU 1999). During treatment, patient position is 
checked with regular images taken with megavoltage (MV) X-Rays using bony 
anatomy as reference. These methods are currently used as standard at St 
Luke’s Cancer Centre (SLCC) at the Royal Surrey County Hospital (RSCH). 
The prostate, however, moves in relation to variations in rectal and bladder 
filling, and this is not detectable with our current verification techniques.
Recently, fiducial markers that can be inserted into the prostate and visualised 
using MV images have been developed. Such markers can be used as a 
surrogate for the position of the prostate. In addition, technology has become 
available in the form of kV X-ray tubes mounted on linear accelerators (Linacs). 
These produce diagnostic quality X-Rays that can be used to more easily 
identify both fiducial markers and bony anatomy. In addition, these kV X-Ray 
tubes can be used to acquire 3D CBCT which give soft tissue anatomy in 
addition to bony anatomy. The use of these technologies is referred to as Image 
Guided Radiotherapy (IGRT). IGRT, by virtue of its ability to increase the 
accuracy of RT delivery, has the potential to improve treatment outcomes in 
terms of reduced toxicity and better local tumour control.
However, whilst the availability of this technology is becoming more 
generalised, its benefits have not been fully quantified, in addition, it is yet to be 
determined which verification protocol gives the best improvement in the 
therapeutic ratio with the available resources and therefore it does not yet form 
part of the standard RT treatment in prostate cancer patients. A linear
20
accelerator with such technology entered clinical use in autumn 2008 at SLCC. 
This study aims to determine the best way to use this technology in order to 
improve the therapeutic ratio and patient’s quality of life, as well as identify the 
most appropriate use of resources.
1.2 Geometric uncertainties
There are several sources of error during the radiotherapy process; some arise 
during the preparation and some during the execution part of the process. The 
main sources of geometric uncertainty in the RT process are target volume 
delineation, microscopic tumour extent, setup variations and organ positional 
variations within the patient(van Herk 2004).
Following ICRU 50 and 62 guidelines(ICRU 1993; ICRU 1999), the target 
volumes delineated should be:
• GTV (gross tumour volume): Defined as the gross palpable or 
visible/demonstrable extent and location of the tumour.
• CTV (clinical target volume): Defined as a volume that contains the GTV 
and any sub-clinical microscopic malignant disease that has to be 
eliminated to achieve the aim of therapy.
• PTV (planning target volume): This is a geometrical concept defined to 
take into consideration the net effect of all possible geometrical variations 
and inaccuracies (patient movement, organ movement and set up 
errors). This is to ensure that the prescribed dose is actually absorbed in 
the CTV.
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1.2.1 Set up errors
For each individual patient, the displacement between the reference image 
(expected position) and one single image acquired during treatment (actual 
position) is considered to represent the variation in patient positioning for that 
single treatment session. This displacement is a combination of both the 
random and systematic error (van Herk, Remeijer et al. 2000; RCR 2008). 
Displacements from multiple images will therefore represent both random and 
systematic errors:
1.2.1.1 Gross errors
These are unacceptably large set-up errors not accounted for in the CTV to 
PTV margins. These errors must be corrected prior to commencement of 
treatment(RCR 2008).
1.2.1.2 Systematic and random errors
Set up uncertainties or errors can be divided into systematic (constant during 
the whole treatment course) and random (represent day-to-day variations) 
errors(van Herk, Remeijer et al. 2000).
The systematic component of the displacement (also called preparation error) 
indicates the magnitude of the error that can exist during the whole treatment 
course. It arises from the translation of set-up information between CT, 
simulator and treatment couch during the treatment preparation process and 
leads to a displacement of the dose distribution with respect to the CTV(van 
Herk, Remeijer et al. 2000). There are several components to the systematic 
error: target delineation error, changes in target position and shape between 
delineation and treatment, phantom transfer error (subject to routine checks as 
part of a machine quality control program) and patient set-up error.
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Mathematically, for each individual patient, the systematic set-up error (SSE) is 
the mean (average) error over a course of treatment.
For a patient population, the systematic set-up error ( I s e t - u p )  is given by the 
spread of the individual means and calculated as the standard deviation (SD) of 
the distribution of the individual SSEs.
The random error (or execution error) represents day-to-day variations during 
the treatment course and consists of set up inaccuracies such as those due to 
the incorrect positioning of the patient in the immobilisation device and patient 
and/or organ motion in between fractions. These occur in the period between 
patient positioning and beam-on or during a treatment fraction and lead to a 
blurring of the dose distribution(van Herk, Remeijer et al. 2000). Mathematically, 
the individual random setup error (RSE) is given by the SD of the measured 
errors over a course of treatment and quantifies the spread of the individual 
errors. For a population of patients, the random error (Oset-up) is calculated as 
the mean of the individual random errors.
1.2.2 Margin determination
Van Herk et al(van Herk, Remeijer et al. 2000) evaluated the influence of both 
systematic and random errors on the RT dose delivered and, based on dose 
population histograms (probability distributions of the cumulative dose over a 
population of patients), proposed a simplified recipe for the determination of 
CTV to PTV margins;
PTV margin= (2.5*SD of the group systematic error) + (0.7*SD of the random 
error), where SD is the standard deviation, and which can be used to ensure a 
minimum dose to the CTV of 95% for 90% of the patients. This formula, 
however, does not take into account organ movement.
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1.2.3 Verification strategies
There are several issues that need to be considered with regards to verification 
strategies. These include offline versus online protocols, bony versus soft tissue 
anatomy, fiducial markers versus CBCT and frequency of images.
Verification protocols can be defined as online or offline(RCR 2008):
• In offline verification protocols, the images are acquired and visually 
checked for gross errors but no other immediate intervention is carried 
out. After a certain number of fractions, the information can be used to 
calculate the systematic and random components of the setup error and 
corrections can be made for the systematic component of the error.
• Within online verification protocols, the images are acquired before each 
fraction and corrections made according to specified protocols prior to 
RT delivery. After a certain number of fractions, the information can be 
used to calculate and correct for both the systematic and random 
components of the setup error.
Protocols that use bony anatomy measure only the patient set-up and phantom 
transfer error components of the systematic error. This applies for both offline 
and online correction protocols. Methods that use fiducial markers measure, in 
addition, changes in target position. This is assuming there are no changes in 
prostate shape during a course of RT, which can be checked using CBCT.
Whilst it is relatively straightforward to correct for movements in the 3 
translational directions, rotational movements remain a challenge. Some groups 
have reported attempts at correction strategies using gantry and collimator 
angle adjustments without rotating the table(Rijkhorst, van Herk et al. 2007).: 
They estimated that the CTV to PTV margin could be reduced from 6mm to
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4mm with the rotational correction. Other groups have reported the use of 
equipment that allows the couch to move to correct for rotation(Alonso- 
Arrizabalaga, Brualla Gonzalez et al. 2007). A more complex way to incorporate 
systematic and random errors was described by Witte et al (Witte, van der Geer 
et al. 2007) who incorporated them in TCP and NTCP objective functions for 
inverse planning. Using TCP and equivalent uniform dose (EUD) to evaluate 
plans accounting for geometric errors, van Herk et al(van Herk, Remeijer et al. 
2002) found a 10mm margin adequate for three-field prostate treatments given 
the accuracy level in their department and that too small margins can lead to a 
significant loss of TCP that is difficult to compensate for by dose escalation. 
Accuracy increases with the number of images obtained but image acquisition 
over the entire treatment course is resource-intense and will increase 
concomitant radiation exposure. On the other hand, increased imaging will 
permit accurate geometric verification of the irradiated volume which can then 
permit reduction of treatment margins and reduced normal tissue exposure 
which would lead to increased compliance with IR(ME)R requirements(RCR 
2008).
Overall, online correction protocols that use CBCT will enable correction for 
phantom transfer, systematic and random set-up error and both systematic and 
random errors associated with target position and shape and can be used to 
reduce the random and systematic components of the CTV to PTV margin. This 
reduction in margin would be larger than that achieved with off-line correction 
protocols that use bony anatomy and can only justify a reduction in the 
systematic set-up component of the margin.
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1.2.4 Image Guided Radiotherapy (IGRT) in prostate RT
IGRT often refers to the use of an in-room imaging device to obtain a 2D kV or 
3D cone beam CT image just before or during treatment to guide treatment 
position in an attempt to overcome geometric uncertainties. The series of IGRT 
images registered against the reference image can be used to collate the shifts 
required throughout treatment. These can be analyzed to support existing 
margin protocols or calculate new ones, as well as calculating the overall mean 
set up error, a strong indicator of unwanted systematic error.
At SLCC patients are positioned for radiotherapy according to skin tattoos. The 
accuracy of set up is determined by carrying out Electronic Portal Imaging (EPI) 
at the time of RT in the form of MV Xrays. These images are compared to digital 
reconstructed radiographs (DRRs) generated from the planning CT scan using 
bony anatomy as a surrogate for the position of the prostate. Within the current 
offline protocol, images are taken daily for the first 3 treatments and, if set up is 
within certain pre-established limits (tolerance), images are then taken on a 
weekly basis.
However, the use of bone as a surrogate for the position of a soft tissue 
structure such as the prostate is imprecise and can result in underdosing of the 
target or overdosing of the OARs and this is particularly relevant for IMRT 
treatments due to higher conformity of dose distributions and sharp dose 
gradients.
Several studies have shown that the prostate is mobile within the pelvis, with 
mismatches closely related to rectal size and shape(Roeske, Forman et al. 
1995; Beard, Kijewski et al. 1996; Antolak, Rosen et al. 1998; Dawson, Mah et 
al. 1998; Padhani, Khoo et al. 1999; Zelefsky, Crean et al. 1999). Prostate
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motion has been reported to be up to ±10-11 mm in the antero-posterior (AP) 
direction and ±0.8-13mm in the supero-inferior (SI) direction with less than 1mm 
movement in the right-left (RL) direction(Roeske, Forman et al. 1995; Beard, 
Kijewski et al. 1996; Antolak, Rosen et al. 1998; Padhani, Khoo et al. 1999; 
Cheung, Sixel et al. 2005). Roeske et al(Roeske, Forman et al. 1995) found 
variations of ±30% in bladder and rectal volumes, ±10% in prostate and as 
much as 100% in seminal vesicle volumes. These variations in volume and 
position can lead to changes in the dosimetry of the actual delivered plan. 
Melian et al estimated PTV undercoverage to be 6%(Melian, Mageras et al. 
1997) and margins of at least 10mm around the prostate and 15mm around the 
seminal vesicles are reportedly required to ensure adequate target 
coverage(Miralbell, Ozsoy et al. 2003). In addition, changes in rectal volume 
have been reported to correlate with toxicity(Miralbell, Taussky et al. 2003; de 
Crevoisier, Tucker et al; 2005) and even biochemical failure(de Crevoisier, 
Tucker et al. 2005; Engels, Soete et al. 2009).
Bladder filling was initially reported not to have as much effect on prostate 
movement although it will affect the dose volume histograms (DVHs)(Roeske, 
Forman et al. 1995; Dawson, Mah et al. 1998). Zellars et al(Zellars, Roberson et 
al. 2000), however, reported that variations in bladder movement and volume as 
well as upper rectum movement were independently associated with prostate 
motion (p = 0 016, p = 0.003, and p = 0.052 respectively). In addition, the 
prostate was observed to shift along a diagonal axis extending from an anterior- 
superior position at the start of a course of radiation to a posterior-inferior 
position towards the end with an average reduction in bladder and rectal
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volumes of 51% (±29%) and 82% (±45%) of their pre-treatment values, 
respectively.
1.2.4.1 Intrafraction motion
There is uncertainty in prostate position during and between fractions 
(intrafraction and interfraction motion) due to physiological variation in bladder 
and rectal filling. Increasing conformality of radiation doses and dose escalation 
mean that accurate patient positioning is increasingly important. Several studies 
have shown that the predominant directions for intrafraction motion are anterior- 
posterior (AP), with median AP displacement of 4 2mm(Padhani, Khoo et al. 
1999), maximal shifts from 6.8-14.0mm(Padhani, Khoo et al. 1999; Huang, 
Dong et al. 2002; Nederveen, van der Heide et al. 2002; Chung, Haycocks et al. 
2004),
Intrafraction motion is generally found to be smaller than interfraction 
motion(Huang, Dong et al. 2002; Aubry, Beaulieu et al. 2004).
1.2.4.2 Prostate and pelvic node radiotherapy
Patients with high risk disease are sometimes offered prophylactic irradiation to 
the pelvic nodes in order to improve PSA control, and potentially progression 
free survival and overall survival (Lawton, DeSilvio et al. 2007; Warde, Mason et 
al. 2011).
The prostate and pelvic bony anatomy move independently and it has been 
suggested that pelvic bony anatomy should not be used as a surrogate for 
prostate motion(Schallenkamp, Herman et al. 2005). Therefore, radiotherapy to 
prostate and nodes can be more challenging when attempting to accurately 
treat both targets whilst avoiding organs at risk.
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1.2.4.3 Fiducial markers 
Several approaches have been evaluated to try and minimise these variations. 
Rectal enemas and changes in diet have been evaluated but there is as yet no 
evidence of their efficacy(Fiorino, Di Muzio et al. 2008; Nijkamp 2008), although 
Smitmans et al(Smitsmans, Pos et al. 2008) showed that a dietary protocol lead 
to an improvement in the CBCT image quality and an increase in the success of 
3D registration due to a significant reduction in the incidence of faeces and 
(moving) gas. Endorectal balloons, which have the additional advantage of 
reducing the dose to the rectal wall by distending the rectum, have also been 
evaluated(Ciernik, Baumert et al. 2002; Wachter, Gerstner et al. 2002; Patel, 
Orton et al. 2003).
A number of studies have examined the use of fiducial markers implanted in the 
prostate, such as gold seeds or highly winding coils (Visicoils®). These showed 
that the greatest shifts required were in the AP and SI directions(Vigneault, 
Pouliot et al. 1997; van der Heide, Kotte et al. 2007), although in morbidly 
obese patients the largest prostate shift was in the left-right direction (median 
8mm, range 0-42mm) with set-up error rather than organ motion being the 
dominant aspect of the overall positional error(Millender, Aubin et al. 2004). 
Statistically significant reductions in systematic and random errors have been 
found with daily online correction protocols using fiducial markers(Van den 
Heuvel, Fugazzi et al. 2006). Soete et al(Soete, De Cock et al. 2007) reported a 
reduction in both random and systematic errors in all directions using fiducial 
markers compared to a control group where bone fusion was used, with 
displacements with regard to the bony pelvis that could have been avoided by 
fiducial marker positioning of 1.6-2.8 mm for random and 1.3-4.3 mm for
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systematic errors. These reductions in error can be translated into smaller PTV 
margins needed to cover 95% of the CTV(Schallenkamp, Herman et al. 2005). 
Time trends over a course of treatment in prostate position using fiducial 
markers, mostly in the vertical and longitudinal directions and with up to one 
third >3mm, were described by van der Heide et al(van der Heide, Kotte et al. 
2007). The authors suggested that offline correction protocols that estimate a 
deviation only in the first fractions of the treatment, such as shrinking action 
level (SAL) and no action level (NAL) protocols, are not effective in following 
these trends and proposed a daily off-line position correction using an adapted 
SAL protocol.
Visibility of implanted markers on MV images has been reported to be 
good(Vigneault, Pouliot et al. 1997) but seed migration has been identified as a 
potential problem with large (>1cm) seed migration noted by several 
authors(Litzenberg, Dawson et al. 2002; Van den Heuvel, Fugazzi et al. 2006). 
Newer fiducial markers include coils that have the advantage of potentially 
lower migration rates.
1.2.4.4 Cone Beam CT 
The cone beam kV imager is a diagnostic X-ray tube and associated imaging 
panel which can be attached orthogonally to the linear accelerator gantry arm 
and electronic portal imaging device (EPID). This allows a full-volume cone 
beam CT scan to be acquired in one single rotation of the Linac with the patient 
in the treatment position. Phantom studies showed good spatial resolution in all 
3 dimensions(Jaffray, Siewerdsen et al. 2002) and Sykes et al(Sykes, Amer et 
al. 2005) demonstrated full automatic 3D registration of high speed (one minute 
or less), ultra low dose scans with the planning scan to 0.1mm and 0.1 degrees
30
accuracy with Elekta Synergy. Static diagnostic images can also be obtained, 
as well as dynamic fluoroscopic images, with the advantage that 2D kV images 
have improved bony resolution compared to MV images. Several key 
practicalities have been described when trying to implement kV CBCT, in 
particular the regular characterization of mechanical flex during gantry rotation, 
the mapping of defects in flat panel image transducers and their response to X- 
ray exposure and the number of X-ray projections and the doses required for 
clinically useful cone beam reconstruction at different therapy sites(Moore, 
Amer et al. 2006).
The main roles for CBCT are 3D monitoring of patient set-up during a course of 
treatment and adaptive treatment planning. Of these, the former is far more 
advanced in its incorporation into clinical practice, whereas the latter is still only 
evaluated as part of research protocols. Sripadam et al(Sripadam, Stratford et 
al. 2008) used daily CBCT to study the effect of rectal motion on CTV coverage. 
This study used rectal wall motion as a surrogate for prostate displacement and 
found that rectal volume decreased over a course of RT in 13 out of 15 patients, 
with regions corresponding to the prostate base displaying the greatest motion 
and larger displacements observed in patients with larger rectal volumes on the 
planning scans. This led to inadequate coverage in some patients and for 
patients with small rectums up to 25% more volume than predicted was 
included in the high dose region.
Concerns have been raised regarding the additional radiation dose with CBCT. 
Oldham et al(Oldham, Létourneau et al. 2005) described an isocentric dose of 
approximately 1.5cGy and a skin dose of 2.4cGy for a prostate imaging 
protocol, although higher isocentric doses of 3-4cGy have also been
31
described(Smitsmans, Debois et al. 2005). Van Herk(van Herk 2007) used 
integral doses to demonstrate that increases in radiation dose with more 
intensive CBCT regimes are offset by gains due to reduction in margins. He 
estimated that a typical integral dose for prostate IMRT to 78 Gy is 150J and, if 
12 CBCT scans with a scan length of 12cm were carried out, there would be an 
additional integral dose of 3J (2% increase). However, the margins could be 
reduced from 10 to 7 mm, sparing 10J (as the field size of all the beams is 
reduced). The net result would be reduction in integral dose by 4% to the whole 
body as well as lowering of rectal dose.
1.2.6 TCP and NTCP
TCP and NTCP are radiobiological models which have also been used to 
compare plans using dose-volume histogram data (DVHs).
A model developed by Webb et al(Webb and Nahum 1993) can be used to 
estimate TCP and incorporates clonogen density and a/p ratio.
The Lyman-Kutcher model(Burman, Kutcher et al. 1991) can be used to 
calculate NTCP(Christodoulou, Bayman et al. 2014), for example, where there 
is dose escalation based on an accepted complication rate.
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Chapter 2 Methods Overview for Prostate IGRT
This chapter will outline the overall objective and provide an overview of the 
methods for Chapters 3-6.
2.1 Overall objective
To test the hypothesis that prostate IG-IMRT can improve target coverage and 
TCP, and minimise organ at risk doses and NTCP.
2.2 Methods
2.2.1 Ethics and Research and Development Approval
A protocol was written for a study entitled ‘Evaluation of image guided 
radiotherapy (IGRT) in patients with prostate cancer’. This was submitted 
electronically to the Integrated Research Application System (IRAS). This was 
presented to and subsequently approved by the Ethics Committee of the 
Brompton, Harefield and NHL! Research Ethics Committee in March 2009. The 
protocol was also submitted and presented to the Royal Surrey County Hospital 
Research and Development Department, with approval in April 2009. Patients 
were enrolled between May 2009 and June 2010.
2.2.2 Study design
This study included patients receiving radiotherapy to prostate, as well as 
prostate and nodes, and were treated as follows:
1. Prostate only patients underwent daily kV online matching to markers 
with zero tolerance and also underwent weekly CBCT. The aim was to 
recruit 20 patients to this group. This is discussed in more detail in 
Chapter 3.
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2. A subset of the prostate only patients had weekly pre- and post-RT 
CBCT to assess intrafraction motion. The aim was to recruit 10 patients 
to this group. This is discussed in more detail in Chapter 4.
3. Prostate and node IMRT patients underwent daily CBCT online matching 
to bone, plus a weekly kV pair (prior to taking CBCT). The aim was to 
recruit 8 patients to this group. This is discussed in more detail in 
Chapter 5.
2.2.3 Patient population
All patients included in this study had histologically confirmed prostate cancer. 
All prostate only or prostate and node IMRT patients were eligible, apart from 
ones with hip prosthesis or contraindications to marker insertion.
2.2.4 Pathway
The sequence of implementation of the study is outlined below, including pre 
and post IGRT analysis, with more detail in subsequent chapters.
2.2.4.1 Preclinical study with phantom for fiducial marker selection 
Two types of fiducial marker (cylindrical metal seed and Visicoil) were placed within 
an Alderson Radiation Therapy (‘Rando’) human phantom to assess ease of 
visualisation and matching on 2D imaging, and also to familiarise local staff with 
new equipment and allow online matching to be carried out without time pressures.
2 2.4 2 Radiotherapy technique 
They were treated according to institutional protocol.
2.2.4 3 Patient verification 
The verification technique differed according to the treatment target.
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Fiducial marker daily online matching with 2D kV pair was chosen as the target 
for prostate only IGRT (Chapters 3 and 4), as the aim was to eventually 
implement this as standard clinical practice in the department. Here, weekly 
additional CBCTs were carried out to allow further dose volume analysis.
3D CBCT daily online matching to bone was chosen as the target for prostate 
and node patients (Chapter 5). This was felt to be at least equivalent to 
standard 2D bone matching, but would also offer additional anatomical 
information. Fiducial markers were inserted into these patients. Weekly 
additional kV pairs were also carried out to allow offline matching to bone and 
markers. Dose volume analysis of various targets were compared to try and 
determine the ideal matching protocol, given that the 2 targets can move 
independently of each other,
2.2.4.4 Post treatment analysis
The CBCT analysis protocol is summarised in Table 2.1 below.
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Table 2.1 CBCT analysis for all study patients.
CBCT obtained
\ /
Prostate, P+SV, Bladder, Rectum 
(+small bowel and nodes) contoured
Volumes recorded
CBCT moved to post-online shift position 
Original plans recalculated on CBCT 
(+PostRT CBCT calculation for intrafraction 
+Alternative offline CBCT shifts and calculation 
for prostate and nodes)
\/
DVHs obtained
Constraints analysis TCP/NTCP analysis
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Prostate and organs at risk were contoured on CBCTs and the volumes were 
compared to those on the planning CTs. Offline review was carried out to match 
to alternative targets. The CBCTs were shifted into online and offline matched 
positions, then the original plans were calculated on CBCT and DVHs were 
generated. Plan comparisons were made for various matching scenarios and 
were also made between groups, for example, number of niarkers.
2.2.4.5 TCP and NTCP calculation 
TCP was estimated for prostate and seminal vesicles, and the Lyman-Kutcher- 
Burman model was used to estimate NTCP for bladder and rectum. In addition, 
pelvic nodes TCP and bowel NTCP were estimated for prostate and node 
patients. Radiobiological parameters were obtained from a literature search 
including updated QUANTEC papers(Marks, Ten Haken et al. 2010).
The published clonogen densities for prostate cancer range from 10®- 
10^/cm®(Nahum, Movsas et al. 2003); (Wang and Li 2005); (De Meerleer, 
Vakaet et al. 2000).
There is little published data on the clonogen density of pelvic nodes. In this 
study, it was assumed to be no greater than the clonogen density of prostate 
itself, for which the upper limit estimated in literature is usually 10^/cm®(De 
Meerleer, Vakaet et a I 2000). Nutting et al(Nutting, Corbishley et al. 2002) 
studied tumour nodules within the prostate and made the assumption that the 
ratio of clonogens in the tumour nodule compared to the rest of prostate was 
90/10. Therefore, a further assumption was used in this analysis that the 
clonogen density of nodes could be one tenth of that in prostate itself. 
Therefore, a pragmatic decision was made to assess node TCP with both
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clonogen densities of 10®/cm® and 10 /^cm®, even though the higher clonogen 
density will likely give an underestimate of TCP.
The a/p ratio of bowel was assumed to be similar to that of rectum. ‘Intestinal’ 
a/p ratio was felt to be 4.3 by Dische et al(Dische, Saunders et al. 1999), when 
studying cervical cancer irradiation.
A radiobiological software package, Biosuite(Uzan and Nahum 2012), was 
used. TCP was estimated using the differential DVHs of the original plan and 
CBCTs, clonogen density and the a/p ratio. NTCP also used the differential 
DVHs, the steepness of the dose-response curve (m), the volume parameter (n) 
and the TD50 and are shown in Table 2.2 below.
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Table 2.2 Parameters used to estimate TCP and bladder, rectal and bowel 
NTCP.
m value n value
TD50
(Gy)
a/p
(Gy)
TCP
Prostate + SV(Webb 
and Nahum 1993) n/a
Clonogen density = 10^/cm^
n/a n/a 1.5
Pelvic nodesA(Wang 
and Li 2005) n/a n/a n/a 1.5
Pelvic nodesB(Webb 
and Nahum 1993)
Clonogen density = 10®/cm  ^
n/a
Clonogen density = 10^/cm^
n/a n/a 1.5
NTCP
Bladder
stricture(Burman, 
Kutcher et al. 1991) 0.110 0.500 80.0 3.0
Rectal stricture- 
bleeding(Burman, 
Kutcher et al. 1991) 0.150 0.120 80.0 3.0
Rectal gr>2 
RTOG(Tucker, Dong et 
al. 2010) 0.140 0.080 78.0 3.0
Rectal gr>2 
bleeding(Rancati, 
Fiorino et al. 2004) 0.190 0.230 81.9 3.0
Rectal gr>2 ; CTCAE 
v3.0(Sohn, Van et al. 
2007) 0.108 0.080 78.4 3.0
Combined gr>2 rectal 
toxicity from QUANTEC 
update(Michalski, Gay 
et al. 2010) 0.130 0.090 76.9 3 0
Small bowel(Burman, 
Kutcher et al. 1991; 
Luxton, Keall et al. 
2008) 0.160 : 0.150 55.0 . . 3.0
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2.2.4.6 Statistical analysis
Descriptive statistics were used to analyse the data. Paired t test was used to 
compare differences between various matching scenarios. T test was used to 
compare between groups.
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Chapter 3 Image Guided Intensity Modulated Radiotherapy In patients 
receiving treatment to prostate only
3.1 Introduction
Prostate, IGRT uses an in-room imaging device to obtain a 2D kV or 3D CBCT 
image which can be used to guide treatment position in an attempt to overcome 
. geometric uncertainties Historically, bone was used as a surrogate for the 
position of a soft tissue structure such as the prostate. However, the prostate is 
mobile within the pelvis which can result in underdosing of the target or overdosing 
of the OARs: IMRT treatments are associated with high conformity of dose 
distributions and sharp dose gradients, therefore accurate positioning is crucial. 
Fiducial rnarkers are a more recent method to act as a surrogate for prostate 
position. CBCT can provide additional anatomical information, both to aid 
positioning, as well as allowing post treatment dose volume analysis, for example, 
to calculate TCP and NTCP.
3.2 Objectives
To identify a suitable type and number of fiducial markers for prostate IGRT 
To compare volumes of prostate, bladder and rectum at planning and during 
treatment, and to assess trends throughout treatment.
To carry out dosimetric analysis on prostate, bladder and rectum at planning 
and during treatment.
To carry out TCP/NTCP calculations on prostate, bladder and rectum at 
planning and during treatment.
To compare the above for patients with small and large bladder and rectal 
volumes.
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To familiarise the department with prostate IGRT and daily online kV marker 
matching with a view to implement as standard treatment.
3.3 Methods
3.3.1 Fiducial marker selection process
A preclinical study was carried out in order to identify suitable fiducial markers 
that were visible with On-board Imaging (OBI), a newly installed portal imaging 
system on the Varian linear accelerator. In particular, it was essential for the 
markers to be visible on MV imaging since the centre only had one Linac with 
kV capability, and markers would have to be visible on all machines in case of 
machine breakdown or service. Another aim was to familiarise local staff with 
new equipment and allow online matching to be carried out without time 
pressures.
It was intended to compare 2 types of fiducial markers; cylindrical markers and 
Visicoils. Prior to the start of the research period, the department already had a 
supply of cylindrical gold markers or seeds measuring 8mm in length, 1mm in 
diameter. The department also had samples of Visicoils, gold coils available at 
1, 2, 3, 4 and 5cm lengths and 0.35, 0.75 and 1.1mm diameters Examples of 
fiducial markers are shown in Figure 3.1 below.
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Figure 3.1 Two fiducial markers, with 1cm length, 1.1mm diameter Visicoil 
(left) and cylindrical seed (right).
■ I l l
3.3.2 Phantom work for marker selection
An Alderson Radiation Therapy (‘Rando’) human phantom was used. This has 
tissue density components resembling the human body. It is made up of a 
number of 2.5cm slices from which small cylindrical plugs of 6mm diameter can 
be removed in order to insert thermoluminescent dosimeters (TLDs) or other 
items.
Fiducial markers of varying lengths and widths were taped with Transpore tape 
into the plug cavities in the pelvic region of the phantom. This was to ensure 
that the markers did not migrate when the marker matching for the phantom 
was carried out.
Several layers of bolus were taped to the anterior and lateral parts of the
phantom. This was to replicate an obese patient and potentially simulate a
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difficult marker matching scenario. A photograph of the pelvic portion of the 
Rando phantom is shown in Figure 3.2 below.
Figure 3.2 Pelvic portion of Rando phantom covered in bolus on the linac 
treatment couch.
* • V a &
3.3.3 Phantom work for practice marker matching
Another phantom study was carried out to allow ‘dummy runs' at the linac to
familiarise staff with online matching before treating a live patient as this was a
new technology at SLCC. The Rando phantom was prepared as above, but only
containing 2 Visicoils. A planning CT was performed on the phantom and an
existing plan was applied to this, with the PTV placed in an anatomically
appropriate location. Digitally reconstructed radiographs (DRRs) and marker
reference images were generated, with settings adjusted for optimal marker and
bony visibility. The phantom was set up and imaged as per a live patient. MV,
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kV and CBCT automatic and manual matching was attempted. The image 
settings were optimised to ensure that the markers could be seen in AP and 
lateral orthogonal images.
3.3.4 Fiducial marker insertion
This was carried out transrectally in all patients with transrectal ultrasound 
guidance under local anaesthetic by trained medical staff. This was performed 
at least one week before planning CT to allow for any swelling or haemorrhage 
to settle. Antibiotic cover was given. Either 2 or 3 markers were inserted, with 
equal numbers of patients in each group, and attempts were made to position in 
different planes.
3.3.5 Radiotherapy technique
Patients were treated according to institutional protocol. This included those 
entered into the Conventional or Hypofractionated High Dose Intensity 
Modulated Radiotherapy for Prostate Cancer (CHHiP) study(Khoo and 
Dearnaley 2008), a national study open at SLCC. This tests the hypothesis that 
patients may benefit from hypofractionated regimens rather than the standard 
74Gy in 37 fractions, which is a well established fractionation (Dearnaley, Sydes 
et al. 2007) because it has been suggested that prostate cancer has a low a/p 
ratio. Doses and treatment techniques are displayed in Table 3.1 below.
It was intended to recruit 20 patients for the prostate group, of whom 10 were 
part of the intrafraction movement substudy.
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Table 3.1 Radiotherapy doses and technique received by study patients.
Dose
(Gy)
No. of 
fractions
Course
length
Radiotherapy
technique Target
74 37 LC IMRT Prostate*
57-60 19-20 SC IMRT Prostate*
LC=long course, SC=short course.
"Subgroup of prostate patients also included in intrafraction group.
The decisions on indications for radiotherapy were made clinically and not 
influenced by entry into the study. All patients gave written consent for study 
entry and fiducial marker insertion. PSA checks and toxicity monitoring were 
part of routine management.
All patients underwent a planning radiotherapy Computed Tomography (CT) 
scan for planning purposes. Following informed consent, patients were scanned 
in the supine position with leg rest and a comfortably full bladder. Patients were 
advised to drink 560ml (3 cups) 30 mins before planning CT, with an eventual 
volume of approximately 200-400 ml and rectal diameter less than 5cm. Non­
contrast radiotherapy planning CT scans, from mid-sacroiliac joints to 3cm 
inferior to ischium, were obtained with 2.5mm slices. Those patients treated 
within CFIHiP had their prostate +/- seminal vesicle volumes defined according 
to trial protocol as per Table 3.2 below.
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Table 3.2 Prostate margin descriptions according to risk group (table from 
CHHiP protocol(Khoo and Dearnaley 2008))
PTV1
L o w  R isk M o d e ra te  R isk T a rg e t Iso d o se
O u M h e : P ro s ta te  +  b a s e  (p rox im al 
2 c m ) o f S V
A d d : 10 m m  marçHn a il d irections
O u tlin e: P ro s ta te  +  S V
A d d : 1 0 m m  m arg in  a ll (E rections
7 6 %  m in im u m  
2; 8 0 %  m e d ia n  to  P T V 1  -  P T V 2
PTV2
O u t l i e :  P ro s ta te  o n ly
A d d :* 1 0 m m  m a rg in  e x c e p t 5 m m  to w a rd s  rectu m  un less  
m o d e ra te /la rg e  d e g re e  o f re cta l d is tens ion  w tie n  
1 0 m m  to w a rd s  rectu m  (o n ly  u s e  10m m  on  individual C T  
s lices  s h o w ing  m o d e ra ted a rg e  recta l d is ten s io n )
9 1 %  m in im u m  
>  9 6 %  m e d ia l  to  P V 2  -  P T V 3
P T V 3
O utlffie : P ro s ta te  o n ly
A d d : 5rren  m arg in  e x c e p t 0 m m  to w a rd s  re c tw n  (a ll c a s e s )
1 0 0 % (± 1 % ) m e d ia n  
9 5 %  m in im u m
Plans were produced with the Varian Eclipse planning system with a median 
target dose of 100%. Patients received 74Gy in 37 fractions to the prostate. The 
target volume objectives are displayed in Table 3.3 below.
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Table 3.3 Target volume objectives.
Rectum
2Gy/# Prescribed Dose [Gy] Dose [%] Max Vo! [%]
30 41 80
40 54 70
50 68 60
60 81 50
65 88 30
70 95 15
74 100 3
Bladder
2Gy/# Prescribed Dose [Gy] Dose [%] Max Vol [%]
50 68 50
60 81 25
74 100 5
Bowel
2Gy/# Prescribed Dose [Gy] Dose [%] Max Vol [cc]
50 68 17
TARGET DOSE ACHIEVED PROSTATE ONLY
Target (Aim)
Min Dose [%] (To 
99% of volume)
PTV1 Min>76%
PTV2 (min>91%)
Min>95%,
99%<med<101%
PTV3 (min>95%.
99%<med<101%)
PTV1-PTV2 (med>80%) Med>80%
PTV2-PTV3 (med>96%) Med>96%
3.3.6 Verification protocol and matching technique
DRRs were used as reference images. An online daily verification protocol was 
used. A daily orthogonal kV pair of electronic portal images (EPIs) was obtained 
immediately before treatment. Automatic marker matching was selected, but the 
shift itself was not carried out. This provided staff with a starting point for 
carrying out online matching. Manual marker matching was then carried out, 
and corrections applied before delivery on each occasion. If a gross 
displacement (>10mm) was observed, set up was revised and a new image
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obtained. There was zero tolerance for correction in AP, superior-inferior and 
lateral directions. There were no adjustments made to correct for rotation, even 
if detected. Weekly cone beam images were obtained after initial patient set up, 
but prior to kV acquisition, and used for dose volume analysis later. The 
protocol is displayed in Figure 3.3 below.
Figure 3.3 Verification and marker matching protocol for prostate only 
patients.
Initial Patient Setup
Weekly PreRT CBCT acquired
Daily kV pair acquired
N/
Online match to markers
\ /
SHIFT
\ /
RT delivered
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3.3.7 Offline review
There was weekly offline review of all matching by trained staff to ensure that 
the standard of matching was satisfactory. Any further shifts were recorded and 
analysed for disagreement between online and offline matching.
3.3.8 Linac service or breakdown
In the event of any interruption to treatment on the sole linac with OBI capability, 
the patients continued treatment on one of the other machines, with the 
standard offline protocol and an MV image pair was taken after treatment to 
allow offline matching.
3.3.9 Image and data storage
The kV, MV and CBCT images were stored on the local server from which 
Eclipse, the planning system, could import image sets for further planning work. 
During the initial part of the study period, verification data was imported into 
existing patient named folders for post-treatment analysis. This took place after 
completion of the radiotherapy course to ensure that it could not be used for 
treatment purposes.
Later on in the study period, there was a change in the method for importing 
data into Eclipse. This acted as a further safeguard against research data being 
accidentally used or deleted. For patients recruited after this decision, ‘ghost’ 
anonymised planning CTs were exported from the actual treatment folders and 
imported back into Eclipse under file names prefixed by ‘zz’ to denote research 
work. Anonymised CBCT datasets were generated on the planning system and 
imported into the research folders.
Data from the 20 prostate only patients was processed with both methods.
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3.3.10 Post treatment analysis
3.3.10.1 Volume analysis
GTV1 (prostate), GTV2 (prostate + seminal vesicles), bladder and rectum 
contours for prostate only patients were originally generated by the treating 
team. The contouring style of the clinician, for example, superior and inferior 
extent of the rectum, was noted by the student. This was in order to allow a 
consistent contouring style for subsequent contouring of weekly CBCT in the 
Eclipse treatment planning system, and minimise inter-observer variability.
The CBCT volumes of the four structures were recorded and compared to the 
planning volumes.
Patterns of organ volume according to week of treatment were analysed.
3.3.10.2 Plan calculation and dose volume analysis
3.3.10.2.1 CT plan calculation
For prostate only patients analysed before the creation of ‘ghost’ folders, 
anonymised DVHs from the original planning CTs were stored for later analysis. 
For prostate only patients with ghost folders, plans were exported from the 
original patient folders and calculated on the ‘ghost’ CTs. Extra checks were 
carried out to ensure that the plans were identical between original planning CT 
and ‘ghost’ planning CT, and involved ensuring the same number of monitor 
units was used, as well as the same minimum, maximum and mean rectal 
doses. For both plan calculation scenarios, the plan was normalised to '100% 
covers 50% target volume'.
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3.3.10.2.2 CBCT plan calculation 
Matching data was stored within Offline Review and used to determine the 
appropriate CBCT shifts for analysis.
The isocentre coordinates of the pre-treatment CBCT were shifted into the 
online marker match position, as this was thought to most closely represent the 
pre-treatment position. This was visually checked to confirm that a plausible 
shift had been carried out, for example, ensuring the prostate was reasonably 
covered. In some cases, an offset from isocentre was carried out at the time of 
treatment to ensure the CBCT covered relevant anatomy. For analysis, the 
CBCT was shifted back into the pre-treatment position.
The original plan was applied to the CBCT and the plan was recalculated. The 
plans were calculated on CBCT using the default diagnostic CT Hounsfield Unit 
(HU) curve. This was carried out on the assumption that the HU calibration 
curve for the CBCT was equivalent to that of a planning CT and this was 
discussed with the radiotherapy department locally. It was felt to be a 
reasonable compromise because the majority of analysis was planned to be 
between DVHs generated from CBCT calculations.
The plans were normalised to ensure that the same number of monitor units 
was used on CBCT as for the plan. For prostate only non-'ghost' patients, the 
CBCT plan normalisation was the same percentage as the greyed out value 
when the planning CT was normalised to '100% covers 50% target volume'. For 
the prostate only ‘ghost’ patients, the CBCT plan normalisation was the same 
percentage as the greyed out value when the ‘ghost’ planning CT was 
normalised to '100% covers 50% target volume'.
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A summary of plan calculations, according to type of CT, is displayed in Table
3.4 below.
Table 3.4 Plan normalisation method according to CT status and type of 
radiotherapy patient, to ensure the same number of MUs used throughout, 
and same rectal doses between actual and ghost CT.
Actual patient 
planning CT
Ghost planning 
CT
CBCT
Prostate only ‘100% covers 50% N/A Plan
non-ghost target volume' normalisation
patient ticked, with greyed = x%
out (‘100% covers
Plan normalisation 50% target
= x*%’ volume’ was
greyed out)
Prostate only ‘100% covers 50% ‘100% covers Plan
ghost patient target volume’ 50% target normalisation
ticked, with greyed volume’ ticked. = y%
out with greyed out
Plan normalisation Plan
= x*%’ normalisation =
y**>
"x is a variable number in the high 90s
"*y is a variable number very close to 100, and does not equal x
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Differential and cumulative DVHs for the original structures on planning CT, as 
well as new CBCT structures, were obtained. For short course patients, 
additional DVHs were calculated for the standard 74Gy in 37 fractions to allow 
for comparison of constraints and TCP/NTCP later. A trial calculation of 
TCP/NTCP confirmed that these differed when comparing an identical plan at 
60Gy/20# and 74Gy/37# and the aim of this study was to assess the effect of 
online matching rather than the effect of hypofractionation. Mean population 
DVHs were also calculated.
3.3.10.3 Plan comparison
Comparisons were made between population mean DVHs for CT and CBCTs, 
in addition to dose statistics at various constraints for DVHs from CT and CBCT.
3.3.10.4 Group comparison
In order to assess the effects of different factors on tissue constraints, TCP and 
NTCP, further analysis was carried out on data from the 20 prostate patients 
after subdividing into the following groups:
1. Small vs large bladder (two groups of 10 patients according to whether 
planning bladder volume was less or greater than median planning CT volume).
2. Small vs large rectum (as above).
3. Two vs three fiducial markers.
The groups were compared using t test, with the latter group compared using 
paired t test.
54
3.4 Results
3.4.1 Preclinical work
3.4.1.1 Phantom work for marker selection
Orthogonal MV and kV imaging was carried out to assess marker visibility with 
AP and lateral kV and MV images in Figure 3.4, Figure 3.5 and Figure 3.6 
below.
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Figure 3.4 Various fiducial markers on AP kV Imaging:
VIslcoll 2cm and 1cm length, 1.1mm diameter (top row, left and right) 
Seeds 8mm length, 1mm diameter (second row)
VIslcoll 1cm length, 0.75mm diameter (third row)
VIslcoll 1cm length, 1.1mm diameter (bottom row).
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Figure 3.5 Fiducial markers (arranged as per Fig. 3.4) on AP MV imaging.
‘It
%
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Figure 3.6 Fiducial markers (arranged as per Fig. 3.4) on lateral kV (left)
and MV (right) imaging.
It was decided to use cylindrical seeds and compare them against one type of 
Visicoil in the study, as this could help with future decisions about the choice of 
fiducial marker in the centre. As the 0.75mm diameter Visicoil was poorly visible 
in the lateral MV image, the 1.1mm diameter was selected. A 1cm length 
Visicoil was felt to be easily visible and was the smallest length available, 
therefore felt to be acceptable to patients.
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It was decided to compare 3 seeds with 2 Visicoils. As the seeds were shorter, 
it was felt that 3 was the minimum number required for satisfactory matching, 
with the centre of each seed being used as a point against which to match. As 
the Visicoils were longer, it was felt to be possible to match both ends of a 1cm 
Visicoil, with a pair giving 4 points against which to match.
3.4.1.2 Phantom work for practice marker matching 
Offline review images are shown in Figure 3.7 below.
Figure 3.7 Offline review of two Visicoils on AP (top left) and lateral (top 
right), with paired images below each; DRR (left) and kV (right).
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Vrt (cm] -0.3 -0.2 «0.2
Lnolcm ] 0.0 0.0 -C l
la t  (cm] -0.2 -0,3 -0.2
R tn trteg] 0.0 0.0 0.0
_SÜ2i 1
A l A l  A lA lA l  
<  ►
Sesson FM 13/03/2009. Image 9,10 of 24
CBCT images (Figure 3.8) were also taken to evaluate marker visibility and 
artefact, as well as to practice CBCT bone matching as this was a new practice 
for the centre.
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Figure 3.8 Offline review of two Visicoils on CBCT.
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3.4.1.3 Fiducial marker artefact 
The artefact caused by either Visicoils or seeds was noted because of potential 
impact on contouring on planning CT, as well as CBCT for this study, and is 
shown below in Figure 3.9 and Figure 3.10 respectively.
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Figure 3.9 Artefact caused by Visicoils on planning CT (top) and CBCT
(bottom) taken from the same patient.
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Figure 3.10 Artefact caused by seeds on planning CT (top) and CBCT
(bottom) taken from the same patient.
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3.4.1.4 Marker positions 
Marker position was also assessed with respect to ease of matching, with ones 
placed in different planes on both AP and lateral images deemed to have ‘good’ 
position, and ones overlying one another deemed to have ‘bad’ position (Figure 
3.11).
Figure 3.11 Orthogonal images with good' (top) and bad' (bottom) marker 
positions.
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3.4.2 Prostate
3.4.2.1 Volume analysis
3.4.2.1.1 Interobserver variability
The prostate and prostate plus seminal vesicles were contoured for 10 patients 
on the planning CT by the student. For five patients, the student’s contours 
were approved by the treating team (TT). For the other five patients, the 
student’s contours were drawn in addition to those by the treating team and the 
volumes, percentage differences and TCPs are shown in Table 3.5 below. With 
regard to volumes, there is between -2.4-3.6% difference for prostate and -1.5- 
7.6% difference for prostate plus seminal vesicles. However, when the original 
plan was applied to the new student volumes, the TCPs were the same for both 
structures. Therefore it was felt that there was minimal interobserver variability, 
with reassurance that the student was able to contour to a similar standard to 
that of the treating team.
Table 3.5 Difference in prostate and prostate + seminal vesicle volumes 
and TCPs between treating team and student.
Volumes
TT
prostate
Student
prostate
%
difference
TT
P+SV
Student
P+SV
%
difference
34.4 34.9 1.5 44.4 45.6 2.7
33.9 35.1 3.6 38.5 41.4 7.6
43.7 43.1 -1.3 60.4 61.1 1.3
82.4 82.0 -0.5 94.7 93.3 -1.5
53.5 52.3 -2.4 59.2 58.7 -0.8
TCP
TT prostate Student prostate TT P+SV Student P+SV
99.4 99.4 98.9 98.9
99.4 99.4 99.3 99.3
99.4 99.4 97.5 97.5
99.2 99.2 98.5 98.5
99.3 99.3 98.8 98.8
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3.4.2.1.2 Prostate and prostate + seminal vesicle volumes 
The median, range and standard deviations of volumes of prostate and seminal 
vesicles on planning CT and CBCT taken weekly throughout treatment are 
displayed below in Table 3.6.
Table 3.6 Median, range and standard deviations of volumes of prostate 
and SV volumes on planning CT and CBCTs.
Prostate Prostate + SV
Planning CT 
volume (cm^)
CBCT pre­
treatment 
volumes (cm^)
Planning CT 
volume (cm^)
CBCT pre­
treatment 
volumes (cm^)
Median
Range
Standard
deviation
45.6
30.5-82.4
15.2
44.5 
29.6-83.2
14.5
59.8
38.5-94.7
15.2
55.2
34.3-94.7
14.8
3.4.22 Dose-volume analysis
3.4.2.2.1 Problems 
Unfortunately it was not possible to calculate plans on 32 of the 94 acquired 
CBCTs. The CBCT appeared ‘crooked’, as seen in Figure 3.12 below. This 
misalignment was consistently found on the CBCTs on which calculation was 
not possible. It was discovered that this was due to the couch position not being 
set exactly at ‘0’ during patient set up or acquisition of CBCT. It was not 
possible to retrospectively realign the CBCT or reimport the images in a format 
in which plan calculation could take place. Therefore, subsequent dose volume 
analysis and TCP/NTCP analysis is based upon about 66% of the acquired 
CBCTs.
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Figure 3.12 Coronal section of CBCT illustrating ‘crooked’ image, 
highlighted in red.
_ I
DVHs were calculated from CBCTs and compared with those from plans. An 
example of DVHs from planning CT and CBCTs for a typical patient is shown 
below in Figure 3.13. DVHs from individual structures will be discussed in more 
detail.
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Figure 3.13 Example of CT and CBCT DVHs for a typical patient with plan 
bladder (red on left), CBCT bladder (yellow variations), plan rectum (red in 
centre), CBCT rectum (brown and green variations in centre), plan and 
CBCT prostate + SVs (green variations on centre right), plan prostate 
(green on far right), CBCT prostate (purple and blue variations on far 
right).
The graphs in Figure 3.14 and Figure 3.15 below show the DVHs of population 
means for prostate GTV and prostate and seminal vesicle GTV on planning CT 
and CBCT respectively. There is slightly improved prostate GTV coverage, and 
slightly poorer prostate and SV GTV coverage with the plan compared to CBCT.
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Figure 3.14 Mean population prostate GTV DVHs for CT and CBCT, 
magnified at high dose region.
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Figure 3.15 Mean population prostate and seminal vesicle GTV DVHs for 
CT and CBCT, magnified at high dose region.
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3.4.2.3 TCP
Prostate and seminal vesicle TCPs for CT and CBCT were calculated, and were 
compared with paired t tests, and are displayed in Figure 3.16 below. There is 
no significant difference between TCP on CT and CBCT. There appeared to be 
a lower prostate TCP on CBCT for Patient 18, and a large discrepancy between 
plan and CBCT. This may be because this patient had the largest recorded 
rectal CBCT volume (293.2cm^), though median rectal CBCT volume was 
118.2cm^, and range was 74.2-293.2cm^, compared to planning rectal volume 
of 137.6cm^.
Figure 3.16 Scatter plot for prostate and seminal vesicle TCPs for 
individual patients calculated on CT and CBCT, with mean, range and p 
value below.
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3.4.2 4 Effect of number of markers implanted 
> Table 3.7 below shows the mean TCP on CT and CBCT, divided according to 
number of markers on planning CT, with p values. There was no significant 
difference in TCP with number of markers.
Table 3.7 Mean TCP on CT and CBCT, divided according to number of 
markers.
2 markers 3 markers p value
TCP (%) Plan 97.7 97.1 0.337
CBCT 97.8 96.6 0.213
3.4.3 Bladder
3.4.3.1 Volume analysis 
The median, range and standard deviations of bladder volumes on planning CT 
and CBCT taken weekly throughout treatment are displayed below in Table 3.8. 
The median CBCT bladder volume was 187.7cm^, which was 40.6% smaller 
than the median planning CT volume of 316.0cm^.
Table 3.8 Median, range and standard deviations of bladder volumes on 
planning CT and CBCTs.
Planning CT volume
/  3v
CBCT pre­
treatment
Median 316.0 187.7
Range 186.9-524.9 36.9-655.9
Standard deviation 98.0 138.9
% change between planning and
CBCT : -40.6 .
Range -82.6 t o +169.4
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3.4.3.2 Variation in bladder volume according to week of treatment
The individual and median bladder volumes for planning CT and weekly CBCTs 
are displayed below in Figure 3.17.
The median bladder volumes for week 1 on CBCT are 14.6% smaller than 
planning CT volumes. The median bladder volumes for final week are 28.0% 
smaller than for planning CT, and 15.8% smaller than for first week volumes. 
There was an overall downward trend in bladder volume throughout the course 
of radiotherapy. Data for all 20 patients is represented in the first 4 weeks, 
where the CBCT volume falls by 43.1% between first and 4*  ^ week. However, 
only 6 patients had long course radiotherapy, and their data is seen in weeks 5- 
8. This may explain the higher median volumes seen in the latter weeks, as 
there are fewer patients and the data may not be representative.
Figure 3.17 Individual and median bladder volumes for planning CT and 
weekly CBCTs.
.«. 400 M e d i a n
5 300
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Figure 3.18 below illustrates the variation between planning and CBCT bladder 
and rectal volumes.
Figure 3.18 Example of weekly CBCT organ contours (bladder in orange, 
rectum in brown) for 1 patient copied onto planning CT to highlight 
variation across treatment course (plan bladder and rectal volume in red, 
GTV1 and GTV2 in green).
' ; r : >  ^.^'4
«
Bladder contouring on CBCT was mostly straightforward, but if the top slice was 
difficult to contour on planning CT, it was more difficult to contour on CBCT, as 
show in Figure 3.19 below.
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Figure 3.19 Example of top slice of bladder on CT (top image) and CBCT 
(bottom image).
*
3.4.3.3 Dose-volume analysis 
The graph in Figure 3.20 below shows the DVHs of population means for 
bladder on planning CT and CBCT, with slightly lower bladder doses with the 
plan compared to CBCT.
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Figure 3.20 Mean population bladder DVHs for CT and CBCT.
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All bladder dose constraints were fulfilled on the original plans. When plans 
were recalculated on CBCT, the percentages of CBCTs in which the constraint 
levels were met are shown in Table 3.9 below.
Table 3.9 Percentage of CBCTs which achieved the bladder constraints.
Bladder constraint % of CBCT where constraint achieved
V50<50% 82.3
V60<25% 66.1
V74<5% 87.1
Paired t tests were carried out comparing percentage volume treated at 
particular constraint levels for plans and CBCTs and are displayed in Table 
3.10. This showed a significant difference between plans and CBCTs for V50 
and V60 constraints.
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Table 3.10 Paired t test for bladder constraints comparing plans and 
CBCTs.
Bladder
constraint Mean plan % volume Mean CBCT % volume p value
V50<50% 24.7 32.1 0.020
V60<25% 16.5 22.6 0.025
V74<5% 0.8 2.1 0.192
Figure 3.21 displays the percentage volume of bladder treated at the V50 
constraint for individual patients, estimated according to calculation on CBCT, 
along with the mean CT and CBCT dose. This shows certain patients 
persistently not meeting the desired constraints on CBCT.
Figure 3.21 Estimated percentage volume of bladder treated at V50 
constraint based on calculations from CBCTs taken throughout treatment, 
with bladder volume constraint ideally <50%.
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34.3.4 NTCP
Bladder NTCPs for CT and CBCT (mean across weeks for each patient) were 
calculated and compared with paired t tests, and are displayed in Figure 3.22. 
There is no significant difference between NTCP on CT and CBCT. Patient 10
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was an outlier, with much higher estimated bladder NTCP on CBCT. This may 
be because their mean CBCT volume was 149.1cm^, approximately half that of 
the planning CT volume, with the smallest CBCT volume 35.9% of the planning 
volume. Furthermore, this patient’s bladder constraints achieved on planning 
CT were closer to the maximum tolerated compared to other patients.
Figure 3.22 Scatter plot for bladder NTCPs for Individual patients 
calculated on CT and CBCT, with mean, range and p value below.
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3.4.3.5 Relationship between initial planning bladder volumes and 
subsequent CBCT volumes
Paired t test was carried out comparing plan volume and mean CBCT volume 
for all 20 patients. This was also carried out according to initial small or large 
bladder volume, and this is displayed in Table 3.11.
76
There was a significant difference (p=0.016) between bladder volume on CT 
and CBCT for all 20 patients, with smaller volumes found during treatment. 
When dividing into small or large bladder groups, there was a significant 
difference for bladder and rectal CBCTs in patients with a large bladder on 
planning CT.
Table 3.11 Mean bladder and rectal volumes on CT and CBCT for 
population and grouped according to Initial bladder size.
Volume (cm^) 
Plan CBCT p value
Population Bladder 324.6 232.2 0.016
Rectum 92.6 83.3 0.102
initial small bladder Bladder 248.7 212.9 0.390
Initial large bladder 400.6 251.5 0.020
Initial small bladder Rectum 80.9 79.0 0.822
Initial large bladder 104.3 87.7 0.032
3.4.3.6 Effect of initial bladder volume on constraints and TCP/NTCP 
The mean % volume on CT and CBCT at various bladder and rectal constraints 
was calculated, then divided according to bladder size on planning CT, with p 
values. There was a significant difference for bladder V50 and V60 on plan 
between small and large bladders, but this was not translated into differences 
on CBCT
There was no significant difference for any TCP or NTCP when comparing 
small or large bladder size on planning CT.
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3.4.4 Rectum
3.4.4.1 Volume analysis 
The median, range and standard deviations of rectal volumes on planning CT 
and CBCT taken weekly throughout treatment are displayed below in Table 
3.12
The median CBCT rectal volume was 74.2cm^, which was 6.7% smaller than 
the median planning CT volume of 79.5cm^.
Table 3.12 Median, range and standard deviations of rectal volumes on 
planning CT and CBCTs.
Planning CT 
volume (cm^)
CBCT pre­
treatment 
volumes (cm^)
Median 79.5 74.2
Range 49.0-161.7 36.5-293.2
Standard deviation 31.6 43.5
% change between planning and 
CBCT -6.7
Range -50.3 to +207.9
3 4.4.2 Variation in rectal volume according to week of treatment 
The individual and median rectal volumes for planning CT and weekly CBCTs 
are displayed in Figure 3.23.
The median rectal volumes for week 1 on CBCT are 6.7% smaller than planning 
CT volumes. The median rectal volumes for final week are 20.0% smaller than 
for planning CT, and 14.3% smaller than for first week volumes.
As with the bladder findings, data for all 20 patients is represented in the only 
the first 4 weeks, with the CBCT volume increasing by 2.3% between first and
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4*^  week. The smaller patient numbers receiving long course treatment may 
explain the higher median volumes seen in weeks 5 and 6.
Figure 3.23 Individual and median rectal volumes for planning CT and 
weekly CBCTs.
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3.4.4.3 Dose-volume analysis
The graph in Figure 3.24 shows the means of DVHs for rectum on planning CT 
and CBCT, with slightly lower rectal doses with the plan compared to CBCT.
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Figure 3.24 Mean population rectal DVHs for CT and CBCT.
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AH rectal dose constraints were fulfilled on the original plans. When plans were 
recalculated on CBCT, the percentages of CBCTs in which the constraint levels 
were met are shown in Table 3.13 below.
Table 3.13 Percentage of CBCTs which achieved the rectal constraints
Rectal constraint % of CBCT where constraint achieved
V30<80% 51 6
V40<70% 74.2
V50<60% 93.5
V60<50% 100.0
V65<30% 98.3
V70<15% . 98.3
V74<3% 93.5
Paired t tests were carried out comparing percentage volume treated at 
particular constraint levels for plans and CBCTs and are displayed in Table 3.14
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below. This showed a significant difference between plans and CBCTs at all 
constraint levels, apart from V74.
Table 3:14 Paired t test for rectal constraints comparing plans and CBCTs.
Rectal constraint Mean plan % volume
Mean CBCT % 
volume p value
V30<80% 74.7 77.8 0.008
V40<70% 56.4 60.6 0.000
V50<60% 38.1 42.9 0.001
V60<50% 18.0 24.2 <0.001
V65<30% 9.7 12.7 0.004
V70<15% 3.0 4.8 0.030
V74<3% 0.0 0.6 0.094
Figure 3.25 displays the percentage volume of rectum treated at V74 for 
individual patients, estimated according to calculation on CBCT, along with the 
mean CT and CBCT dose. Patient 4 had the highest rectal CBCT doses 
because of his high rectal volumes throughout treatment (median 101.7cm^, 
range 68.1-223.2cm^, compared to planning volume of 72.5cm^)
Figure 3.25 Estimated percentage volume of rectum treated at V74 
constraint (100% dose) based on calculations from CBCTs taken 
throughout treatment, with rectal volume constraint ideally <3%.
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3.44.4 NTCP
Rectal NTCPs for CT and CBCT were calculated for the following parameters: 
Rectal stricture-bleeding(Burman, Kutcher et al. 1991), Rectal grade>2 
RTOG(Tucker, Dong et al. 2010), Rectal grade>2 bleeding(Rancati, Fiorino et 
al. 2004), Rectal grade>2 CTCAE v3.0(Sohn, Van et al. 2007), Combined 
grade>2 rectal toxicity from QUANTEC update(Michalski, Gay et al. 2010), and 
were compared with paired t tests. An example is displayed in Figure 3.26 
below. There are significant differences between NTCP on CT and CBCT 
across all parameters.
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Figure 3.26 Example of scatter plot for rectal NTCP (Combined grade>2 
rectal toxicity from QUANTEC update) for Individual patients calculated on 
CT and CBCT, with mean, range and p values of other parameters below.
CBCT
2 3 4 5 6 7 8 9  10 11 12 13 14 15 16 17 18 19 20 
Patient
Rectal NTCP parameter
Mean (range) 
Plan CBCT p value
Rectal stricture-bleeding 
Rectal grade>2 RTOG 
Rectal grade>2 bleeding
Rectal grade>2 CTCAE v3.0
Combined grade>2 rectal 
toxicity from QUANTEC update
1.4 2.1
(0.6-2.3) (0.8-4.0)
2.8 3.9
(1.4-4.6) (2.1-7.3)
1.4 2.1
(0.6-2.2) (0.6-3.8)
0.6 1.1
(0.2-1.3) (0.4-3.1)
1.9 2.9
(0.8-34) (1.3-6 0)
0.001
0.003
0.000
0.005
0.003
3.4.4.1 Relationship between initial planning rectal volumes and 
subsequent CBCT volumes
Paired t test was carried out comparing plan volume and mean CBCT volume 
for all 20 patients. This was also carried out according to initial small or large 
rectal volume, and this is displayed in Table 3.15.
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When dividing into small or large rectum groups, there was a significant 
difference for bladder and rectal CBCTs in patients with a large rectum on 
planning CT.
Table 3.15 Mean bladder and rectal volumes on CT and CBCT for 
population and grouped according to Initial rectal size.
Volume (cm^) 
Plan CBCT p value
Population Bladder 324.6 232.2 0.016
Rectum 92.6 83.3 0.102
Initial small rectum Bladder 292.0 245.0 0.433
Initial large rectum 357.2 219.4 0.005
Initial small rectum Rectum 68.9 72.0 0.681
Initial large rectum 116.2 94.6 0.006
S.4.4.2 Effect of initial rectal volume on constraints and TCP/NTCP 
The mean % volume on CT and CBCT at various bladder and rectal constraints 
was calculated, then divided according to rectal size on planning CT, with p 
values. There was a significant difference for rectal V30 on plan between small and 
large rectums, but this was not translated into differences on CBCT, and is 
probably not clinically relevant. There were no significant differences in bladder 
constraints.
Table 3.16 shows the mean TCP on CT and CBCT, divided according to rectal size 
on planning CT, with p values and there was a significant difference in TCP on 
CBCT for patients with initial large rectum. There were no significant differences for 
NTCP.
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Table 3.16 Mean TCP on CT and CBCT, divided according to small or large 
rectum on planning CT.
Small
rectum
Large
rectum p value
TCP (%) Plan 97.7 97.0 0.292
CBCT 98.1 96.3 0.038
3.4.6 Effect of number of markers
There was no significant difference in mean % volume on CT and CBCT at 
various bladder constraints when divided according to 2 or 3 markers.
There was a significant difference for rectal V50, but this was on the plan, 
therefore not related to the number of markers and is likely not to be clinically 
relevant.
There was no significant difference in bladder or rectal NTCPs on CT and 
CBCT when divided according to 2 or 3 markers.
3.5 Discussion
3.5.1 Volume Analysis
Zelefsky et al(Zelefsky, Crean et al. 1999) reported that initial large bladder and 
rectal volume correlate with increased prostate displacement, particularly in AP 
and SI directions.
More recently, increased pretreatment rectal cross section area was found to 
correlate with poorer biochemical progression free survival(de Crevoisier, 
Tucker et al. 2005; Heemsbergen, Hoogeman et al. 2007; Engels, Soete et al. 
2009).
In this study, the bladder and rectal volumes were overall smaller on median 
CBCT compared to planning CT (40.6% and 6.7% respectively).
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When assessing according to week of treatment, there was a trend towards a 
fall in bladder volume between planning CT and first week CBCT, and between 
first week CBCT and final week CBCT, and this trend was less pronounced with 
rectal volumes
This is supported by findings from Anderson et al(Anderson, Yu et al. 2011) 
who measured rectal volume and diameter pre-treatment and at 45Gy in 315 
patients who underwent prostate IMRT. There was a significant decrease in 
mean change of rectal volume of 8.62cm^ (13.6%) and 50.5% of patients had a 
decrease of 10%. A larger decrease was seen in patients who had a larger 
initial volume.
p ’Doherty et al(0'Doherty, McNair et al. 2006) investigated bladder volume at 
planning and during treatment, before and after the introduction of a patient 
information sheet. This confirmed the findings of this study.
McNair et al(McNair, Wedlake et al. 2011) assessed an individualised fluid and 
fibre prescription and reported that it did not improve the consistency of rectal 
filling.
The patients were grouped according to whether initial planning CT bladder or 
rectal volume was ‘small’ or ‘large’ (less than or greater than mean volume). 
Initial bladder volume did not result in any significant differences in bladder or 
rectal constraints, nor on TCP or NTCPs on CBCT.
Initial rectal volume did not result in any significant differences in bladder or
rectal constraints. However, there was a significantly lower prostate TCP
calculated from CBCT in patients with a larger initial rectal volume. This is
supported by evidence that larger rectum is a factor in poorer PSA
control(Decrevoisier, Tucker et al. 2005; Engels, Soete et al. 2009).
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Munck Af Rosenschold et al(Munck Af Rosenschold, Desai et al. 2014) studied 
267 patients undergoing daily IGRT with fiducials and reported that higher pre­
treatment bladder volume, rectal cross section area and body mass index were 
associated with increased inter-fractionation positioning uncertainty. Stillie et 
al(Stillie, Kron et al. 2009) did not find any association between rectal cross 
sectional area and positioning uncertainty. Thor et al(Thor, Bentzen et al. 2013) 
evaluated acute rectal toxicity in patients receiving treatment to prostate and 
nodes and reported that it was significantly associated with smaller on- 
treatment rectal volume. There was no significant association between bladder 
volume and toxicity.
It has to be assumed that regardless of instructions on bladder filling and rectal 
emptying, there is a trend for OAR volumes to reduce during the course of 
treatment, and this could be misleading as the OAR DVHs underestimate the 
risk of toxicity and overestimate CTV coverage.
3.5.2 Dose volume analysis
This study intended to compare how well the plan DVH reflected the actual 
delivered dose. Unfortunately, it was not possible to calculate on about 34% of 
CBCT.
The assumption was made that plan calculation on CBCT was acceptable. This 
was based on internal assessment from the medical physics 
department(Abolaban 2012). Ding et al(Ding, Duggan et al. 2007) reported that 
there was agreement within 1-3% when comparing DVHs calculated on 
planning CT with those calculated on CBCT and felt that this could be used for 
adaptive planning.
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Hatton et al(Hatton, McCurdy et al. 2009) used various CBCT Hounsfield unit to 
electron density calibration curves to calculate doses on phantoms and 
compare to measured doses. Significant dosimetric differences were found, 
particularly when the amount of scattering material, for example, phantom 
length, or diameter was increased. Further to this, the group performed dose 
calculations on CBCTs and reported that all CBCT doses are lower that 
planning CT doses (Hatton, Greer et al. 2011). To avoid bias, they renormalized 
the CBCT dose to the prescribed dose at the ICRU point and confirmed that this 
point dose was consistent, with only 0.3% daily variation. To test their method 
further, deformable registration between CT scan and CBCT, followed by dose 
recalculation, was also carried out, which again showed minimal variation of 
0.2%. This method could be carried out if this study were to be expanded in 
future.
Comparison of mean population DVHs for various structures was carried out. It 
was accepted that any mean DVH would not be completely representative of a 
population's plans because it would not demonstrate extremes of dose and may 
give a falsely reassuring mean DVH. However, it was useful as it allowed 
comparison between, say, plan and CBCT DVH, or pre and postRT DVH. The 
data was examined in more detail and also looked at individual patients.
There was little difference between plan and CBCT prostate/prostate and 
seminal vesicle DVHs.
However, for bladder and rectal DVHs, there were higher doses on CBCT and
there were statistically significant differences between plans and CBCTs for V50
and V60 bladder constraints, and between plans and CBCTs for all but one of
the rectal constraints. The constraints were exceeded by the same few patients
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at each level, but the magnitude at which constraints were exceeded tended to 
be greater for the bladder.
A possible cause of differences between DVHs on plan and CBCT may be due 
to differences in plan calculation between the two modalities. This may also 
have an impact on subsequent TCP/NTCP calculations.
Similar results were found by Hatton et al(Hatton, Greer et al. 2011) who carried 
out dose calculations on CBCT acquired twice weekly during the course of 
IMRT on 12 patients. The mean on treatment bladder and rectal V40, V60 and 
V7ÜS were compared to the values predicted on the initial plan. For bladder 
doses, there were significant differences for V40, V60 and V70 for twelve, 
twelve and eight patients, respectively, again with higher on treatment doses 
compared to predicted. For rectal doses, there were significant differences for 
V40, V60 and V70 for twelve, eleven and nine patients, respectively, with 65% 
of all on treatment plans higher than predicted. A similar increase in rectal and 
bladder treatment doses was reported by Kupelian(Kupelian, Langen et al.
2006) and similar rectal treatment doses were reported by Chen (Chen, 
Paskalev et al. 2010).
Our bladder findings were in contrast to Akino et al(Akino, Yoshioka et al. 2013) 
who compared bladder doses of 8 patients on plan with those calculated on MV 
CBCT with deformable image registration and did not find any significant 
difference in V60 or V70. Their study also found that an increase in rectal 
volume is not always accompanied by an increase in rectal dose, as the rectum 
may be displaced away from the high dose region.
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3.6.3 TCP/NTCP
The prostate and seminal vesicle TCP on CT and CBCT was 97.4% and 97.2% 
respectively and there was no significant difference. Tudor et al(Tudor, Rimmer 
et al. 2012) compared TCP between non-IGRT protocols and IGRT (online 
marker match) and reported 72.3% and 72.6% respectively with their two-phase 
technique, and 70.7% and 72.1% respectively with their concomitant boost 
technique. Their TCP was calculated using an EUD-based formula(Gay and 
Niemierko 2007).
Rothe Arnesen et al(Rothe Arnesen, Eilertsen et al. 2008) assessed different 
margin scenarios and did not find any significant difference in TCP between 
margins of 7.5 and 10mm, and approximately 3% decrease in TCP with 
reduction of margin from 7.5 to 5mm.
There was no significant difference between bladder NTCPs on CT and CBCT. 
However, there were significantly higher rectal NTCPs calculated for CBCT 
compared to planning CT across all parameters. This is concerning as prostate 
cancer patients usually have a reasonable prognosis, therefore a higher risk of 
rectal complication is likely to significantly impact on quality of life. However, all 
rectal NTCPs on CBCT were still low at less than 5%. Another less likely 
explanation is due to possible inaccuracies from CBCT calculation, however, 
Hatton et al(Hatton, Greer et al. 2011) reported that the CBCT dose tends to be 
an underestimate. This study did not assess TCP/NTCP for different matching 
or margin scenarios, which is what was carried out by Kasaova et al(Kasaova, 
Sirak et al. 2014) who investigated 2 different margins, with and without IGRT. 
There was higher rectal NTCP with the larger margin, with improved CTV and
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PTV coverage. Similar findings were reported by Wen (Wen, Kumarasiri et al. 
2013). There was no reported data on bladder NTCP with IGRT.
3.5.4 Effect of number of markers
The patients were grouped according to whether they had two or three markers. 
The number of markers did not result in any significant differences in bladder or 
rectal constraints, nor on TCP or NTCPs on CBCT which suggests that two 
markers here did not lead to poorer matching or outcome. Most studies reported 
the insertion of 3 markers(McNair, Hansen et al. 2008; Rimmer, Burnet et al. 
2008; Pawlowski, Yang et al. 2010; Hatton, Greer et al. 2011). Van der 
Vight(van der Vight, van Lin et al. 2008) inserted 4 markers. Van den 
Heuvel(Van den Heuvel, Fugazzi et al. 2006) inserted 5 or 6, therefore 3 
markers would be reasonable for the centre in future.
Marker migration was felt to be minimal in a number of studies(Dehnad, 
Nederveen et al. 2003; Poggi, Gant et al. 2003; Pouliot, Aubin et al. 2003; 
Kupelian, Willoughby et al. 2005; McNair, Hansen et al. 2008).
In future, the markers could be contoured as a separate volume and the HU 
could be changed to that of prostate. This could be in order to reduce the 
likelihood of the marker density causing any problems with dose calculation on 
CT or CBCT,
3.5.5 Practical issues
As discussed in the next chapter on intrafraction changes, the median time 
between pre and postRT CBCT was 12.7min (range 9.9-24.8min). This could be 
used as an approximation of the total ‘in room’ time, though this does not 
include initial patient set up or assisting the patient off the couch after treatment
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delivery. Also, this may be an overestimate as acquisition of 1 or 2 CBCT may 
not be required in standard practice. There were some longer ‘in room' times 
due to the fact that this was new technology at the centre. However, this is 
comparable to published data. Rimmer et al(Rimmer, Burnet et al. 2008) 
assessed practical issues relating to the implementation of IGRT and reported a 
3 minute increase in each treatment session duration to 13.1 minutes, and an 
increase in machine workload time of 2.2hr/day if all radical prostate patients 
received IGRT. Herman et al(Herman, Pisansky et al. 2003) reported a 1.4 
minute increase in treatment duration with online marker matching. Perrier et 
al(Perrier, Morelle et al. 2013) reported on the cost of prostate IGRT, comparing 
daily and weekly IGRT based on data from 7 French cancer centres. They 
reported daily treatment time of 21.0 minutes for daily CBCT and 18.3 minutes 
for daily kV marker matching. They then estimated the additional cost per 
patient of daily versus weekly IGRT to be 679euro and 187euro for CBCT and 
kV marker match respectively.
It would also be reasonable to propose daily online kV marker match as routine 
practice for the centre. Ding et al(Ding and Munro 2013) estimated the 
additional pelvis imaging dose from Varian daily kV orthogonal pair to be 
O.IcGy. This compares to a dose of 1 4cGy for pelvic On Board Imaging 
(version 1.4/1.5) kV CBCT.
The following areas were not investigated due to time constraints, but would be
interesting to pursue in future. These include examining acute and late toxicity
and correlate with bladder and rectal volumes. It may also be useful to correlate
with weight and BMI as there is conflicting evidence regarding relationships
between shifts and BMI, with increased shifts with increasing BMI reported by
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Wong et al(Wong, Gao et al. 2009), though reduced intrafraction SI 
displacements with higher BMI reported by Thompson et al(Thompson, Gill et 
al. 2011). Further correlation between TCP/NTCP/PSA control would also be 
useful.
It was suggested by Flatten et al(Flatton, Greer et al. 2011) that a possible 
strategy in future might be to recalculate on CBCT for certain ‘at risk’ patients, 
given the trend for higher on treatment doses compared to predicted, and allow 
adjustment of dose or margins or replanning with the aim to reduce late toxicity. 
These patients may be those with smaller or larger volume prostate (<12cc, 
>50cc). Murthy at al(Murthy, Shukla et al. 2012) also suggested a method of 
identifying patients who are likely to fail to meet planning constraints during 
treatment based on rectal and bladder volumes for the first 3 to 5 fractions. It 
would be interesting to also pursue further strategies in adaptive radiotherapy.
3.6 Conclusion
This study has demonstrated that both types of markers are acceptable for daily 
online kV matching and this technique could be introduced as standard at the 
centre. An online strategy would be useful to overcome variation in bladder and 
rectal volume as these are generally smaller on CBCT compared to CT.
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Chapter 4 Effects of intrafraction changes on Image Guided Intensity 
Modulated Radiotherapy in patients receiving treatment to prostate only
4.1 Introduction
There is uncertainty in prostate position during and between fractions 
(intrafraction and interfraction motion) due to physiological variation in bladder 
and rectal filling. Increasing conformality of radiation doses and dose escalation 
mean that accurate patient positioning is increasingly important. Pre and post 
treatment CBCT can be used to provide dose volume information on 
intrafraction changes.
4.2 Objectives
To compare volumes of prostate, bladder and rectum at planning, before and 
after treatment, and to assess trends throughout treatment.
To carry out dosimetric analysis on prostate, bladder and rectum at planning, 
before and after treatment.
To assess the impact of intrafractional bladder and rectal volume variation on 
DVHs and TCP/NTCP..
4.3 Methods
4.3.1 Verification technique
This was the same as per Chapter 3, except that a pair of CBCT images was 
obtained weekly, with one CBCT taken after set up and the other immediately 
after treatment delivery. The protocol is displayed in Figure 4.1.
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Figure 4.1 Verification and marker matching protocol for prostate only 
patients.
Initial Patient Setup
Weekly PreRT CBCT acquired
Daily kV pair acquired
Online match to markers
SHIFT
RT delivered
Weekly PostRT CBCT acquired
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4.3.2 Post treatment analysis
In addition to the analysis in Chapter 3, volume changes and rate of change 
between pre-treatment (pre RT) and post-treatment (post RT) CBCT were also 
calculated.
4.4 Results
4.4.1 Prostate
4.4.1.1 Dose-volume analysis
As mentioned in the last chapter, it was not possible to calculate plans on some 
of the CBCT due to unintended couch rotation. Calculation was possible on 31 
of 49 CBCT pairs (63% of pairs).
The graphs in Figure 4.2 and Figure 4.3 show the population means of DVHs 
for prostate GTV and prostate and seminal vesicle GTV respectively on 
planning CT and pre and post RT CBCT. There is slightly improved prostate 
GTV coverage, and slightly poorer prostate + SV GTV coverage with the plan 
compared to CBCT. The coverage for pre and post RT CBCT was similar.
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Figure 4.2 Mean population prostate GTV DVHs for CT and pre and post
RT CBCT, magnified at high dose region.
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Figure 4.3 Mean population prostate and seminal vesicle GTV DVHs for CT 
and pre and post RT CBCT, magnified at high dose region.
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4.4.1.2 NTCP
Prostate and seminal vesicle TCPs for CT, preRT and postRT CBCT were 
calculated, along with paired t test comparing preRT and post RT CBCT, and 
are displayed in Figure 4.4 below. The p value from paired t test is 0.028 as the 
95% confidence interval of the differences is -0.445 to -0.032, but this is likely 
not to be clinically relevant.
Figure 4.4 Scatter plot for prostate and seminal vesicle TCPs for individual 
patients calculated on CT and preRT and postRT CBCT, with mean and 
range.
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4.4.2 Bladder
4.4,2.1 Volume analysis
The bladder volumes on planning CT, median and range of volumes from 
preRT CBCT, intrafraction changes in volume and rates of change are 
displayed below in Table 4.1. The median CBCT bladder volume was 227.4cm^, 
which was 26.3% smaller than the median planning CT volume of 308.5cm^. 
The median intrafraction change was an increase by 49.0cm^, and the median 
intrafraction rate of change in volume was 3.9cm^/min (range 0.5-12.9 cm^/min). 
The median time between pre and postRT CBCT was 12.7min (range 9.9- 
24.8min).
Table 4.1 Bladder volumes for planning CT and preRT CBCTs, 
intrafraction (IF) changes in volume, rates of change and % change.
Planning 
CT volume 
(cm^)
CBCT pre­
treatment 
volumes 
(cm^)
IF change 
in volume 
(cm^)
IF rate of 
change in 
volume 
(cm^/min)
% IF 
change in 
volume
Median 308.5 227 4 49.0 3.9 23.0
Range
Standard
203.8-524.9 54.4-478.5 : 6.7-159.4 0.5-12.9 3.3-59.4
deviation 96.5 113.0 35.3 2.6 14.0
4.4.2.2 Variation in bladder volume according to week of treatment
The individual and median bladder % intrafraction changes in volume according 
to week of treatment are displayed below in Figure 4.5. There is no weekly 
trend seen, which can likely be explained by the fact that bladder filling is 
physiological.
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Figure 4.5 Individual and median bladder % intrafraction changes in 
volume according to week of treatment.
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4.4.2.3 Dose-volume analysis
The graph in Figure 4.6 below shows the means of DVHs for bladder on 
planning CT and CBCT, with slightly higher bladder doses with the plan 
compared to pre RT CBCT, but slightly lower plan doses compared to the post 
RT CBCT.
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Figure 4.6 Mean population bladder DVHs for CT and pre and post RT
CBCT.
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All bladder dose constraints were fulfilled on the original plans. When plans 
were recalculated on pre and post CBCT, the percentages of CBCTs in which 
the constraint levels were met are shown in Table 4.2 below.
Table 4.2 Percentage of preRT and postRT CBCTs which achieved the 
bladder constraints.
Bladder
constraint
% of preRT CBCT where 
constraint achieved
% of postRT CBCT where 
constraint achieved
V50<50% 87.1 87.1
V60<25% 74.2 80.6
V74<5% 90.3 90.3
Figure 4.7 displays the percentage volume of bladder treated at V74 dose 
constraint for individual patients, for plan and mean pre and post RT CBCT, 
along with the mean CT and CBCT doses. This shows certain patients
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persistently not meeting the desired constraints on CBCT, in particular. Patient 
10 who was discussed previously.
Figure 4.7 Estimated percentage volume of bladder treated at V74 
constraints based on calculations from CBCTs taken throughout 
treatment, with bladder volume constraint ideally <5%.
i f
25 1
(U
E 20 -
3
>
? 15 -
1
3
in 10 -
k 5 -
o
0
1 0 -
■  Plan
■  Pre
■  Post
I ___L
9T
44.2.4 NTCP
Bladder NTCPs for CT, preRT and postRT CBCT were calculated, along with 
paired t test comparing preRT and post RT CBCT, and are displayed in Figure 
4.8 below. There is no significant difference between NTCP on preRT and 
postRT CBCT.
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Figure 4.8 Scatter plot for bladder NTCPs for individual patients calculated 
on CT and preRT and postRT CBCT, with mean and range.
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4.4.3 Rectum
4.4.3.1 Volume analysis 
The rectal volumes on planning CT, median and range of volumes from preRT 
CBCT, intrafraction changes in volume and rates of change are displayed below 
in Table 4.3. The median CBCT rectal volume was 68.6cm^, which was 19.8% 
smaller than the median planning CT volume of 85.2cm^. The median 
intrafraction change was a decrease by 0.9cm^, and the median intrafraction 
rate of change in volume was -O.lcm^/min (range -1.6-3.2cm^/min).
104
Table 4.3 Rectal volumes for planning CT and preRT CBCTs, intrafraction 
(IF) changes in volume, rates of change and % change.
Planning
CT
volume
(cm^)
CBCT pre­
treatment IF change 
volumes in volume 
(cm^) (cm^)
IF rate of 
change in 
volume 
(cm^/min)
% IF change 
in volume
'+' denotes positive change, denotes negative change
Median 77.6 68.6 -0.9 -0.1 -1.5
Range 49.0-125.0 36.5-223.2 -26 to -^40.6 -1.6 to +3.2 -28.0 to +54.3
Standard
deviation 23.8 40.1 12.3 0.9 15.0
4.4.3.2 Variation in rectal volume according to week of treatment 
The individual and median rectal % intrafraction changes in volume according to 
week of treatment are displayed below in Figure 4.9. There is no definite weekly 
trend seen, though it highlights that certain patients tend to have a larger 
magnitude of intrafraction change than others.
Figure 4.9 Individual and median rectal % intrafraction changes in volume 
according to week Of treatment.
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4.4.3.3 Dose-volume analysis
The graph in Figure 4.10 below shows the means of DVHs for rectum on 
planning CT and CBCT, with slightly higher rectal doses on the CBCT 
compared to the plan.
Figure 4.10 Mean population rectal DVHs for CT and CBCT.
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All rectal dose constraints were fulfilled on the original plans. When plans were 
recalculated on pre and post CBCT, the percentages of CBCTs in which the 
constraint levels were met are shown in Table 4.4 below.
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Table 4.4 Percentage of preRT and postRT CBCTs which achieved the 
rectal constraints.
Rectal constraint
% of preRT CBCT where 
constraint achieved
% of postRT CBCT where 
constraint achieved
V30<80% 48.4 41.9
V40<70% 71.0 64.5
V50<60% 96.8 100.0
V60<50% 100.0 100.0
V65<30% 100.0 96.8
V70<15% 96.8 93.5
V74<3% 90.3 90.3
4.43.4 NTCP
Rectal NTCPs for CT and preRT and postRT CBCT were calculated as 
previously and were compared with paired t tests. An example is displayed in 
Figure 4.11 below. There is no significant difference between NTCP on preRT 
and postRT CBCT.
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Figure 4.11 Example of scatter plot for rectal NTCP (Combined grade>2 
rectal toxicity from QUANTEC update) for Individual patients calculated on 
CT and preRT and postRT CBCT, with mean, range and p values of other 
parameters below.
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Mean (range)
Rectal NTCP parameter Plan PreRTCBCT
PostRT
CBCT p value
Rectal stricture-bleeding 1.5
Q.7-2.3
1.8
04-7.0
1.6
0.3-10.8
0.122
Rectal grade>2 RTOG 2.9 
1.4-4.6
3.3
0.8-13.1
3.0
0.7-18.0
0.056
Rectal g rade >2 bleeding 1.5
0.8-2.1
1.9
06-4.6
1.8 : 
0.5-7.8
0.154
Rectal grade>2 CTCAE 0.6 0.8 0.7 0.290
v3.0 0.2-1.3 0.1-6.8 0.1-11.0
Combined grade>2 rectal 2.0 2.3 2.1 0.088
toxicity from QUANTEC
update 0.8-34 0.4-11.4 0.4-16.7 .
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4.5 Discussion
4.5.1 Prostate
There was little variation between prostate CT volume and CBCT volume and 
differences were likely due to a combination of intraobserver variability and 
organ deformation. There was a statistically significant difference between 
preRT and postRT prostate and seminal vesicle TCPs (97.4 and 97.2% 
respectively) but this is likely to be clinically irrelevant.
The prostate doses were similar between CT and CBCT. This was reflected in 
the work by Godley et al(Godley, Ahunbay et al. 2012), with less than 3% 
difference between planned and delivered prostate coverage.
Kron et al(Kron, Thomas et al. 2010) assessed prostate motion with pre and 
post treatment kV imaging. The group reported that 4.7% and 0.4% of 
intrafraction displacements were above 5 and 10 mm respectively. They found 
that there were increased displacements as the time between pre and post 
treatment images increased, with estimated AP margin of 2.8mm with interval 
less than 6 minutes, and 4.0mm with interval greater than 9 minutes. The group 
also highlighted the limitations of assessing intrafraction motion using a kV pair, 
for example, that it does not provide information of movement during treatment 
delivery and does not take prostate deformation into account. However, it is a 
quick and straightforward method of assessment.
A more detailed assessment of prostate motion can be achieved by continuous
real time tracking of the prostate, for example, with fluoroscopy(Shimizu, Shirato
et al. 2000; Kitamura, Shirato et al. 2002) or the Calypso system(Langen,
Willoughby et al. 2008; Noel, Parikh et al. 2009; Mayyas, Chetty et al. 2013)
which uses electromagnetic intraprostatic markers. Noel et al(Noel, Parikh et al.
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2009) used this system to compare pre and post treatment imaging, and 
intermittent imaging with continuous tracking. The sensitivity of the first method 
to determine prostate intrafraction motion was less than 60%. Intermittent 
imaging improved this to 88-96% for 15s intervals, but this fell as the sampling 
interval increased. Overall, they concluded that pre and post treatment imaging 
was insensitive and they favoured continuous, real-time tracking. Mayyas et 
al(Mayyas, Chetty et al. 2013) compared various localisation methods (3D 
ultrasound, kV pair, CBCT) and found reasonable correlation between the 
methods, with best correlation between kV and CBCT in AP and LR directions 
(0.80 and 0.90 respectively) though this was 0.50 in SI direction. Correlation 
was worst between US and kV in AP and LR directions (0.61 and 0.68 
respectively). They concluded that 10-11mm margin was sufficient for setting up 
according to skin tattoos, and that image guidance would reduce this to less 
than 4rnm. They also assessed intrafraction motion with the Calypso system 
and reported mean intrafraction error of 0mm with SO within 2-3mm.
4.6.2 Bladder
The median intrafraction change in bladder volume on CBCT was an increase 
by 49.0cm^, and the median intrafraction rate of change in volume was 
3.9cm^/min. The median increase in bladder volume was by 23% and this is 
comparable to the 14% increase published by Adamson et al (Adamson and Wu
2009) who assessed pre and post treatment volumes with CBCT. The group 
also estimated bladder volume by measuring the maximum length in each axis 
(x, y, z) and calculating the volume with the following formula:
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V=47t xyz
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This correlated well with bladder volumes from CBCT contouring, with 
correlation coefficient of 0.93 and difference of 4.6+20.2cm3 (mean +SD) 
suggesting that this method could be used in future when a quick estimation of 
bladder volume is required, for example, if selecting a plan of the day’. They 
found weak correlation between bladder filling and posterior drift of prostate in 
the presence of little or no rectal gas. Overall, they concluded that bladder filling 
had limited use in predicting prostate intrafraction motion.
The mean plan bladder DVH was between the preRT and postRT DVHs. As few 
as 74.2% constraints were met on CBCT despite all constraints being achieved 
on plans. There was a significantly lower postRT Bladder V50 and certain 
patients persistently failed to meet the desired constraints on CBCT. This is 
likely related to small CBCT volumes compared to planning volumes and 
bladder constraints on plan being closer to tolerance compared to the other 
patients.
4.6.3 Rectum
The median intrafraction change in rectal volume was a decrease by 0.9cm^, 
and the median intrafraction rate of change in volume was -0.1cm^/min. 
Adamson et al(Adamson and Wu 2009) reported that rectal filling and increased 
rectal gas correlated with maximum prostate displacement, with patients with 
gas volume greater than 0.5 cm^ having larger prostate intrafraction motion. 
They postulated that rectal gas volume on CBCT for initial fractions could be 
used to aid margin calculation for adaptive radiotherapy.
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The mean plan rectal DVH demonstrated lower doses than both preRT and 
postRT DVHs. Between 41.9-71.0% of constraints were met on CBCT for rectal 
V30 and V40, though this increased to over 90% for V50 and above. There 
were significantly higher postRT rectal V30, V40, V50 and V60 compared to 
preRT parameters.
Inter and intrafraction variation in bladder and rectal volumes occur in all 
patients due to physiological changes. Although some of these could be 
minimised with strict adherence to bladder filling and rectal emptying guidelines 
and short treatment times, it is difficult to predict the rate of bladder filling.
There was no significant difference between bladder or rectal NTCPs on preRT 
and postRT CBCT and literature searches could not find evidence of this having 
been carried out elsewhere.
The median time between pre and postRT CBCT was 12.7min (range 9.9- 
24.8min). Other studies reported intervals of 5 to 7 min (Kotte, Hofman et al.
2007) , 15.5+4.2 min (Adamson and Wu 2009) from beginning of CBCT to end 
of treatment delivery, and 9 min (Chung, Haycocks et al. 2004). The increased 
use of arc therapy, with a typical treatment time of 1.8-3.7 min(Wolff, Stieler et 
al. 2009; Tsai, Wu et al. 2011) will reduce the opportunity for intrafraction 
motion.
However, the trend for hypofractionation in prostate cancer(Liao, Joiner et al.
2010), with its potential radiobiological advantages, highlights the ongoing 
importance of accurate verification.
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4.6 Conclusion
With an online matching protocol to prostate fiducial markers, the impact of 
intrafraction motion on TCP and late bladder and rectal NTCP values appears 
small.
This work assessed intra and interfraction volume changes and effect of dose 
constraints and TCP/NTCP. Unfortunately it did not quantify actual intra or 
interfraction motion though this could be attempted in future if using a centroid 
(centre of mass) or reference position.
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Chapter 5 Image Guided Intensity Modulated Radiotherapy in patients 
receiving treatment to prostate and nodes
5.1 Introduction
Patients with high risk disease are sometimes offered prophylactic irradiation to 
the pelvic nodes. The prostate and pelvic bony anatomy move independently of 
each other, therefore radiotherapy to prostate and nodes can be more 
challenging when attempting to accurately treat both targets whilst avoiding 
organs at risk. There is uncertainty as to the ideal matching target for this 
treatment.
5.2 Objectives
To compare volumes of prostate, pelvic nodes, bladder, rectum and bowel at 
planning and during treatment.
To carry out dosimetric analysis on prostate, pelvic nodes, bladder, rectum and 
bowel at planning and during treatment.
To carry out TCP/NTCP calculations on prostate, pelvic nodes, bladder, rectum 
and bowel at planning and during treatment.
To assess various correction protocols for prostate and node patients.
To familiarise the department with prostate IGRT and daily online CBCT bone 
matching.
5.3 Methods
5.3.1 Radiotherapy technique
Pelvic nodal volume included external iliac, internal iliac, presacral and 
obturator nodes.
Patients received 74Gy in 37 fractions to the prostate, 55Gy in 37 fractions to 
involved nodes and 50Gy in 37 fractions to prophylactic node according to their
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clinical indication. Further target volume objectives were used here, in addition 
to those in Chapter 3, and are displayed in Table 5.1 below.
Table 5.1 Target volume objectives.
Bowel
2Gy/# Prescribed Dose [Gy] Dose [%]
Max Vol [cm^, 
toxicity grade 0/1
45 61 78/158
55 74 14/28
60 81 0.5/6
65 88 0.0
TARGET DOSE ACHIEVED PROSTATE/NODES
Volume constraint, 
Dose required Prostate PTV (Gy) Nodal PTV (Gy)
99%. 90% 66.6 49.5
95%, 95% 70.3 52.3
50%, 100% 74.0 55.0
<=5%, 105% 77.7 n/a
5.3.2 Verification protocol and matching technique
The planning CT scan was used as a reference image and matching performed 
to bony anatomy. CBCT was acquired daily and an online correction protocol 
was used. CBCT images were obtained daily immediately before treatment. 
Automatic bone matching was selected, but the shift itself was not carried out. 
This provided staff with a starting point for carrying out online matching. Manual 
matching was then carried out, and corrections applied before delivery on each 
occasion. Weekly kV image pairs were obtained after patient set up, prior to 
CBCT acquisition and matching. The protocol is displayed in Figure 5.T below.
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Figure 5.1 Verification and bone matching protocol for prostate and node 
patients.
Initial Patient Setup
V
Weekly PreRT kV pair acquired
\/
Daily preRT CBCT acquired
\/
Online match to bone
\/
SHIFT
\/
RT delivered
kV images were taken as reference images to compare bony matching with 
CBCT, br kV marker matching, and to allow dose-volume analysis to take place;
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5.3.3 Image and data storage
All patients in this group had ‘ghost’ anonymised planning CTs exported from 
the actual treatment folders and imported back into Eclipse under file names 
prefixed by ‘zz’ to denote research work. Anonymised CBCT datasets were 
generated on the planning system and imported into the research folders.
5.3.4 Post treatment analysis
5.3.4.1 Volume analysis
GTV1 (prostate), GTV2 (prostate + seminal vesicles), pelvic nodes, bladder, 
rectum and bowel contours were all outlined by the student throughout..
The planning volumes were reviewed and approved by the treating clinician. All 
volumes were calculated and recorded. Patterns of organ volume according to 
week of treatment were analysed.
5.3.4 2 Plan calculation and dose volume analysis
5.3.4.2.1 CT plan calculation
All research calculations were generated from ‘ghost’ data and the 
normalisation method differed from that of prostate only patients. The reason is 
unclear, but it was done in order for the monitor units and rectal doses to be 
identical between the actual plan and the ‘ghost’ plan. The actual patient 
planning CT was normalised to a certain percentage in the high 90s. For the 
‘ghost’ planning CT, the plan was normalised to 100%
5.3.4 2.2 CBCT plan calculation 
The plans were norrnalised to ensure that the same number of monitor units 
was used on CBCT as for the plan. Here, the CBCT plan was normalised to
100%L
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A summary of plan calculations, according to type of CT, is displayed in Table
5.2 below.
Table 5.2 Plan normalisation method according to CT status and type of 
radiotherapy patient, to ensure the same number of MUs used throughout, 
and same rectal doses between actual and ghost CT.
Actual patient 
planning CT
Ghost planning 
CT
CBCT
Prostate and 
node (all ghost)
Plan
normalisation=z***%
Plan
normalisation
=100%
Plan
normalisation
=100%
***z is a variable number in the high 90s
For the prostate and node patients, CBCT calculations were also carried out 
after shifting to the following positions: offline CBCT bone match, offline kV 
bone match and offline kV marker match.
5.3.4 2.3 Plan comparison 
Comparisons were made between population mean DVHs for CT and CBCTs, 
in addition to dose statistics at various constraints for DVHs from CT and CBCT.
5.3.4 3 Group comparisons 
The constraints, TCP and NTCP were compared according to matching 
scenario, namely for planning CT, online CBCT bone match, and offline CBCT 
bone, kV bone and kV marker match.
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5.4 Results
5.4.1 Problems
As mentioned in the last chapter, it was not possible to calculate plans on some 
of the CBCT due to unintended couch rotation. Calculation was carried out on 
33 CBCT, approximately alternate weeks for each patient.
The CBCT DVHs appear slightly ‘hotter’ compared to the plan DVHs, and the 
CBCT DVHs generally appear similar. An example of this is shown in Figure 5.2 
below. There is likely not to be a true comparison between the plan DVH and 
the CBCT DVHs and may be explained by problems with the plan normalisation 
method in Table 5.2.
Figure 5.2 Mean population prostate and seminal vesicle G TV DVHs for CT 
and various matching scenarios, magnified at high dose region.
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Plan comparisons between plan and CBCT were felt to be flawed and 
implausible because of the dose calculation issues and were excluded from 
these results.
However, it was felt to be reasonable to compare between CBCTs because 
they shared a dose calculation method and these comparisons could offer 
guidance on the appropriateness of matching to various targets.
6.4.2 Prostate
5.4.2.1 Volume analysis 
The median, range and standard deviations of volumes of prostate and seminal 
vesicles on planning CT and CBCT taken weekly throughout treatment are 
displayed below in Table 5.3.
Table 5.3 Median, range and standard deviations of volumes of prostate 
and SV volumes on planning CT and CBCTs.
Planning CT volume 
(cm^)
CBCT pre-treatment 
volumes (cm^)
Median 59.4 : 58.6
Range 26.4-97.6 26.1-94.9
Standard deviation 24.1 23.5
5.4.22 TCP
Prostate and seminal vesicle TCPs for CBCT are displayed in Figure 5.3 below. 
These were calculated for the following matching scenarios: mean online CBCT 
bone, mean offline CBCT bone, mean offline kV bone and mean offline kV 
marker. The reason for Patient 4 being an outlier may be related to lower PTV
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coverage being accepted on plan initially. Prostate PTV coverage was slightly 
lower than the others, however his mean nodal PTV coverage was much lower 
(plan V55=74.7% compared to mean 91.1% for 8 patients, and mean online 
CBCT bone match V55=48.5% compared to mean CBCT of 83.3% overall). His 
bladder and rectal volumes were similar between planning CT and CBCT.
Figure 5.3 Scatter plot for prostate and seminal vesicle TCPs for individual 
patients calculated on CBCT, with population mean and range below.
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There were no significant differences between TCPs when comparing between 
online CBCT and offline matching scenarios, as well as between offline CBCT 
bone and offline kV bone matching.
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5.4.3 Pelvic nodes
5.4.3.1 Volume analysis 
The median, range and standard deviations of volumes of prostate and seminal 
vesicles on planning CT and CBCT taken weekly throughout treatment are 
displayed below in Table 5.4.
Table 5.4 Median, range and standard deviations of volumes of pelvic 
node volumes on planning CT and CBCTs.
Planning CT 
volume (cm^)
CBCT pre-treatment 
volumes (cm^)
Median 259.5 241.5
Range 196.4-370.7 198.2-360.6
Standard deviation 61.3 58.2
5.43.2 TCP
Pelvic node TCPs for CBCT are displayed in Figure 5.4 below, assuming 
clonogen density of 10®/cm ,^ and were calculated for the 4 matching scenarios. 
Lower TCP was seen again for Patient 4 which is likely to be related to the 
same reason as above.
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Figure 5.4 Scatter plot for pelvic node TCPs for individual patients 
calculated on CBCT, based on an estimated clonogen density of 10^/cm^, 
with population mean and range below.
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5.4.3.3 Comparison between online CBCT bone match and other
matching scenarios
5.4.3.3.1 Constraints
Nodal V55 for online CBCT and offline matching scenarios are shown below in
Table 5.5. There were no significant differences when pairs of scenarios were
compared.
Table 5.5 Nodal V55 for different matching scenarios.
Mean V55 (%)
Mean online CBCT bone 832
Mean offline CBCT bone 84.3
Mean offline kV bone 77.0
Mean offline kV marker 79:4
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5.4.3.32 TCP
Nodal TCP for online CBCT and offline matching scenarios are shown below in 
Table 5.6. There was a significant difference between online CBCT bone match 
and offline kV bone match when comparing calculation on CBCT, but there was 
no significant difference between online and offline CBCT bone match, or offline 
CBCT bone and offline kV bone match.
Table 5.6 Nodal TCP and comparisons fo r d ifferent matching scenarios.
TCP (%)
Mean online CBCT Mean offline CBCT
bone bone p value
Nodes (CD 10®) 843 828 0.346
Nodes (C D IO I 74.8 729 0.354
Mean online CBCT Mean offline kV
bone bone
Nodes (CD 10®) 843 849 0.046
Nodes (CD 10^ 74a 71.8 0.042
Mean online CBCT Mean offline kV
bone marker
Nodes (CD 10®) 843 822 0.234
Nodes (CD 10 )^ 748 723 0.228
Mean offline CBCT Mean offline kV
bone bone p value
Nodes (CD 10®) 828 849 0.876
Nodes (CD 10 )^ 729 748 0.772
5.4.4 Volume analysis of organs at risk 
The median, range and standard deviations of bladder, rectal and bowel 
volumes on planning CT and CBCT taken weekly throughout treatment are 
displayed below in Table 5.7.
The differences between the median planning CT volume and median CBCT 
bladder, rectal and bowel volumes were -53.1%, +7.3% and -25.9% 
respectively.
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Table 5.7 Median, range and standard deviations of OAR volumes on 
planning CT and CBCTs.
Planning CT 
volume (cm^)
CBCT pre-treatment 
volumes (cm^)
BLADDER
Median
Range
Standard deviation
305.0
172.1-483.0
119.7
137.9
76.0-459.2
131.8
% change between 
planning and CBCT 
Range in % change
-53.1 
-77.2 to -4.9
RECTUM
Median
Range
Standard deviation
52.2 
45.8-75.0
9.2
62.4
46.2-74.4
7.9
% change between 
planning and CBCT 
Range in % change
7.3
-11.4 to +35.9
BOWEL
Median
Range
Standard deviation
364.6
199.3-762.4
210.5
275.4
183.4-443.2
87.8
% change between 
planning and CBCT 
Range in % change
-25.9 
-54.5 to +22.9
It was sometimes more difficult to contour bowel on CBCT, especially when 
there was a large amount of bowel gas. Attempts were made to try and contour 
accurately, for example, by comparing with the planning CT, and by looking at 
slices above and below and interpolating. Figure 5.5 below shows examples of 
bowel that is easily visible and more difficult to delineate.
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Figure 5.5 CBCT images of easily visible (top image) and difficult to 
delineate (bottom image) small bowel.
k
5.4.4.1 Variation in OAR volume according to week of treatment 
The median bladder, rectal and bowel volumes for planning CT and weekly 
CBCTs are displayed below in Figure 5.6. As with the prostate only patients, 
there is a downward trend for bladder volume throughout treatment, with
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median bladder volumes for week 1 on CBCT 29,3% smaller than planning CT 
volumes, and final week volumes 65.2% smaller than for planning CT, and 
50.9% smaller than first week volumes. There does not appear to be a definite 
trend with rectal and bowel volumes.
Figure 5.6 Median bladder, rectal and bowel volumes for planning CT and 
weekly CBCTs.
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5.4.5 Bladder-further analysis
5.4.5.1 Dose-volume analysis 
The graph in Figure 5.7 below shows the population means of DVHs for bladder 
on CBCTs, calculated for online CBCT bone matching, as well as offline CBCT 
bone, offline kV bone and offline marker matching. There are similar DVHs 
between offline kV bone and marker matching, and between online and offline 
CBCT bone matching.
127
Figure 5.7 Mean population bladder DVHs for various matching scenarios.
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All bladder dose constraints were fulfilled on the original plans, apart from V74 
for one patient being 6.90% rather than the desired 5%. When plans were 
recalculated on CBCT with online CBCT bone match, the percentages of 
CBCTs in which the constraint levels were met are shown in Table 5.8 below. 
As can be seen in Table 5.7, certain patients had persistently underfilled 
bladders which may have contributed to this, as well as the calculation problem 
on CBCT.
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Table 5.8 Percentage of online matched CBCTs which achieved the 
bladder constraints.
Bladder constraint % of CBCT where constraint achieved
V50<50% 51.5
V60<25% 45.5
V74<5% 45.5
5 .4 .52  NTCP
Bladder NTCPs for CT and CBCT are displayed in Figure 5.8 below. These 
were calculated for the following matching scenarios: mean online CBCT bone, 
mean offline CBCT bone, mean offline kV bone and mean offline kV marker. 
There appears to be much higher NTCP for Patient 1, this is because their 
median bladder CBCT volume was 81.9cm^ compared to a planning CT volume 
of 359.1cm^.
Figure 5.8 Scatter plot for bladder NTCPs for individual patients calculated 
on CBCT with population mean and range below.
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5.4.5.3 Comparison of constraints and NTCP for different matching
scenarios
Comparisons were made between online CBCT and offline matching scenarios, 
as well as between offline CBCT bone and offline kV bone matching. There 
were no significant differences between online and offline NTCP.
5.4.6 Rectum-further analysis
5.4.6.1 Dose-volume analysis
The graph in Figure 5.9 below shows the population means of DVHs for rectum 
on CBCTs, calculated for online CBCT bone matching, as well as offline CBCT 
bone, offline kV bone and offline marker matching. The ‘hottest’ DVH is with 
offline kV bone matching, followed by offline kV marker matching, then similar 
DVHs between online and offline CBCT bone matching.
Figure 5.9 Mean population rectal DVHs for CT and various matching 
scenarios.
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The percentages of plans and CBCTs in which the rectal constraint levels were 
met are shown in Table 5.9 below. Some of the constraints were fulfilled on the 
original plans, these being none of V30<80%, one of eight patients for V40<70, 
all of V50, V60 and V65, and all but one for V70 and V74. This was lower when 
plans were recalculated on CBCT. This may have been related to the 
calculation problem on CBCT, as well as larger rectal volume expanding into 
PTV.
Table 5.9 Percentage of plans and online matched CBCTs which achieved 
the rectal constraints.
Rectal
constraint
% of plans where constraint 
achieved
% of CBCT where constraint 
achieved
V30<80% 0.0 0.0
V40<70% 12.5 3.0
V50<60% 100.0 63.6
V60<50% 100.0 100.0
V65<30% 100.0 75.8
V70<15% 87.5 45.5
V74<3% 87.5 51.5
54.6.2 NTCP
An example of rectal NTCPs for CBCT is displayed in Figure 5.10 below. These 
were calculated for the 4 matching scenarios. Patient 5 was an outlier as they 
had the largest recorded rectal CBCT volume of 95 1cm^ compared to a 
planning CT volume of 51.3cm^.
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Figure 5.10 Example of scatter plot for rectum NTCPs for Combined 
grade>2 rectal toxicity from QUANTEC update parameter, for Individual 
patients calculated on CBCT, with population means and ranges below.
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5.4.6.3 Comparison of constraints and NTCP for different matching 
scenarios
Comparisons were made between online CBCT and offline matching scenarios, 
as well as between offline CBCT bone and offline kV bone matching. There 
were only significant differences at V65 and V70 between online CBCT bone 
match and offline kV bone match when comparing calculation on CBCT and the 
clinical relevance is uncertain. There were no other significant differences 
between online and offline volumes treated when comparing calculation on 
CBCT.
There were no significant differences between online and offline NTCP.
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6.4.7 Bowel-further analysis
5.4.7.1 Dose-volume analysis 
The graph in Figure 5.11 below shows the population means of DVHs for bowel 
on CBCTs, calculated for online CBCT bone matching, as well as offline CBCT 
bone, offline kV bone and offline marker matching. The ‘hottest’ DVHs are with 
online and offline CBCT bone matching, followed by similar DVHs for offline kV 
bone and marker matching.
Figure 5.11 Mean population bowel DVHs for various CBCT matching 
scenarios.
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The percentages of plans and CBCTs in which the bowel constraint levels were 
met are shown in Table 5.10 below. Most of the bowel dose constraints were 
fulfilled on the original plans, including all of the Grade 1 toxicity constraints. All 
but one of the Grade 1 constraints were fulfilled on CBCT and none of the 
Grade 0 constraints were rtiet on CBCT.
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Table 5.10 Percentage of plans and online matched CBCTs which 
achieved the bowel constraints.
Bowel constraint % of plans where constraint achieved
% of CBCT where constraint 
achieved
V45<78cc (Gr 0) 87.5 66.7
V45<158cc (Gr 1) 100.0 100.0
V50<17cc(Gr0) 62.5 27.3
V50<110cc(Gr 1) 100.0 100.0
V55<14cc(Gr 0) 100.0 78.8
V55<28cc (Gr 1) 100.0 100.0
V60<0.5cc (Gr 0) 75.0 57.6
V60<6cc (Gr 1) 100.0 84.8
V65=0cc 62.5 60.6
Figure 5.12 displays an example of the percentage volume of bowel treated at 
V60 for individual patients, for mean online CBCT bone match, and offline 
matching scenarios (CBCT bone, kV bone, kV marker), along with the mean 
CBCT doses. This shows that many constraints were not met on CBCT, 
particularly for certain patients, but this may be related to bowel volume, for 
example, patient 4 had the largest bowel volume on planning CT of 762.4cm^, 
but their median CBCT bowel volume was 443.2cm^.
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Figure 5.12 An example of estimated absolute volume of bowel treated at 
60Gy constraint based on calculations from CBCTs taken throughout 
treatment, with bowel volume constraint ideally <0.5cm^ (grade 0) or 6cm^ 
(grade 1).
16 
14 
gr. 12 -
J, 10 - 
"  8 -  
= 6 
>  4
VQ X V  . 'C r  ^
o '& '' o 'a -'' o 'i> "  c ' y  o 'f r '” o '^ ' ’ ^  - f .  s i r  \ < P
f
I Mean online CBCT 
bone
■  Mean offline CBCT 
bone
I Mean offline kV 
bone
■  Mean offline kV 
marker
5.4.72 NTCP
Bowel NTCPs for CBCT are displayed in Figure 5.13 below. These were 
calculated for the 4 matching scenarios. A possible explanation for the highest 
NTCPs for patient 6 is that they had one of the smallest bowel volumes on 
planning CT, with accepted constraints close to tolerance. Their subsequent 
CBCT bowel volumes were also small.
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Figure 5.13 Scatter plot for bowel NTCPs for Individual patients calculated 
on CBCT with population mean and range below.
20.0 -1
1 8 . 0  -
1 6 . 0  -
^  1 4 . 0  -  
'  12.0 -o.
z 10.0 
I  8.0 
â  6.0
4 . 0
2.0
0.0
2 60 1 3 4 5 7 8
■  M e a n  o n l i n e  C B C T  b o n e  
A  M e a n  o f f l i n e  C B C T  b o n e  
X  M e a n  o f f l i n e  k V  b o n e  
X  M e a n  o f f l i n e  k V  m a r k e r
Patient
Mean online Mean offline Mean offline kV Mean offline kV
CBCT bone CBCT bone bone marker
Mean 3.3 3.5 3.7 3.2
Range 0.6-7.9 0.7-7.8 0.7-9.8 0.6-10.1
5.4.7.3 Comparison of constraints and NTCP for different matching 
scenarios
Comparisons were made between online CBCT and offline matching scenarios, 
as well as between offline CBCT bone and offline kV bone matching. There was 
only a significant difference at V50 between online CBCT bone match and 
offline CBCT bone match when comparing calculation on CBCT and the clinical 
relevance is uncertain. There were no other significant differences between 
online and offline volumes treated when comparing calculation on CBCT.
There were no significant differences between online and offline NTCPs.
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5.5 Discussion
5.5.1 Volume analysis
The prostate and nodal volumes were similar between CT and CBCT, with the 
prostate volumes reflecting the findings in Chapter 3.
The planning bladder volumes were similar to those in the prostate only group 
(305.Ocm^ compared to 316.Ocm^), but the median prostate and nodes CBCT 
bladder volume was 137.9cm^, which was 54.8% smaller compared to planning 
CT, whereas the median CBCT bladder volume in the prostate only group was 
40.6% smaller than planning CT. 4/8 (50%) of the prostate and node patients 
had a median CBCT bladder volume <100cm^, whereas only 2/20 (10%) of the 
prostate only patients had similarly small bladders. This could be related to the 
higher treated volume leading to increased bladder toxicity and difficulty 
maintaining volume. Also, as this group had higher risk prostate cancer, they 
could have been more prone to lower urinary tracts symptoms. Therefore, it 
would have been useful to assess their symptoms as baseline and during and 
after treatment.
The mean and median planning rectal volumes for prostate and node patients
were generally lower compared to those in the prostate only group (56.1 cm^
and 52.2cm^ compared to 92.6cm^ and 79.6cm^ respectively). The reason for
this is unclear as patients underwent similar bowel preparation, but may be
explained by the small numbers. The median CBCT rectal volume was 62.4cm^
which was 19.0% larger compared to planning CT, whereas the median CBCT
rectal volume in the prostate only group was 6.7% smaller than planning CT.
The mean planning rectal volumes before and after individualised bowel advice
reported by McNair et al(McNair, Wedlake et al. 2011) were 66.7-72.4cm^
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(range 26.7-175.Ocm^). Mean planning rectal volume reported by Reddy et 
al(Reddy, Nori et al. 2009) was 108cm^ (range 28-223cm^). A possible 
explanation for the larger mean CBCT rectal volume could again be due to the 
larger treated volume, including small bowel, which may have led to increased 
bowel gas. However, this conflicts with the finding that the mean CBCT bowel 
volume was 25.9% less than the planning CT volume. This could partly be due 
to intraobserver variability, though care was taken to ensure that the upper and 
lower contouring limits were similar between CT and CBCT. Another 
explanation was poorer resolution of CBCT with increased artefact, particularly 
where there was increased bowel gas, and it was not possible to contour these 
areas on CBCT. One further explanation is that the contouring for prostate and 
node patients was all carried out by the student, whereas for prostate only 
patients, the planning contours were done by the treating consultant, with the 
student adapting their style of contouring, for example, upper and lower limit of 
rectum, for subsequent CBCT contours. As there were several treating 
consultants, this could have introduced further variability in volume. Brierley at 
al(Brierley, Cummings et al. 1994) assessed patients receiving adjuvant pelvic 
radiotherapy for rectal cancer and reported that bladder filling could not reliably 
reproduce small bowel displacement during a course of treatment. Acker et 
al (Acker and Marks 1995) assessed small bowel position after receiving 39.6- 
46.0Gy to pelvis and reported that the position appeared unchanged compared 
to bony landmarks after receiving this dose though this is less relevant when 
using a simultaneous integrated boost technique.
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5.5.2 Dose volume analysis
There appeared to be a difference in the shape of plan DVHs and CBCT DVHs 
for prostate and node patients, particularly at high dose. The mean CBCT DVHs 
for prostate and pelvic nodes appeared similar to each other, with ‘shouldering’ 
at high dose, but this was absent for the mean plan DVHs. This difference was 
not apparent with the prostate only patients. It was felt that this was due to 
differences in the plan normalisation methods and creation of 'ghost' plans, 
rather than a genuine difference between plans, though unfortunately it was not 
possible to rectify this. Therefore, comparison between plan and CBCT is likely 
to be unreliable, with impact on subsequent constraint analysis and TCP/NTCP. 
Comparison between CBCT does appear to compare ‘like with like’.
There was little difference between CBCT DVHs for prostate or pelvic nodes for 
the various matching scenarios. This is reflected in work reported by Thornqvist 
et al(Thornqvist, Bentzen et al. 2011) who also compared different matching 
scenarios and reported no significant difference in coverage of prostate, 
seminal vesicle or nodal CTV. Rossi et al(Rossi, Schreibmann et al. 2008) 
assessed CTV coverage with online fiducial matching and reported that there 
was underdosing of nodes by 9% and 29% respectively in 2/10 patients (20%). 
Excluding these 2 cases, they reported undercoverage of nodes by 2.2%. 
Although the bladder constraints were mostly fulfilled on the original plans, only 
about 50% of the online match CBCTs achieved the bladder constraints. Again, 
this appeared mainly due to certain patients having small CBCT bladder 
volumes. There was no significant difference between bladder doses for online 
CBCT bone match and the other matching scenarios.
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Thor et al(Thor, Bentzen et al. 2013) assessed bladder doses on plan and with 
marker match and reported a significant association between acute GU toxicity 
and V59 (2Gy equivalent) on plan, and between late GU toxicity and V I9 and 
V65 (2Gy equivalent) on marker match.
The lowest rectal doses were for online CBCT bone match, then offline CBCT 
bone and offline kV markers, with highest dose for mean offline kV bone. 
Thornqvist et al(Thornqvist, Bentzen et al. 2011) reported significantly higher 
rectal doses with 2D marker matching compared to CT bone matching. There 
were significant differences between online CBCT bone and offline kV bone for 
V65 and V70, but the clinical significance is uncertain. Thor et al(Thor, Bentzen 
et al. 2013) assessed rectal doses on plan and with marker match and reported 
that V60 and V70 (2Gy equivalent) constraints were fulfilled with both methods. 
There was a significant association between acute Gl toxicity and V76 (2Gy 
equivalent) with marker matching.
There were lowest bowel doses for offline kV markers and bone, with highest 
doses for online and offline CBCT bone match. There was a significant 
difference between online CBCT bone and offline CBCT bone for V50, but the 
clinical significance is uncertain. Most of the bowel dose constraints were met 
on the original plans, including all of the Grade 1 toxicity constraints. All but one 
of the Grade 1 constraints were fulfilled on CBCT, but only between 27.3-78.8% 
of the Grade 0 constraints were met on CBCT. Again, this appeared mainly to 
affect certain patients and may be due to the smaller bowel volume bn CBCT, 
which may be related to artefact and difficulty contouring due to bowel gas, in 
addition to the calculation problem.
There was no reported data on bowel doses or NTCP from the literature search
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5.6.3 TCP/NTCP
Prostate TCP was similar between matching scenarios, but there was one 
patient who had much lower TCPs on CBCT, and the reason for this is unclear 
as there was not a large discrepancy between CT and CBCT volumes. Overall, 
prostate TCP appeared to be higher for offline kV marker match (99.5%), with 
similar TCPs for the other matching scenarios (99.1%) and there were no 
significant differences between the groups. In contrast, the nodal TCP was 
highest for online bone CBCT match. There was a significant difference 
between nodal TCP for online CBCT bone match and offline kV bone match 
(84.3% and 74.8% compared to 81.9% and 71.8% for clonal density of 10®/cm^ 
and 10^/cm^ respectively).). This was surprising as similar results would have 
been expected for the same target, but highlighted the limitations of comparing 
2D and 3D matching techniques. There was no significant difference in nodal 
TCP between online CBCT bone match and offline kV marker match and this 
could provide reassurance that there would be adequate coverage whether 
matching to prostate or bone.
Two patients had much higher CBCT bladder NTCPs which corresponded to 
much smaller CBCT bladder volumes compared to the planning CT. The 
NTCPs tended to be lower with kV matching compared to CBCT matching. 
Viswanathan et al and Rosewall et al(Rosewall, Catton et al. 2010; 
Viswanathan, Yorke et al. 2010) reported that it is difficult to predict any dose- 
response relationship for bladder toxicity, most likely related to the variability in 
bladder volume throughout a course of treatment.
In contrast to bladder NTCP, the rectal NTCPs tended to be higher with kV
matching compared to CBCT matching. The highest NTCP was with offline kV
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bone match, followed by offline kV marker match, with both CBCT bone 
matching giving similar results. There were no significant differences on CBCT, 
though there was a trend towards difference between online CBCT bone match 
and offline kV bone match. Singh et al(Singh, Greer et al. 2013) compared 
rectal toxicities with and without IGRT for prostate +/- SV 3D-CRT. IGRT was 
daily online marker match, and ‘without IGRT was assumed to be bone match. 
They reported lower rectal toxicity with IGRT, though unexpectedly rectal doses 
were significantly higher with IGRT and this could not be fully explained. There 
was no correlation between rectal toxicities and DVHs.
There were no significant differences on bowel NTCPs on CBCT, though offline 
kV bone match had highest NTCP.
5.5.4 Effect of alternative matching targets
5.5.4.1 Effect of kV bone matching 
Overall, with CBCT matching, there tended to be a lower prostate TCP, higher 
nodal TCP, higher bladder NTCP, lower rectal NTCP and similar/equivocal 
bowel NTCP. Even though one would expect similar results between bone 
matching for CBCT (online or offline) and kV, the outcomes differed, suggesting 
that there is a difference in one's ability to perform a bony match between kV 
and CBCT.
Also, there was similar TCP/NTCP between kV bone and kV marker match 
even though a difference was anticipated because of the independent 
movement of the prostate relative to bony anatomy.
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5.5.4.2 Effect of marker matching
Comparing online CBCT bone match with offline kV marker match, there was a 
significantly lower nodal TCP with marker match.
In a poster by Thogersen et al(Th0gersen EH 2011), kV marker matching was 
assessed in the setting of prostate and nodes radiotherapy for 10 patients. The 
largest systematic error was 2.7mm in AP direction, with similar random error in 
AP and SI directions (2.4mm and 2.5mm respectively). They reported 
systematic error for rotation of 0.6-1.0 degree and random error of 0.5-0.9 
degree. They suggested that using daily fiducial marker based set-up as 
acceptable providing adequate PTV margins and controlled rectal filling. 
Thornqvist et al(Thornqvist, Bentzen et al. 2011) compared fiducial matching to 
bone matching. The largest deviation between fiducial matching and bony 
matching was in AP direction with SD of 3mm. However, the largest drop in 
delivered compared to intended prostate CTV coverage occurred when 
matching to bone rather than markers. This is reflected in results from this study 
with lower prostate TCP with bone matching. Their group concluded that 
matching to fiducials offered the best ‘trade-off’ for satisfactory coverage 
between prostate, SV and nodes. However, it is uncertain whether this same 
strategy could be proposed here because of the relatively higher proportion of 
AP displacements. Furthermore, bony matching did not appear to result in any 
fall in prostate coverage or TCP compared to marker matching, and marker 
matching resulted in a lower nodal TCP in this study.
The same group also reported on marker and bony matching in the setting of
proton therapy(Thornqvist, Muren et al. 2013) and selected patients with large
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interfraction variations in bladder and rectal volume. They concluded that there 
was decreased SV and nodal coverage with either matching strategy even with 
10mm CTV to PTV margin.
Hsu et al (Hsu, Pawlicki et al. 2007) assessed pelvic nodal coverage when 
matching to fiducial markers and reported that nodal dose was compromised by 
less than 1% for 90% coverage. A 10mm offset was associated with up to 10% 
drop in nodal coverage. Marker matching had minimal impact on bowel and 
femoral head dose.
Adamczyk et al(Adamczyk, Piotrowski et al. 2014) assessed prostate and nodal 
coverage, with prostate soft tissue CBCT matching and bone matching. They 
reported that there was up to 2.6% variation in coverage of prostate or nodes, 
and recommended 10mm CTV to PTV SI margin for nodes.
Eminowicz et al(Eminowicz, Dean et al. 2014) treated prostate and nodes using 
marker matching. They recalculated dose at 1mm increments up to 10mm in all 
directions. They estimated that there was <0.25% chance of an offset in 
anterior, left or right directions resulting in failure to cover nodal PTV. This 
likelihood remained <1% for a posterior offset.
Rossi et al(Rossi, Schreibmann et al. 2008) reported that 10mm CTV to PTV
margin was insufficient for nodal coverage with online marker matching. They
suggested that in cases of sequential treatment prostate and node treatment, it
may be appropriate to treat the prostate (or ‘boost’) first, and to use the initial
displacement data to identify the ideal nodal PTV margin.
Xia et al(Xia, Qi et al. 2010) proposed a Multiple Adaptive Plan’ strategy to
overcome the difficulty with 2 independently moving targets, and suggested
generating multiple plans and selecting the plan based on that day’s prostate
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position. A similar approach has been utilised in bladder cancer(Lalondrelle, 
Huddart et al. 2011), though generation of multiple plans can be resource­
intensive and may not be practical at all centres.
5.6 Conclusions
There was little difference between CBCT DVHs for prostate or pelvic nodes for 
the various matching scenarios. It is reasonable to propose an online bone 
matching protocol with daily CBCT to offer satisfactory coverage to prostate and 
nodes.
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Section 2: Biophysical estimation of DNA damage and second cancer risk using 
gamma H2AX and TLDs in prostate cancer IMRT
Chapter 6
6.1 Introduction and aims
6.1.1 Radiotherapy and second cancer risk
6.1.1.1 General aspects 
Patients receiving treatment with radiotherapy are exposed to increased levels 
of radiation in areas that are neither part of the target volume nor part of the 
path of the radiation beams. The main sources of absorbed dose outside the 
treatment volume are:
- Leakage of photons through or scattered by the linear accelerator 
head shielding and collimators.
- Photons scattered out of the treatment volume.
- Neutrons arising from photon-neutron activation interactions in the 
treatment head and leaking through the head shielding, particularly at 
energies above 10 Megavoltage (MV) (National Council on Radiation 
Protection and Measurements, and National Council on Radiation 
Protection and Measurements. Scientific Committee 60. 1984; 
Howell, Hertel et al. 2006).
IMRT is a potential source of increased radiation exposure compared to 
conventional techniques and thereby may be associated with an increased risk 
o f second malignancy. IMRT couples increased conformality of the dose 
distributions with a reduction of the normal tissue volume irradiated to high dose
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levels. This is achieved by superimposing multiple radiation beams from 
different directions, in which at least some are intensity-modulated, and 
intentionally deliver a non-uniform intensity to the target (Bortfeld 2006). A lower 
dose is therefore delivered and distributed to a larger volume of normal tissues 
around the target.
It has been suggested that IMRT treatments require 4-5 times the number of 
monitor units (MUs) of standard techniques (National Council on Radiation 
Protection and Measurements. 2005). This means that, compared to an open 
field, irradiation of a given target requires a larger output, which results in a 
larger whole body exposure due to increased leakage radiation (d'Errico 2006). 
In the UK, the modality commonly used for IMRT is 6 MV photons. The use of 
higher energies, particularly for deep seated tumours, is of routine use in 3D- 
CRT and it has been suggested to provide both better target coverage and 
normal tissue sparing (Steneker, Lomax et al. 2006). These factors have been 
identified as potential issues when estimating the risk of second malignancy 
following irradiation, which has been deemed to be increased with IMRT, 
particularly where higher energy beams are used (Verellen and Vanhavere 
1999; Hall and Wuu 2003; Hall 2006).
6.1.1.2 In vivo dosimetry using biomarkers of DNA damage
Ionising radiation causes DNA double strand breaks (DSBs) which, if left 
unrepaired, are the most important lesion for cell death and carcinogenesis 
(Jackson 2002). Several studies have looked at quantifying DSBs after ionising 
radiation.
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6.1.1.3 Early biomarkers of chromosomal damage
DNA damage was initially evaluated using alkaline comet assay, analysis of 
structural chromosome aberrations and micronucleus assay. Gamulin et al 
(Gamulin, Kopjar et al. 2008) analysed peripheral blood lymphocytes of 
oropharyngeal cancer patients during RT with these techniques. Blood samples 
were taken 2 hours before irradiation on day 1 of the first radiotherapy dose, 2 
hours after the application of the first dose, in the middle of the radiotherapy 
cycle, within 2 hours after the last received radiotherapy dose, and at 6 and 12 
months after radiotherapy. In most participants, the highest level of primary 
DNA damage was after the first radiation dose. Later on, the levels of primary 
DNA damage, as recorded by the comet assay, slightly diminished. The 
frequency of structural chromosome aberrations and micronuclei in lymphocytes 
gradually increased during the radiation cycle and mostly did not return to pre­
therapy values.
6.1.1.4 GammaH2AX as a biomarker for DNA damage
A more recent technique that has been used to quantify radiation induced DNA 
breaks is measurement of gammaH2AX (Rogakou, Pilch et al. 1998; Rogakou, 
Boon et al. 1999; Rothkamm and Lobrich 2002; Kuhne, Riballo et al. 2004).
H2AX is one of the genes coding for the histone H2A and is involved in 
maintaining the structure of DNA. After DSB induction, an early cellular 
response is the rapid phosphorylation of H2AX at serine 139 to become 
gammaH2AX or yH2AX, forming a focus at the DSB site. H2AX phosphorylation 
occurs at sites of chromatin structural change and is involved in recruitment of 
repair proteins. ;
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Antibody techniques can be used to detect gammaH2AX foci in mammalian and 
other cells(Rogakou, Boon et al. 1999). Nuclear foci of gammaH2AX appear 
within one minute of exposure to ionising radiation, peak at 30 minutes after 
exposure and fall gradually over a period of hours.
Radiation doses as low as ImGy lead to the formation of gammaH2AX foci and 
yields increase linearly with doses up to 100Gy(Rothkamm and Lobrich 2003). 
DSB repair results in a fall in the number of foci, therefore, residual foci above 
baseline levels can represent residual DNA damage.
In the context of diagnostic imaging, an increase in DNA damage in leukocytes 
by a factor of 10 above baseline 5 minutes after whole body CT scanning was 
found, with an increase from 0.06 foci/cell + 0.02 to 0.52 foci/cell + 0.02. Repair 
was suggested by a reduction 5 to 30 minutes after irradiation. In addition, 
gammaH2AX levels were lower in patients undergoing chest CT compared to 
whole body scans, suggesting that gammaH2AX foci levels may reflect levels of 
radiation exposure (Rothkamm, Balroop et al. 2007).
A relationship between the number of DSBs and length of body exposed in CT
examinations as well as repair (assessed by foci loss) was also reported by
Lobrich et al (Lobrich 2005), with the rate of foci loss among individuals being
similar, despite the different doses received. In addition, the group found that
healthy individuals repair gammaH2AX DSBs to background levels.
More recently, Geisel et al (Geisel, Heverhagen et al. 2008) used gammaH2AX
foci formation to demonstrate DNA DSBs after percutaneous transluminal
angioplasty (PTA) and CT. The study showed DSB repair capacity is
compromised in patients who undergo PTA of lower limb arteries. Blood
samples were taken before the first exposure to ionizing radiation and 5
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minutes, 1 hour, 6 hours, and 24 hours after the last exposure. After CT there 
was an increase in number of gammaH2AX foci, which returned to background 
levels within 24 hours. It also increased by factors of 4.08-20.67 5 minutes after 
PTA compared with mean numbers of foci before PTA. Mean number of foci at 
24 hours (0.07 focus per cell) was significantly higher than mean number of foci 
in cell background (0.04 focus per cell, P < .05).
So far, the majority of studies assessing radiation effect on gammaH2AX have 
been in vitro. GammaH2AX has been used to detect DNA damage in vivo after 
irradiation in the setting of diagnostic CT and therapeutic PTA, as described 
above, but not yet after a fractionated course of radical RT. The only published 
study assessing therapeutic irradiation effects on DNA determined damage with 
comet assay, a less sensitive technique compared to gammaH2AX (Gamulin, 
Kopjar et al. 2008).
Measurement of gammaH2AX DSBs could be useful as a biological dosimeter 
for evaluating whole body radiation exposure with different radiotherapy 
techniques. Given its sensitivity at even low radiation doses, and the 
reproducibility of the technique, this technique has been employed to 
investigate biological damage arising from using different energies for IMRT.
The baseline gamma H2AX levels are shown below in Table 6.1.
Table 6.1 Mean baseline (pre radiation/intervention) gamma H2AX level 
from published data, at the start of this thesis.
Study Baseline gammaH2AX foci/ceil
Rothkamm(Rothkamm, Balroop et al. 2007) 0.06
Geisel(Geisel, Heverhagen et al. 2008) 0.04 .
Sak(Sak, Grehl et al. 2009) 0 11
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6.1.1.5 Physical dosimetry issues around IMRT 
IMRT requires an increase in beam-on time compared to conventional 
radiotherapy. Verellen et al showed that with IMRT (tomotherapy) an average 
4492 MUs were required, compared to 458 MUs with conventional RT which 
translates in larger whole-body equivalent doses per MU (Table 6.2). (Verellen 
and Vanhavere 1999)
Table 6.2 Estimates of photon contribution to the whole-body equivalent 
dose per MU obtained from TLD measurements(Verellen and Vanhavere 
1999).
Hp(10)conv (mSv/MU) Hp(1 0) im rt  (mSv/MU)
Head 1.05x10^ 2 73x10-^
Sternum 1.18x10’^ 1.55x10'^
Gonads 0.17x10’^ 0.31x10'^
Followill et al obtained neutron dose equivalent estimates and measured 
scattered X-ray dose and also showed an increase in estimated total whole- 
body dose equivalent (mSv), from 67mSv with conventional RT to 190mSv with 
IMRT with a 6MV beam delivering 70Gy at the isocentre (Followill, Geis et al. 
1997)
Whole-body equivalent doses for patients having RT treatments, however, vary 
considerably and depend not only on treatment technique, but also on linear 
accelerator design, treatment set-up and beam energy. Thermo-Luminescent 
Dosimeter (TLD) measurements have been performed in an Alderson Radiation 
Therapy (Rando) phantom for both step-and-shoot and dynamic IMRT
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deliveries for energies of 6 to 18 MV photons (Verellen and Vanhavere 1999; 
Kry, Salehpour et al. 2005; Howell, Hertel et al. 2006). Howell et al reported an 
effective dose to the out-of-field organs of 0.0543Sv per Gy and 0.0554Sv per 
Gy for 6 and 18 MV respectively. Stenekeret al concluded that using 15MV 
IMRT in head and neck tumours reduces the total dose delivered to normal 
tissues in comparison with 6MV, even taking into account additional scatter 
radiation and neutron contamination (Steneker, Lomax et al. 2006).
Neutron production is known to increase at energies above 10MV. Kry et al 
found, for step-and-shoot IMRT, neutron equivalent doses that were 
independent of distance, decreased with increasing depth and were a 
significant contributor to out-of-field dose equivalent for beam energies >15MV 
(Kry, Salehpour et al. 2005). Howell et al(Howell, Hertel et al. 2006) calculated 
effective doses from 6, 15 and 18MV conventional and IMRT plans and 
compared neutron contribution for 15MV and 18MV. The effective dose and 
neutron contribution increased with beam energy, there was no neutron 
contribution reported at 6MV. Measurements performed for 18MV using Cr-39® 
track etch detectors calculated a neutron equivalent dose range between 2 -  
6mSv per photon Gy delivered (Reft, Runkel-Muller et al. 2006). The whole body 
neutron dose equivalent was felt to be less than 50mSv for the whole treatment 
for 4 different types of 15MV IMRT treatments(Becker, Brunckhorst et al. 2008). 
Interestingly, Verellen et al also found that in their IMRT treatments for 18MV 
there was some neutron contribution, whereas there was none in the 
conventional treatments (Verellen and Vanhavere 1999). However, for energies 
less than 10MV, neutron contribution is very small and considered to be 
negligible.
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In vivo measurements, like those done in the Verellen study, neglected the 
photon contribution from the irradiated volume (Verellen and Vanhavere 1999). 
Mutic et al showed that the internal scatter dose becomes negligible relative to 
the leakage dose beyond 20cm from the edge of the target in phantom studies, 
and internal scatter should be similar for IMRT and conventional treatments 
(Mutic and Low 1998). Woo et al showed a large variation in scattered dose 
measured at various points that depended mainly on the distance from the field 
edge (Woo, Pignol et al. 2006).
Another parameter that can be measured is the peripheral dose (PD: measured 
at a specified distance from the beam central axis), which is increased with 
IMRT. PD is widely variable, however, depending on the intensity modulated 
delivery technique, complexity of the intensity modulated beam (IMB), linear 
accelerator head design, treatment site and X-ray energy (Sharma, Animesh et 
al. 2006). Sharma et al showed that the peripheral dose per MU decreases 
almost exponentially with out-of-field-distance and increases with increasing 
field dimensions for patient specific IMBs (Sharma, Animesh et al. 2006).
6.1.1.6 Risk of second malignancy following therapeutic irradiation
Ionising radiation carries a risk of second malignancy, although this risk is 
deemed to be low. It has been estimated that about 0.45% of new cancers 
registered in the UK in 2007 were related to previous radiotherapy for cancer. 
The most common primary cancers treated with radiotherapy and associated 
with second cancer were breast, prostate and cervix uteri. The most common 
second cancers attributable to radiotherapy were lung cancers, followed by
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oesophageal and female breast cancer. 54% of second cancers associated with 
radiotherapy were in patients over 75(Maddams, Parkin et al. 2011).
Recently, it has been postulated that the higher radiation exposure with IMRT 
coupled with potential improved outcomes related to its dosimetric advantages 
could translate into an increased risk of second malignancy. Assessing the risk 
of second malignancy is difficult as often there are confounding lifestyle and 
even genetic factors. There is some evidence that the cancer incidence 
increases steeply as a function of radiation dose at low doses and then 
plateaus, but does not fall rapidly at high doses because of cell kill (Hall 2006). 
Verellen et al estimated the increased risk of second cancer using the absorbed 
dose to the sternum from Table 6.2(Verellen and Vanhavere 1999). This yielded 
a total of 242mSv for 70Gy delivered conventionally and 1969mSv delivered 
with IMRT, which translated into a probability coefficient increase for cancer 
from 1.2x10-2 for conventional RT to 9.9x10-2 for IMRT (Verellen and 
Vanhavere 1999). Kry et al also evaluated the risk of fatal second malignancy 
with IMRT, with an estimated risk for 6MV plans of 2.9% with a Varian linear 
accelerator and 3.7% for treatment with the Siemens accelerator, as well as 
using 15-MV X-rays: 3.4% (Varian) and 4.0% (Siemens) (Kry, Salehpour et al. 
2005).
The estimated risks of fatal radiation induced malignancy after various types of 
prostate RT are summarised below in Table 6.3(Hall and Wuu 2003; Kry, 
Salehpour et al. 2005; Hall 2006):
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Table 6.3 Estimated risk of fatal radiation-induced malignancies after RT 
for prostate cancer (%).
Type of radiation Estimated risk 
(%)
Hail and Wuu (Hall Conventional 6MV 1.5
and Wuu 2003) IMRT 6MV 3.0
Kry et al (Kry, Conventional ISMVVarian 1.7
Salehpour et al. 2005) IMRT 6MV Varian 2.9
IMRT 6MV Siemens 3.7
IMRT 10MV Varian 2.1
IMRT 15MV Varian 3.4
IMRT 15MV Siemens 4.0
IMRT 18MV Varian 5.1
Hall, 2006:
It has been suggested that overall, compared with 3D-CRT, IMRT may double
the incidence of solid cancers in long-term survivors because of a combination
of the increase in MUs and the changed dose distribution (Hall and Wuu 2003;
Hall 2006). Interestingly, using Monte Carlo simulations, a doubling in the
induced cancer risk for prostate cancer patients was found with IMRT versus
3D-CRT, although this risk was not related to increases in MUs (Stathakis, Li et
ai. 2007). There is as yet no epidemiological data for radiation induced
malignancy in patients with prostate cancer who received treatment with IMRT.
A modest increase in second malignancies (1 in 70 patients undergoing
radiation and surviving more than 10 years) was reported with 3D-CRT with
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most common sites for secondary cancers being the bladder and rectum 
(Bostrom and Soloway 2007).
6.1.1.7 Effect of beam energy in IMRT treatments 
Common photon energies available for RT delivery are 6, 10, 15 and 18 MV. 
The energy used currently for all IMRT plans at most centres is 6MV but there is 
considerable interest to consider the use of higher energy beams in deep 
seated tumours due to potential dosimetric improvements.
More recently, the effect of 6MV and 15MV prostate IMRT on theoretical risk of 
second malignancy was investigated by Hussein at al(Hussein, Aldridge et al. 
2012).
The average number of MUs delivered per prescribed Gy of photons for 
different energies in this group of patients is shown in Table 6.4.
Table 6.4 Average number of monitor units delivered per prescribed 
photon Gy(Hussein, Aldridge et al. 2012)
Energy (MV) Average MU/
prescribed photon Gy
6 351 +/-17
15 294+/- 12
TLD measurements for both energies, and polyallyl-diglycol-carbonate (PADC) 
neutron measurements for 15MV were used to estimate second cancer risk in 
out of field organs as well as dose^volume parameters for rectum, bladder and 
prostate. There was found to be a small increased fatal cancer risk with 6MV. 
Dose-volume parameters were superior for rectal and bladder sparing at less
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than 70Gy for 15MV, however, the reverse was seen at greater than 70Gy with 
an associated raised rectal NTCP of 3.6% compared with 3.0% for 6MV. It was 
felt that the neutron equivalent dose contributed to 2% of the photon effective 
dose at 15MV.
6.1.1.8 Summary
Recent advances in fractionated external beam radiation therapy have allowed 
us to deliver radiation doses that conform more tightly to the tumour volume 
allowing more normal tissue to be spared for the same tumour coverage. The 
steeper dose gradients associated with these treatments make it increasingly 
important to ensure the precise position of both the patient and the internal 
organs. This increased accuracy of radiotherapy will be potentially associated 
with increases in local tumour control, reductions in the incidence and severity 
of radiation related side effects, and facilitate the development of more efficient 
shorter schedules(Khoo and Dearnaley 2008).
Verification protocols add an imaging dose to an already high level of 
therapeutic radiation which has long been regarded as negligible. More 
intensive IG RT procedures require, however, a more careful evaluation of the 
therapeutic and imaging doses and suggest the possibility of optimizing rather 
than simply minimizing the imaging dose in order to design image guidance 
protocols that are as effective and efficient as possible(Murphy, Balter et al. 
2007). This is in keeping within the “ALARA” radiation safety principle where the 
radiation dose is kept “As Low As Reasonably Achievable”.
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In addition, those patients with high risk disease are sometimes offered 
prophylactic irradiation to the pelvic nodes(Lawton, DeSilvio et al. 2007; Warde, 
Mason et al. 2011) in order to potentially improve PSA control and survival.
As such, factors such as the volume of tissue irradiated (prostate only vs 
prostate and pelvic nodes) and dose per fraction (standard 2Gy per fraction vs 
hypofractionation) will impact on the potential risk of second malignancy.
In addition, RT planning techniques are continuing to be refined in order to 
generate optimised plans. The use of high energy beams is standard in 3DCRT 
of deep seated tumours. However, its use is uncertain for IMRT, despite the 
potential for improved dosimetry. The potential increased risk of second 
malignancy may be particularly relevant, given the increasing life expectancy of 
patients. The work presented in this chapter is an exploratory evaluation of 
second cancer risk, using both biological and physical dosimetry to assess the 
impact of volume of irradiated tissue, dose per fraction and beam energy.
At the time of the study design, there was evidence that gammaH2AX increased 
linearly with radiation dose, and was a straightforward method of quantifying 
DNA damage. In addition, there was limited published work on in vivo 
radiotherapy effects.
6.1.2 Objectives of the study
The hypothesis tested in this section is that second malignancy risk varies with 
the prostate radiotherapy technique and beam energy.
The aim of the project was to quantify and correlate biological and physical 
effects of IMRT of varying energies as demonstrated by gammaH2AX formation 
with measurements from TLD readings.
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6.2 Materials and methods
6.2.1 Patient population
A protocol was written for a study entitled ‘DNA damage in patients receiving 
Intensity Modulated Radiotherapy’. This was submitted electronically to the 
Integrated Research Application System (IRAS). This was presented to and 
subsequently approved by the Ethics Committee of the Royal Surrey County 
Hospital in March 2009. The protocol was also submitted and presented to the 
Royal Surrey County Hospital Research and Development Department, with 
approval in April 2009. Patients were enrolled between May 2009 and June 
2010.
All patients included in this study had histologically confirmed prostate cancer. 
They were treated according to institutional protocol. This included patients 
entered into the CHHiP study(Khoo and Dearnaley 2008). Doses and treatment 
techniques are displayed in Table 6.5 below. We intended to recruit 5 patients 
per group.
Table 6.5 Radiotherapy doses and technique received by study patients.
Dose
(Gy)
No. of 
fractions
Course
length
Radiotherapy
technique
Energy
(MV) Target
74 37 LC 3DRT 6. 15 Prostate
74 37 LC IMRT 6 Prostate
57-60 19-20 SC IMRT 6 Prostate
57-60 19-20 SC IMRT 15 Prostate
74 37 LC IMRT 6 P+P
LC=long course, SC=short course, P+P=prostate and pelvis
The decisions on indications for radiotherapy were made clinically and not
influenced by entry into the study. All patients gave written consent for venous
blood samples to be taken and for the use of beam energies other than 6MV.
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6.2.2 Radiotherapy technique
All patients underwent a planning radiotherapy Computed Tomography scan for 
planning purposes. Patients who had prostate only radiotherapy had the 
prostate +/- seminal vesicles irradiated with a margin. Those patients treated 
within CHHiP had their prostate +/- seminal vesicle volumes defined according 
to trial protocol.
Patients who had pelvic radiotherapy also had pelvic nodes in the volume 
(common iliac, external iliac and internal iliac)
Plans were produced with the Varian Eclipse planning system. Patients 
received 74Gy in 37 fractions to the prostate, 55Gy in 37 fractions to involved 
nodes and 50Gy in 37 fractions to prophylactic node according to their clinical 
indication.
6.2.3 Blood sample collection
Venous blood samples were taken before, during and after radiotherapy. 
Samples were taken on the day of the planning CT, immediately prior to, and at 
exactly 30 minutes, after completion of the planning CT and these blood 
samples were labelled CTpre and CTpost respectively. Pre-radiotherapy and post­
radiotherapy samples were generally termed RTpre and RTpost and taken on the 
day of and immediately prior to radiotherapy delivery and 30 minutes post­
irradiation.
Pre-radiotherapy and post-radiotherapy blood samples were taken at Fraction 1 
(F1), Fraction 2 (F2), and weekly thereafter till completion and a final sample 
was taken 10 weeks from the start of RT. However, due to time constraints, this 
had to be changed after 7 patients to F I, F2, mid treatment fraction (Mid), end
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of RT fraction (End) and week 10. Table 6.6 shows the schedule of blood 
sampling.
Table 6.6 Patient time points for blood samples. 
Initial schedule
Radiation exposure
CT F1 F2 Week 1 up to week 8 of RT Week 10
CTpre F1pre F2pre WkOpre
Blood sample taken CTpost F 1 Dost F2post Wk Hpost Week 10
Final schedule
Radiation exposure
CT F1 F2 Mid Final Week 10
CTpre F1pre F2pre Midpre Finalpre
Blood sample taken CT post F 1 Dost F2D0St Midpost FInalpost Week 10
Each pair of samples was transferred to the laboratory immediately after CTpost 
or RTpost was obtained.
6.2.4 Laboratory techniques
6 2.4.1 Immunocytochemical staining 
The protocol was an adaptation of one used by Rothkamm et al(Rothkamm, 
Balroop et al. 2007) who analysed gammaH2AX changes with CT and was 
discussed in the introduction. One difference was the use of dedicated Sodium 
Citrate/Ficoll containing bottles for lymphocyte separation in this study. These 
bottles have been developed recently and allow for more rapid lymphocyte 
separation.
Four mL of venous blood was collected in Sodium Citrate/FicOll containing
bottles (BD Vacutainer CRT; NJ, NY) and inverted 8 times. Blood samples were
centrifuged at 1600g for 20 minutes to separate lymphocytes. The serum was
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pipetted off and discarded and the remaining lymphocyte layer was extracted 
and added to 4mL phosphate-buffered saline (PBS). This was centrifuged at 
250g for 10 minutes. The supernatant was discarded and the remaining pellet 
was resuspended in 100 uL of PBS. 20uL of the lymphocyte suspension was 
pipetted onto a slide and this was spread and air-dried. At the start of thé study, 
2 slides were generated per blood sample. After the recruitment of 12 patients, 
it was decided to switch to 3 slides per sample to allow the standard error of the 
mean to be calculated. Slide fixation was for 10 minutes with lOOuL 3.7% 
formalin at room temperature, 10 minutes 100% methanol and 1 minute 100% 
acetone (both -20°C). Cells were washed in PBS with 2% bovine serum albumin 
(BSA) for 2 minutes. Cells were then incubated at 4°C overnight with 40uL 
1:300 mouse anti-gammaH2AX antibody (clone JBW301, Upstate; 
Charlottesville, VA). The following day, cells were washed in PBS with 2% BSA 
for 2 minutes, then incubated with 80uL 1:500 Alexa Fluor 488-conjugated goat 
antimouse secondary antibody (Invitrogen, Paisley, UK) for 1 hour at room 
temperature. Cells were washed in PBS with 2% BSA for 2 minutes, and 
samples were then mounted with DAPI-containing mounting medium (Vector 
Laboratories, Burlingame, CA).
There was a ‘needle to slide fixation’ time of 45 minutes (time from phlebotomy 
to start of fixation process, including the time in between 2 centrifugations and 
pipetting onto slides).
6.2.4 2 Quantification of DSB 
Fluorescent images were visualised and captured using a confocal microscope. 
Image capture took place using a Leica TCS SPE confocal microscope at
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University College London (UCL) through a collaboration with Dr Susan Short. 
All slides included in the analysis were evaluated with the same microscope at 
UCL.
An objective magnification of x63 was used. There was sequential scanning of 2 
emission channels, 488 and 460nm. For quantitative analysis, cell counting was 
performed by eye by the student at a later point using Image J, an image 
processing programme(Collins 2007). An evaluation of intraobserver variability 
was carried out by assessing 10 images on 10 separate occasions. Only cells 
with lymphocyte-like morphology were counted. At least 100 cells per slide, and 
between 1-3 slides per sample, were counted. In the confocal microscopy 
image (Figure 6.1) below, 3 lymphocytes (blue) are visualised and there are 2 
cells with one gammaH2AX focus (green) each.
Figure 6.1 Lymphocytes stained for gammaH2AX viewed using a confocal 
microscope.
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6.2.6 Physical measurements
Physical measurements were carried out using TLDs placed in a Rando 
phantom.
TLD-100 (Thermo Fisher Scientific Inc, Waltham, MA) were only used for the 
6MV plans because of their over-responsiveness to higher energies and 
subsequent tendency to overestimate out of field dose. TLD-700 were used for
the 15MV plans because they do not respond to neutrons and are more 
accurate at measuring out of field dose at higher beam energies. (Kry, Price et 
al. 2007)
Prior to the first measurement, the TLDs were annealed in a dedicated oven. 
TLDs were read using a QADOS Harshaw 5500 reader. On subsequent 
measurements, TLDs in the high dose/treatment regions were not reused until 
they were re-annealed. Between two to four TLDs were loaded per slice, and 
this was done for every slice less than 35cm from the treated volume, then 
alternate slices were loaded at distances greater than 35 cm.
Verification plans from the IMRT plans of the study patients were created and 
applied to a planning CT of the phantom. Adjustments were made so that the 
isocentre was in the centre of the PTV, then a fraction was delivered to the 
phantom.
TLD measurements were used to calculate out-of-field doses. In order to 
estimate doses received by out of field organs, the planning CT of the phantom 
was contoured by a physicist for brain, salivary glands, spinal cord, thyroid, 
lungs, heart, oesophagus, spleen, stomach, liver, kidneys, colon, small 
intestine, skin, gonads and red bone marrow.
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The organs’ corresponding tissue weighting factors, from International 
Commission on Radiological Protection 103(ICRP 2007), are shown in Table
6.7 below, and were then used to calculate effective dose and to estimate 40 
year post exposure and age-corrected lifetime risks(Muirhead 1993) in Table 
6 .8 .
Table 6.7 Recommended tissue weighting factors(ICRP 2007).
Tissue
Tissue weighting factor, 
wT
Sum of wT 
values
Bone-marrow (red), colon, lung, 
stomach, breast, remainder tissues^
0.12 0.72
Gonads 0.08 0.08
Bladder, oesophagus, liver, thyroid 
Bone surface, brain, salivary glands,
0.04 0.16
skin 0.01 0.04
T otal 1.00
^Remainder tissues: Adrenals, extrathoracic (ET) region, gall bladder, heart, 
kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate, small 
intestine, spleen, thymus, uterus/cervix.
Table 6.8 Estimates of radiation-induced fatal cancer in a UK population of 
both sexes according to age at exposure(Muirhead 1993).
Age at exposure (years) Deaths (10'  ^Sv"")
Risk up to 40 years after 
exposure
Lifetime
projection
30-39 2.8 4.5
40-49 3.8 4.2
50-59 4.0 4.0
60-69 3.1 3.1
70-79 1.6 1.6
80+ 0.75 0.75
Neutron measurements were not carried out.
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6.2.6 Statistical analysis
Descriptive statistics were used to define the biological and physical data. The 
mean, standard deviation (SD) and standard error of the mean (SEM) were 
calculated for yH2AX foci levels and TLD data.
Foci levels at baseline (CTpre) and week 10 were compared using paired t test. 
This was to evaluate whether there was any evidence of residual DNA damage 
due to different types of RT.
Repeated measures AN OVA was used to compare results at FI with those at 
F2 and subsequent time points to assess for possible evidence of cumulative 
damage.
Foci levels and physical data between 2 groups, for example, IMRT 6MV vs 
IMRT 15MV, were compared using t test to evaluate whether there was any 
evidence of effect of beam energy or other RT variables.
Foci levels and physical data between all the groups were compared using one­
way AN OVA to assess for possible differences between the groups.
Correlation (Pearson and Spearman) was also used to assess for any 
association between biological data and physical data.
6.2.7 Methodological issues
These were noted in the first half of the recruitment period, and addressed at 
the Mid-Term Assessment, so a number of changes to the study protocol were 
made.
The coordination of blood sampling and processing was labour intensive, 
particularly taking weekly samples during RT. It was anticipated that it would not 
be possible to complete the intended recruitment in the planned timeframe.
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Also, for the initial 7 study patients (3 short course IMRT, 2 3DRT, 1 long course 
IMRT and 1 Prostate and pelvis IMRT), samples were not processed in the 
laboratory immediately and it was felt that some DNA repair may have occurred 
in the interim. Therefore, yH2AX foci levels in those samples may not have 
accurately reflected DNA damage and these slides were not included in the 
analysis.
The initial maximum time between blood sampling and processing was over 2 
hours due to batching of samples. Samples processed >10 minutes from 
acquisition were subsequently discarded due to inaccuracies in gammaH2AX 
estimation. Only samples processed immediately (10 minutes from acquisition) 
were included in the final analysis.
In addition, there was uncertainty regarding the quality of microscopy images 
taken at Surrey University. The slides of the initial 9 patients (the above 7 
patients, plus 2 P+P patients) were analysed there. The first 7 were excluded 
from analysis due to sample processing delay issues and not re-imaged at UCL, 
but the latter 2 had satisfactory sample processing timing and were reanalysed 
at UCL and included in the final analysis.
A decision was made to recruit fewer patients and to abandon weekly blood 
sampling during RT, instead taking samples in the middle and end of RT. It was 
also decided to only include IMRT patients because this technique became the 
standard of care for prostate cancer. It allowed for a homogenous group to be 
evaluated in the final analysis. In total, 7 patients were discarded, and there 
were 20 patients included in the final analysis, as shown in Table 6.9 below.
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Table 6.9 Radiotherapy doses and technique received by patients 
included in final analysis.
Group Dose (Gy) No. of fractions
Course
length
Radiotherapy
technique
Energy
(MV) Target
1 74 37 LC IMRT 6 Prostate
2 57-60 19-20 SC IMRT 6 Prostate
3 57-60 19-20 SC IMRT 15 Prostate
4 74 37 LC IMRT 6 P+P
6.3 Results
6.3.1 Patient characteristics
27 patients were initially entered into the study. 7 were subsequently excluded 
from the final analysis as discussed above. Therefore, all further results were 
collated from 20 all treated with IMRT, with 5 patients per group.
All 10 long course patients received 37F. There were 5 19F and 5 20F short 
course patients.
Mid-RT samples were taken at F10 (median, range 7-16) for short course and 
at F18 (median, range 15-26) for long course. End of treatment samples were 
taken at F I9 (median, range 17-20) for short course and at F36 (median, range 
33-37) for long course.
Failure to obtain samples at the precise mid and end points were due to a 
combination of researcher, patient and treatment unit factors, for example, it 
was not possible to process samples from 2 patients if their radiotherapy slots 
were within 3 hours of one another. 17 patients had samples taken in the 10^  ^
week after the start of RT. Two patients had week 11 and 1 patient had week 12 
samples due to patient availability.
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The radiotherapy doses and technique, blood sample time points and inclusion 
in final analysis for individual patients are shown in Table 6.10 below. Patient 13 
was scheduled for 19F but did not have Finalpre/post at FI 9 due to sampling error. 
A Finalpre sample was taken the following day as a substitute since this would
have been equivalent to Finalpre for a patient scheduled for 20F. It was not 
possible to have a Finalpost sample.
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6.3.2 Biological data
6.3.2.1 Sample Characteristics 
Of the 20 patients, 9 had 2 or more slides created (at the start of the study) and 
11 had 3 slides created per sample to allow calculation of SEM. The sample 
characteristics are shown in Table 6.11 below. At least 100 cells were scored 
per slide and at least 200 cells were scored per sample. Over 300 cells were 
scored for 85.5% of samples, and 90.4% of these were across 3 slides. 
Inadequate samples were those which yielded very few, or no visible 
lymphocytes on the slides. This may have been due to technique failure and 
accounted for 9 1% of samples.
The final analysis was based on results from 198 (90.0%) samples in which at 
least 200 cells from at least 2 slides, or at least 300 cells from 1 slide, were 
scored. This was based on published data scoring 100-200 cells, per 
slide(Klokov, Macphail et al. 2006). Over 60 000 cells were counted overall.
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Table 6.11 Sample characteristics.
Number
of
samples
% of samples
Inclusion for 
analysis
Total
Inadequate samples
220
20 9.1 No
Number with <3 slides, <200 cells 
counted 2 0.9 No
Number with <3 slides, >300 cells 
counted 18 8.2 Yes
Number with <3 slides, 200-300 cells 
counted 10 4.5 Yes
Number with >300 cells counted from 
3 slides 170 77.3 Yes
6.3.2.2 Intraobserver variability 
Foci counting was repeated by the same observer on 10 slides on 10 different 
days. The count results are shown in Table 6.12 below. Cells contained 
between 0-2 foci. The mean number of foci/cell was 0.103 (SD 0.007). There 
was complete agreement on 4/10 images throughout all 10 counting events. For 
the remaining 6/10 images, there was agreement on between 70-90% of the 
counting events, with a maximum difference of 1 foci.
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Table 6.12 Intraobserver variability demonstrated by repeat counting of 10 
images on 10 different days.
Day Total no. of cells Total no. of foci Foci/cell
1 131 15 0.115
2 132 15 0.114
3 131 13 0.099
4 130 14 0.108
5 130 12 0.092
6 130 13 0.100
7 130 13 0.100
8 130 13 0.100
9 130 13 0.100
10 130 13 0.100
Mean
SD
0.103
0.007
Number of cells counted Number of foci counted
Image Mean SD 95% Cl Mean SD 95% 01
1 13.00 0.00 13.00 4.00 0.00 4.00
2 11.00 0.00 11.00 1.10 0.32 0.90-1.30
3 11.00 0.00 11.00 0.20 0.63 0-0.59
4 11.10 0.32 10.90-11.30 2.00 0.47 1.70-2.29
5 14.00 0.00 14.00 2.00 0.00 2.00
6 16.20 0.63 15.81-16.59 1.00 0.00 1.00
7 12.00 0.00 12.00 2.10 0.57 1.75-2.45
8 13.00 0.00 13.00 0.00 0.00 0.00
9 15.00 0.00 15.00 1.00 0.00 1.00
10 14.10 0.32 13.90-14.30 0.00 0.00 0.00
6.3.2.3 Population analysis of gamma H2AX levels
6.3.2.3.1 Baseline levels
For the entire population, the mean baseline gamma H2AX level was 0.030 
(SD=0.009), and at Week 10 was 0.036 (SD=0.012).
6 3.2.3.2 Changes in gamma H2AX levels with irradiation
A statistically significant increase in gammaH2AX levels post-irradiation was
seen at all time points during radiotherapy (paired t test p<0.0001). Mean
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gammaH2AX levels, with error bars representing standard error of the mean, 
are depicted in Figure 6.2.
Figure 6.2 Graph showing mean gammaH2AX foci/cell levels at each time 
point for all 20 patients.
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6.3.2.3.3 Recovery after irradiation
Paired t test for the population was carried out for the following 3 situations-
1. Comparing baseline (CTpre) with F1pre to assess for recovery from the 
planning CT.
2. Comparing F1pre with F2pre to assess for recovery after one fraction. This 
is to be interpreted as a measure of return to baseline approximately 24 
hours after a single radiotherapy fraction.
3. Comparing baseline (CTpre) with corresponding week 10 result to assess 
for recovery from the radiotherapy course.
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There was no significant difference in any of the cases, with p values of 0.151,
0.121 and 0.196 respectively, suggesting a return to baseline levels post­
irradiation.
6.3.2.3.4 Cumulative changes throughout the radiotherapy course 
Data from FI was compared with that of subsequent treatments to assess 
whether there was evidence of increased H2AX changes with RT at certain time 
points. The absolute difference (defined as ‘RTpost minus RTpre’), as well as the 
ratio (defined as ‘RTpost divided by RTpre’), between post-irradiation and pre­
irradiation gammaH2AX levels were calculated and compared. This was done in 
an attempt to compensate for intraobserver variability during the counting 
process.
6.3.2.3.4.1 Changes in absolute difference between post-irradiation 
and pre-irradiation gamma H2AX levels
The population means of absolute difference between post-irradiation and 
pre-irradiation gammaH2AX levels at each time point, were calculated as 
shown in
Table 6.13 below. The mean overall absolute difference between all pre and 
post levels was 0.036. Paired t test did not show statistical significance between 
the absolute difference at FI against the differences at subsequent treatments. 
This indicates that the possible trend of cumulative damage shown by the 
increasing RTpost gam ma H2 AX levels throughout treatment as seen in Figure
6.2 was not statistically significant.
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Table 6.13 Mean differences in mean gammaH2AX foci/cell between post- 
and pre-radiation exposure at 5 time points and p value for paired t test 
comparing FI with subsequent treatments.
Timepoint
Difference
CT
Difference
F1
Difference
F2
Difference
Mid
Difference
Final
Population
Mean 0.039 0.036 0.032 0.035 0.037
Range 0.003-0.070 0,023-0,054 0.004-0.066 0.005-0.052 0.003-0.061
SD 0.020 0.010 0.015 0.016 0.015
p value n/a n/a 0.438 0.797 0.927
6 3.2.3.4.2 Changes in ratio between post-irradiation and pre­
irradiation gamma H2AX levels
The population means of ratio between post: pre-irradiation gammaH2AX levels 
at each time point, were calculated as shown in Table 6.14 below. The mean 
overall ratio between all post and pre levels was 2.0. Paired t test did not show 
statistical significance between the ratio at FI against the ratio at subsequent 
treatments, again supporting a lack of evidence of cumulative damage 
throughout treatment.
Table 6.14 Mean ratios between post:pre radiation gammaH2AX levels at 5 
time points and p value for paired t test comparing FI with subsequent 
treatments.
Time point Ratio CT Ratio F1 Ratio F2 Ratio Mid Ratio Final
Mean 2.6 2.1 1.9 1.9 1.9
Range 1.1-6.4 1.5-3.7 1.1-2.7 1.1-2.8 : 1.1-2,8
SD 1:3 0.6 0:4 0.5 0.4
p value n/a ; n/a 0.222 0.770 0.304
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6.3.2 3.5 Changes at CT compared with subsequent radiotherapy 
The magnitude of gammaH2AX changes following planning CT scan were 
compared with those from RT to assess for possible differences compared to 
irradiation. The absolute difference and ratio between CTpost and CTpre were 
compared with those of RTpost and RTpre with a paired t test, and there was no
significant difference, as shown below in Table 6.15.
Table 6.15 p values of paired t test comparing changes in gammaH2AX at
CT to changes with radiotherapy.
Time point
F1 F2 Mid Final
Absolute difference 0.647 0.530 0.840 0.622
P value
Ratio 0.235 0.197 0.251 0.136
6.3.2.4 Group analysis of gamma H2AX levels
The mean number of gammaH2AX foci/cell at all time points (raw data) for each 
group is depicted in Table 6.16 below. It also shows the range, SD and p value 
for paired t test at each time point.
6 3.2.4.1 Changes in gammaH2AX levels with irradiation according 
to group
A statistically significant increase in gammaH2AX levels post-irradiation was 
seen for each group at almost all time points during radiotherapy, except for 
mid-RT measurements in Groups 1 and 2, and final measurement in Group 3. 
This may be explained by the fact that up to 2 of the 5 possible results in those 
groups were unavailable at those time points due to sample failure. Mean 
gammaH2AX levels for each group, with error bars representing standard error 
of the mean, are depicted in Figure 6.3 below.
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6.3.2.4.2 Recovery after irradiation according to group
Paired t test was carried out for the following 2 situations for each of the groups-
1. Comparing F1pre with F2pre to assess for recovery after one fraction. This 
could be interpreted as a measure of return to baseline approximately 24 
hours after a single radiotherapy fraction.
2. Comparing baseline (CTpre) with the corresponding week 10 result to 
assess for recovery from the radiotherapy course.
Paired t test was carried out comparing group means of FI pre with F2pre, and
CTpre with Wk 10, and there was no significant difference between the groups.
There was a trend towards lack of return to baseline levels in the 15MV group
(p=0.110).
Table 6.17 Group mean (SD) baseline CTpre and week 10 gamma H2AX
levels with paired t test.
CTpre Wk 10
P value for paired t test 
within groups
(1) Prostate LC 
6MV 0.035 (0.011) 0.030 (0.013) 0.510
(2) Prostate SC 
6MV 0.025 (0.009) 0.028 (0.010) 0.647
(3) Prostate 80  
15MV 0.028 (0.011) 0.047 (0.007) 0.110
(4) P+P LC 
6MV 0.034 (0.007) 0.041 (o!o12) 0:444
6.3.2 4.3 Cumulative changes throughout the radiotherapy course 
according to group
One-way AN OVA tests were carried out to determine whether there was any 
difference in the absolute difference or ratio between the 4 groups. No 
significant differences were detected, with f statistic=1.03 and 1.44, p=0.414 
and p=0.281 respectively.
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Paired t test comparing absolute difference and ratio at F1 with subsequent 
radiotherapy treatments for each group was carried out, to assess for possible 
evidence of cumulative damage. There is one p value of 0.033 in Group 2 
(prostate SC 6MV) with comparison of absolute difference between F1 and Mid 
treatment. However, there is an outlier value, with a difference of 0.005 foci/cell 
between Midpre and Midpost for one patient. Otherwise, there were no statistically 
significant differences comparing F1 with subsequent time points for any group.
6.3.2.5 Effects of different radiotherapy variables
As seen above, one way AN OVA comparing the 4 groups did not show any 
significant difference in either absolute difference (f statistic=1.03, p=0.414) or 
ratio (f statistic=1.44, p=0.281) between the groups.
Below, the independent t test was used to compare between pairs of groups to 
assess for the following-
1. Dose per fraction effect (group 1 vs group 2, prostate LC 6MV vs 
prostate SC 6MV)
2. Energy effect (group 2 vs group 3, prostate SC 6MV vs prostate SC 
15MV)
3. Volume effect (group 1 vs group 4, prostate LC 6MV vs prostate + pelvis 
LC 6MV)
6.3.2.5.1 Dose per fraction effect
The absolute differences and ratios were compared between group 1 (prostate 
LC 6MV) and group 2 (prostate SC 6MV) to assess for any effect of dose per 
fraction on the amount of DNA damage detected. There was an isolated 
significant p value of 0.011 when comparing F2post: F2pre. The reason for this is 
uncertain and will be discussed later.
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6.3.2.5.2 Energy effect
The absolute differences and ratios were compared between group 2 (prostate 
SC 6MV) with group 3 (prostate SC 15MV) to assess for any effect of energy on 
the amount of DNA damage detected. There was no significant difference seen 
when comparing the 2 groups.
6.3.2.5.3 Volume effect
The absolute differences and ratios were compared between group 1 (prostate 
LC 6MV) with group 4 (prostate and pelvis 6MV) to assess for any effect of 
treatment volume on the amount of DNA damage detected. There was no 
significant difference seen when comparing the 2 groups.
6.3.3 Physical data
6.3.3.1 TLD dose data
6.3.3.1.1 Individual TLD dose data
TLD measurements were carried out by delivering a plan to a Rando phantom 
loaded with several TLDs per slice. These were placed on alternate slices up to 
35cm from the isocentre as described in the methods. This was carried Out for 
all 20 patients. The population mean TLD measurements and standard error of 
the mean are shown in Table 6.18 below.
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Table 6.18 Population mean TLD readings at various distances from 
isocentre.
Distance from Isocentre (cm) Mean TLD reading SEM
-2.5 2671.47 205.17
0 2533.39 128.86
2.5 1683.02 163.79
5 1070.48 183.56
7.5 455.28 117.77
10 407.99 134.02
12.5 174.35 58.60
15 67.73 14.51
17.5 44.20 7.78
20 38.93 5.45
22.5 27.53 4.55
25 19.43 3.23
27.5 14.13 2.17
30 11.99 1.79
32.5 9.46 1.43
35 8.48 1.24
37.5
40 6.18 0.89
42.5
45 5.96 0.83
47.5
50 3.85 0.45
52 5
55 2.95 0.34
57.5
60 2.71 0.30
62,5
65 2.62 0.35
67.5
70 2.75 0.39
72.5
6.3.3.12 Group TLD dose data 
In Figure 6.4 below, mean TLD doses were plotted according to distance from 
PTV for the population and each of the 4 groups. There is a rapid drop-off of 
dose as distance from PTV increases! The dose is slightly lower for 15MV
183
compared to 6MV with identical fraction size of 3Gy. There is increased dose at 
further distances from PTV with prostate and node treatment, reflecting the 
increased treated volume. However, doses distant to PTV were similar between 
the groups.
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6.3.3.2 Total of organ equivalent doses
6.3.3.2.1 Individual organ equivalent doses 
Average organ doses for each patient were calculated.
An example of organ equivalent doses for one patient, and the summed total of 
organ equivalent doses, is displayed below in Table 6.19. This was carried out 
for all 20 patients.
Table 6.19 Individual and total organ equivalent doses for one patient.
Organ Organ Equivalent dose (Gy/mSv)
Thyroid 0.007
Lungs 0.102
Oesophagus 0.036
Stomach 0.254
Liver 0.047
Colon 0.427
Skin 0.038
Leukaemia 0.466
Bladder 0.271
Rectum 0.024
Total of organ equivalent doses 1.672
A summary of physical parameters recorded, as well as the calculated risks, for 
the 4 groups and population is displayed below in Table 6.20. These will be 
outlined in more detail below.
One-way AN OVA test was carried out to determine whether there was any 
difference in the total organ equivalent doses, effective doses, monitor units or 
age-specific risks between the 4 groups. Significant differences between the 
means of the four groups were detected, with f statistic=4.78, p=0.015, f
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statistic=5.95, p=0.0063, f statistic=9.32, p=0.0008 and f statistic=4.54, 
p=0.0174 respectively.
Table 6.20 Total organ equivalent doses, effective dose, monitor units, 
age-specific risk for group and population.
Total of 
Organ 
Equivalent 
doses 
(Gy/mSv)
Effective 
dose (Sv) MU
Age at 
exposure 
(years)
Age-
specific
risk(%)
(1)
Prostate 
LC 6MV
Mean
Range
SD
3.332
1.494-5.105
1.714
2.49
0.964-3.920
1.058
690.8
550-803
100.4
72.9
70-76
3
1.634
0.569-3.768
1.306
(2)
Prostate 
SC 6MV
Mean
Range
SD
2.021
1.826-2.333
0.193
2.373
1.359-4.417
1.262
926.8
765-
1176
151.2
70.5
60-75
6.2
1.052
0.696-1.504
0.376
(3)
Prostate 
SC15MV
Mean
Range
SD
1.958
0.893-3.276
1.056
1.458 
0.891-1.729 
0.332
727.8
660-767
45.4
70
63-76
5.3
1.016
0.472-2.130
0.692
(4) P+P LC Mean
Range
SD
4.385
3.558-6.451
1.247
3.85
2.899-4.602
0.666
1159.8 
920- : 
1539 
254.3
63
53-75
8.2
3.456
1.369-6.142
1.86
Population Mean
Range
SD
2.924
0.893-6.451
1.501
2.543
0.891-4.602 
1.207
876.3 
550- 
1539 
240.1
69.1
53-76
6.7
1.789
0.472-6.142
1.502
6.3.3.3 Effects of different radiotherapy variables 
As seen above, there were significant differences when comparing the 4 groups 
using one way ANOVA.
Below, the independent t test was used to compare between pairs of groups to 
assess for the following-
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1. Dose per fraction effect (group 1 vs group 2, prostate LC 6MV vs 
prostate SC 6MV).
2. Energy effect (group 2 vs group 3, prostate SC 6MV vs prostate SC 
15MV).
3. Volume effect (group 1 vs group 4, prostate LC 6MV vs prostate + pelvis 
LC 6MV).
6.3.3.3.1 Dose effect
The total of organ equivalent doses, effective doses, monitor units and age- 
specific risks were compared between group 1 (prostate LC 6MV) and group 2 
(prostate SC 6MV) to assess for any effect of dose per fraction. There was an 
isolated significant p value of 0.02 when comparing monitor units per fraction, 
as expected, given the different dose per fraction. There was no significant 
difference once MU per Gy were compared.
6.3.3.3.2 Energy effect
The above variables were compared between group 2 (prostate SC 6MV) and
group 3 (prostate SC 15MV) to assess for any effect of energy. There was an 
isolated significant p value of 0.023 when comparing monitor units, which could 
be related to increased dose at depth for 15MV.
6.3.3.3.3 Volume effect
The above variables were compared between group 1 (prostate LC 6MV) and
group 4 (prostate and pelvis LC 6MV) to assess for any effect of treatment 
volume, and shown in Table 6.21 below. There were significant p values of 
0.041 and 0.005 with effective dose and monitor units, respectively. This may 
translate into a trend towards increased age-specific risk (p=0.111).
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Table 6.21 Mean total of organ equivalent doses, effective doses, monitor 
units and age-specific risks for group 1 (prostate LC 6MV) and group 4 
(prostate and pelvis LC 6MV), and p values of independent t test 
comparing 2 groups.
Variable
Group RT site
Total organ 
equivalent doses 
(Gy/mSv)
Effective 
dose (Sv) MU/F
Age-specific 
risk (%)
1 Prostate 
74Gy 6MV 3.332 2.49 690.8 1.634
4 P+P 74Gy 
6MV 4.385 3.85 1159.8 3.456
p value for 
independent t test 
comparing 2 groups 0.299 0.041 0.005 0.111
6.3.4 Association of biological data and physical data
The biological variables (absolute differences and ratios for radiotherapy time 
points) were tested for correlation with physical variables (total of organ 
equivalent doses, effective doses, monitor units and age-specific risks), as well 
as patient age, using Pearson and Spearman correlation. There were 2 
instances of statistically significant correlation, but the clinical significance is 
doubtful.
There was a weak positive correlation between the difference between post and 
pre-final treatment gamma H2AX level and effective dose (r=0.48, 0.46, 
01=0.03-0.77, 0.01-0.76, p=0.038, 0.048 for Pearson and Spearman
respectively), as shown in Figure 6.5 below. There was a weak negative 
correlation between the ratio of FI post: FI pre gamma FI2AX level and age-
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specific risk (r=-0.46, -0.57, CI=-0.78-0.04, -0.83- -0.11, p=0.070, 0.020 for 
Pearson and Spearman respectively), as shown in Figure 6.6 below.
Figure 6.5 Relationship between difference in gamma H2AX level at final 
fraction and effective dose.
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6.4 Discussion
6.4.1 Biological data
Since the protocol was devised, new studies have reported on DNA damage 
with radiotherapy. Some are of similar design, and are outlined below. In 
addition, some studies have illustrated possible future directions for this work to 
take and these are also discussed.
6.4.1.1 Baseline results
There was some variation in baseline gammaH2AX level between this study
(0.03) and published data (range 0.04-0.23) and this is summarised in Table
6.22 below. In this study, the foci were scored fairly consistently, as
demonstrated by the relatively narrow confidence intervals found in the
intraobserver variability test. Therefore, the variation could be due to differing
processing, image acquisition and scoring techniques between studies, as well
as different patient study populations and volumes of tissue irradiated.
In this study, the laboratory protocol was identical to that of the UCL group,by
Sivabalasingham et al (unpublished data)(Sivabalasingham S. 2010) but it was
applied to a different study population. Their patients received a course of IMRT
for brain tumours. The initial training in foci counting took place at UCL, and all
samples included in the final analysis were imaged there. Their baseline level
was 0.23 foci/cell and the reason for the difference with our study remains
uncertain, but it is likely related to the different study populations and may have
to do with differences in blood flow to the different areas irradiated.
Our protocol was an adaptation of one used by Rothkamm et al(Rothkamm,
BalrOop et al. 2007) which had a baseline level of 0.06 foci/cell. This group
analysed gammaH2AX changes with CT, which was also a component of this
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study and the Sivabalasingham study. They found an 8-10-fold increase in 
gammaH2AX at 5 minutes after CT, which halved at 30 minutes, compared to a 
mean of 2.6-fold found 30 minutes after CT in this study (unpublished data). 
One difference in protocol was the use of Ficoll density-gradient centrifugation 
with Flistopaque 1077 for lymphocyte separation in Rothkamm’s technique, 
whereas the other 2 studies used dedicated Sodium Citrate/Ficoll containing 
bottles. These bottles were a more recent development and allowed for more 
rapid turnover of samples.
A study by Fleckenstein et al(Fleckenstein, Kuhne et al. 2010) examined 31 
patients receiving RT or chemoRT for head and neck cancer and correlated 
results with oral mucositis. The baseline was 0.07 foci/cell which is 
approximately double that found in this study. 5466 lymphocytes were counted. 
The initial processing of blood samples was different in this study, using heparin 
bottles followed by dilution with RPMI. The remainder of the method was 
similar.
Sak et al(Sak, Grehl et al. 2009) examined 28 patients receiving chemoRT with
cisplatin for intrathoracic, pelvic and head and neck cancers and the baseline
was 0.11 foci/cell. This technique also used heparin bottles, and the
centrifugation took 20 minutes as opposed to 30 minutes in this study.
A study that evaluated a similar population was by Zwicker et al,(Zwicker,
Swartman et al. 2011) who examined 40 prostate cancer patients receiving
either 3D conformai RT (72Gy/36#, 18MV) or IMRT (76Gy/35#, 6MV).Their
baseline was 0.06 foci/cell. The laboratory technique was similar to ours, apart
from using a Cytospin centrifuge to spread lymphocytes on a slide and the use
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of a permeabilisation buffer to allow antibody to enter the nucleus. The latter 
component was not used in other published studies.
Table 6.22 Mean baseline (pre radiation/intervention) gamma H2AX level 
from own and published data.
study Baseline gammaH2AX foci/ceil
Own 0.03
Rothkamm(Rothkamm, Balroop et al. 2007) 0.06
Geisel(Geisel, Heverhagen et al. 2008) 0.04
Sak(Sak, Grehl et al. 2009) 0.11
Fleckenstein(Fleckenstein, Kuhne et al. 2010) 0.07
Slvabalasingham(Sivabalasingham 8. 2010) 0.23
Zwicker(Zwicker, Swartman et al. 2011) 0.06
6.4.1.2 Changes in population gammaH2AX levels with irradiation 
There was a significant increase in H2AX levels due to radiation in this study, 
with an approximately 2-3 fold increase from baseline levels in all cases and at 
all time points. The magnitude of increase in gammaH2AX post-irradiation was 
similar between the initial CT exposure, and subsequent therapeutic radiation 
exposures, with no significant differences detected when these were compared. 
The cause for this is unclear, since it would have been reasonable to expect a 
larger change with RT, given the associated greater equivalent dose. Also, up 
to 16-fold increases were seen post-RT in some studies(Fleckenstein, Kuhne et 
al; 2010). For this study, the initial CT findings may have been an overestimate, 
with subsequent RT changes a more accurate reflection of damage, but the 
cause of this is uncertain
In the study by Fleckenstein(Fleckenstein, Kuhne et al. 2010), samples were
taken at 30 minutes after the first 2Gy fraction, as per this study, but were also
taken at 2.5h, 5h and 24h. No samples Were taken later on in the course. The
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30 minute sample recorded an increase in H2AX of 13-16 times baseline, and 
the 24h sample recorded an increase of 2-3 times, whereas in this study, there 
was no significant difference between FI pre and F2pre suggesting recovery.
Sak et al(Sak, Grehl et al. 2009) took samples at 30 minutes post radiotherapy. 
However, it is difficult to compare results since the study involved analysis of 
patients receiving cisplatin chemoRT. The group reported a 34% decrease in 
radiation induced gammaH2AX at days 0-3 after cisplatin compared to days 
without cisplatin, but the study did not report on absolute changes post-RT.
In the study by Zwicker(Zwicker, Swartman et al. 2011), post radiation samples 
were taken at 10 minutes after the first fraction only, and these underwent 
lymphocyte separation, then the slide fixation occurred consistently at 2 hours 
from irradiation to allow comparability of samples. Mean H2AX levels were 0.49 
(3DRT) and 0.47 (IMRT), 8-9 times baseline levels.
There may be different reasons for variations at baseline and with radiotherapy.
The differences common to both situations may relate to variation in techniques
or patient population, such as diagnosis, age and radiosensitivity. Additional
reasons for radiotherapy variation include methodological reasons relating to
timing of processing of samples. The needle to slide fixation’ time can involve
transit time from phlebotomy to laboratory, as well as the actual laboratory
process, and was 45 minutes, on average, in this study. This is not directly
stated in most published studies, apart from that of Zwicker(Zwicker, Swartman
et al. 2011) which reported a fixation time of 2 hours after irradiation. DNA
repair may occur during this time, with an estimated halving of induced foci
within 30 minutes of CT from an initial 8-10-fold increase from baseline at 5
194
minutes(Rothkamm, Balroop et al. 2007). The repair was non-linear, therefore 
small differences in timing methodology may result in large differences in the 
number of foci.
There was also unavoidable variation in the time period between blood sample 
analysis and confocal microscopy. This related to practicalities in the conduct of 
the study and having to continue patient recruitment with blood sampling (which 
required having to be in the hospital at specified days and times), sample 
processing in the lab and confocal microscopy at a different institution. This led 
to slides having to be batched for confocal microscopy to allow continuous 
recruitment and blood sampling. All slides in the final analysis were counted 
using the same microscope. Measures were taken to ensure that images were 
acquired and counted consistently. Microscope settings were adjusted to alter 
the brightness and contrast of foci and images were adjusted in Image J, an 
image processing programme, because of variation in staining and possible 
fading over time. Inherent variation in staining necessitated adjustment of 
settings even for freshly made slides.
Despite standardised methodology, there may still be variation in radiotherapy 
factors between studies, for example. RT technique (3DRT, step and shoot or 
dynamic IMRT or arc therapy), dose per fraction, monitor units, treatment 
volume and use of chemotherapy.
6.4.1.3 Changes in group gammaH2AX levels with irradiation 
In order to assess whether there was any difference between the groups, the 
absolute difference, as well as the ratio, between post irradiation and pre 
irradiation levels were calculated and compared. This was done in an attempt to
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compensate for any inaccuracies or inconsistencies due the counting process. It 
was felt to be reasonable to accept there were some differences with published 
data, providing the counting was performed consistently.
A possible cumulative effect may have been detected, with a trend for increased 
post RT values seen in the mean results but there was only an isolated 
significant difference when using paired t test comparing F1 values with 
subsequent values. This was a p value of 0.033 in Group 2 (prostate SC 6MV) 
with comparison of absolute difference between F1 and mid treatment, but this 
may be explained by an outlier value.
There was an isolated significant p value of 0.011 when comparing post:pre 
H2AX ratio of group 1 (prostate LC 6MV) with group 2 (prostate SC 6MV) at #2 
with independent t test. However, this is unlikely to be clinically significant.
There was a trend towards lack of return to baseline in the 15MV group 
(p=0.110) when comparing baseline with week 10 levels. This could be due to 
contribution from neutrons and could be explored in future studies. There has 
been limited in vitro work studying effects of neutrons on gammaH2AX, Kinashi 
et al(Kinashi, Takahashi et al. 2011) examined the effect of boron neutron 
capture reaction on Chinese hamster ovary cells. The effect of neutrons has 
been studied more widely using physical parameters (see next section).
There were limitations in using t test for the statistical analysis because the 
phosphorylation of H2AX foci is relatively rarely, therefore there was a higher 
likelihood of false positive results. These rare events follow a Poisson, 
distribution and it would have been more appropriate to use a dispersion index 
test.
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6.4.1.4 Future directions
This chapter reported on data from a small study with only 5 patients per group, 
and 20 patients in total, therefore results have tended to be descriptive, with 
limited statistical tests.
For future studies, a number of methodological suggestions are proposed 
below.
An automated counting programme would have been a useful method of 
verifying manual counting, and could allow increased throughput of samples in 
future.
Metacyte (http://www.metasvstems-international.com/toxicoloqv). a commercial 
image analysis programme, is able to capture foci at various planes throughout 
the cell and count these automatically.
FociCounter, a freeware programme, has been developed by Jucha et al 
(Jucha, Wegierek-Ciuk et al. 2010), and is available at 
htto://focicounter.sourceforae.net. This automatically counts foci after 
determining threshold settings. Manual marking of foci is also possible; this is 
recommended in cases of possible foci overlap where there is high foci density. 
It can store data in a text file for later analysis. Results were found to be 
reproducible. It was compared with Metacyte and automated flow cytometry and 
strong correlations were found.
An automated fluorescence interpretation system, AKLIDES(R), used pattern 
recognition algorithms to quantify gamma FI2AX foci in irradiated rat cell 
lines(Runge, Fliemann et al. 2012). Manual counting was performed by 5 
observers across 3 laboratories. There was a high inter-laboratory variability of
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38.4%, and there was high correlation between automated counting and visual 
counting (determination coefficient R2=0.889).
This high inter-laboratory variability was demonstrated in the wide range in 
baseline gammaH2AX found during the literature search, therefore a 
standardised technique would be useful for comparison between research 
groups in future.
Automated flow cytometry is another technique that has been used to quantify 
H2AX. This was not assessed here due to concerns about accuracy of foci 
estimation, given the relatively small size of H2AX focus compared to nucleus 
size and the potential difficulty in adequately detecting the foci for accurate 
scoring
This technique was used by Andrievski et al(Andrievski and Wilkins 2009), who 
measured gammaH2AX in different lymphocyte subpopulations following 
irradiation of peripheral blood to 0-1 OGy. Phosphorylation peaked at 1.5 hours 
and returned to baseline at 24 hours. It was felt that there was large inter­
individual variation, which may limit its use as a biological dosimeter.
Flow cytometry was also used by Bourton et al(Bourton, Plowman et al. 2011), 
who assessed H2AX levels in patients who had experienced severe normal 
tissue toxicity following radiotherapy. They were identified via follow up clinics, 
and compared with patients with minimal RT toxicity, as well as healthy 
controls. Blood samples were taken from all patients and irradiated. They found 
a 1.5-2 fold increase in fluorescence with 2Gy irradiation of blood from healthy 
controls. This returned to normal at five hours. Results were similar for patients 
with minimal toxicity. For the severe toxicity patients, the fluorescence
immediately after irradiation was interestingly the lowest of the three groups, but
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there was a lack of return to baseline at 24 hours. Results were comparable to 
those of a patient with ataxia telangiectasia, who was also sampled in the study. 
An automated high-throughput system, RABIT (Rapid Automated Biodosimetry 
Tool), has been developed (Turner, Brenner et al. 2011). This has been 
validated as a method of quantifying H2AX fluorescence via a fingerprick blood 
sample. These other techniques may allow studies to take place on a much 
larger scale.
Another suggested method to validate H2AX levels as a biological dosimeter 
was to separately irradiate a patient’s blood sample alongside analysing blood 
irradiated in vivo. This took place in a number of studies(Rothkamm, Balroop et 
al. 2007; Sak, Grehl et al. 2007; Zwicker, Swartman et al. 2011). This was not 
possible here due to time constraints and lack of availability of linear accelerator 
slots to deliver RT to the blood sample at consistent time points.
Alternative biomarkers of DNA damage could also be considered to look at 
correlation against gammaH2AX, but this was not possible due to time 
constraints. Examples include Rad51, a key protein involved in homologous 
recombination repair(Short, Martindale et al. 2007), and 53BP1, a binding 
protein that undergoes ATM-dependent phosphorylation at sites of 
DSB(Harding, Coackley et al. 2011).
It may have been useful to take a further sample at a later time point, for 
example, 1 year from RT. This may have been a better predictor of residual 
damage and second malignancy risk. However, week 10 results were already 
similar to baseline, and it would have been difficult to detect very small 
differences.
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Individual variations in baseline levels and radiosensitivity, possibly due to age, 
were difficult to detect due to small numbers of patients in the study, as well as 
a limited number of foci counted. However, age-related changes were factored 
into the physical analysis.
6.4.2 Physical data
The prostate and pelvis group were found to have the highest mean total organ 
equivalent doses, effective dose, monitor units and age-specific second cancer 
risk compared to the other groups. There was a significant difference in 
effective dose and MUs when compared with the prostate long course group. 
However, there was no significant difference in age-specific risk (3.456% 
compared with 1.634%, p=0.111). The number of monitor units required for a 
15MV short course plan was significantly lower than for a 6MV short course 
plan, and there was no significant difference of second cancer risk (p=0.922). 
This may . suggest that the use of 15MV fields in IMRT plans could be 
considered in future, as there is no evidence it leads to increased risk.
There was minimal correlation between biological and physical data, and this 
was not likely to be clinically significant. Again, this was limited by small study 
numbers. There was an isolated positive correlation between the difference 
between Finalpre and Finalpost treatment gamma H2AX level and effective dose 
but this did not translate to a correlation with age-specific risk.
The clinical significance of the negative correlation between the ratio of Flpost: 
Flpre gamma H2AX level and age-specific risk is uncertain. It is likely to be a 
spurious result since it does not seem plausible for the ratio of Flpost: Flpre to be 
inversely related to risk.
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Only one other study was seen to attempt biophysical correlation(Zwicker, 
Swartman et al. 2011). In addition to radiotherapy test samples, they also took 
samples from 5 volunteers, which were irradiated externally at 6 dose levels. 
This was used as a calibration line and allowed a dose level to be assigned 
according to the number of foci/cell seen. This was then used to generate a 
dose lymphocyte histogram (DLH), and was compared against the DVH, a 
surrogate of total body dose. DVHs confirmed there was higher low dose 
exposure (<20% prescribed dose) with IMRT compared to 3DRT, but lower 
medium dose exposure (30-90% prescribed dose) with IMRT. H2AX levels in 
3DRT and IMRT patients correlated with physical dose distribution. However, 
they acknowledged a limitation of the study that circulating lymphocytes during 
irradiation may affect the accuracy of using H2AX as a biological dosimeter, 
whereas the DLH was not influenced by body site or blood flow. This was also 
noted by Sak(Sak, Grehl et al. 2009).
Future studies could examine correlation between H2AX levels and PTV 
parameters, for example, volume and D95. The effect of lymphocyte circulation 
could be modelled and included in the correlation.
Another option would be to calculate TCP/NTCP for the various groups and 
correlate with dosimetry and second cancer risk.
IMRT with higher energy photons is associated with a higher neutron
contribution and may therefore have a higher risk of second cancer. Neutron
measurements were carried out for one of the patients in a local pilot study
(unpublished)(Hussein 2008) using polyallyl diglycol carbonate (PADC) track
etch detectors. The neutron equivalent doses ranged between 0.5 -  3.6 mSv
per photon Gy, which is comparable to published data. For a 74 Gy treatment
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the neutron equivalent doses ranged from 37 -  263 mSv. Kry et al(Kry, 
Salehpour et ai. 2009) used Monte Carlo modelling to estimate second cancer 
risk with 6MV and 18MV IMRT. This predicted lower neutron dose equivalents 
than previously calculated. However, it was noted that there was high 
uncertainty in estimating neutron dose equivalents, possibly due to 
discrepancies between this and previous studies’ methods of estimating neutron 
energy, and variation in accounting for depth of organs of interest within the 
patient. Future work could include more detailed neutron measurements.
Also, studies could include comparisons with various rotational techniques such 
as RapidArc or protons. Work has been carried out by Sivabalasingham et 
al(Sivabalasingham S. 2010) comparing H2AX levels in patients with brain 
tumours receiving either RapidArc therapy or static field IMRT. There was a 
similar study design, but with weekly blood samples. There was a trend towards 
a smaller increase in H2AX levels with RapidArc compared to IMRT (0.165 
foci/cell compared to 0.358 foci/cell respectively, p=0.167). There did not 
appear to be cumulative damage, nor evidence of residual damage. 
Gerelchuluun et al(Gerelchuluun, Hong et al. 2011) has compared H2AX levels 
in human tumour cell lines receiving either 200MeV protons or 10MV photons. It 
was found that DSB induction was significantly higher for protons than X-rays, 
with average ratios of 1.28 and 1.59 at 30 min after irradiation, with the ONS76 
and M0LT4 cell lines respectively. However, the differences became 
insignificant at 6 hours.
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6.5 Conclusion
Gamma H2AX is potentially a promising biological dosimetry marker to add to 
physical parameters used to provide estimates of second cancer risk with IMRT. 
There is a trend towards failure to return to baseline levels at week 10 with 
15MV suggesting possible incomplete recovery. However, there was no 
significant difference in age-specific risk, and significantly fewer MUs were 
required compared to 6MV. This could be due to improved dose at depth with 
15MV, as well as possible limitations of the small study number and laboratory 
technique.
There is no definite evidence of increased DNA damage or increased estimated 
second cancer risk with any particular group, which could potentially be 
reassuring to support the continued use of IMRT treating larger volumes. 
Increased numbers are required to draw further conclusions.
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Chapter 7 Summary and conclusions
7.1 Summary of introduction and aims of the thesis
Ensuring accurate delivery is one of the key challenges in radiotherapy, and can 
be addressed by the use of IGRT. There are a number of geometric 
uncertainties associated with treating prostate cancers, particularly with prostate 
and node patients. This is because the prostate moves independently to pelvic 
bony anatomy due to variations in rectal and bladder filling, and this can occur 
during and between fractions (intrafraction and interfraction motion). This can 
potentially result in underdosing of the target or overdosing of the OARs. This is 
especially relevant for IMRT treatments due to higher conformity of dose 
distributions and sharp dose gradients.
Strategies for prostate IGRT include using intraprostatic fiducial markers which 
can act as a surrogate for prostate position and are visualised using kV or MV 
images, or alternatively CBCT for soft tissue or bony matching.
It has become increasing important to consider the risk of late second cancer, in 
particular, for patients receiving curative treatment and who may have a 
prognosis of decades.
IMRT can lead to increased radiation exposure compared to conventional 
techniques because it superimposes multiple intensity modulated radiation 
beams and requires a higher number of MUs. Other factors such as the volume 
of tissue irradiated (prostate only vs prostate and pelvic nodes), dose per 
fraction (standard 2Gy per fraction vs hypofractionation) and beam energy may 
also impact on the potential risk of second malignancy.
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Biological markers of DNA damage and physical out of field doses can be 
measured to estimate these risks. GammaH2AX is a biological marker that 
increases linearly with radiation dose and has been used to quantify DNA 
damage.
Chapter 1 provided a review of prostate IGRT methods, TCP and NTCP. 
Chapter 2 outlined the IGRT methods used in this study for patients receiving 
radiotherapy to prostate only and prostate and nodes. It also described the post 
treatment analysis of dose-volume data.
Chapter 3 evaluated the role of prostate IGRT on 20 patients who received 
prostate IG-IMRT with online kV 2D matching to fiducial markers, and its impact 
on constraints, TCP and NTCP.
Chapter 4 reported on a substudy of 10 patients receiving prostate IG-IMRT 
who had pre and postRT CBCT to assess the effects of intrafraction motion. 
Chapter 5 evaluated the role of prostate and nodes IG-IMRT on 8 patients with 
online CBCT 3D matching to bone, and its impact on constraints, TCP and 
NTCP, as well as the effect of different matching scenarios.
Chapter 6 assessed the biological and physical effects of 6MV and 15MV IMRT 
and its potential impact on late second cancer risk.
The overall aims of this thesis was to evaluate suitable markers for prostate 
IGRT, compare volumes throughout treatment, assess the impact of IG-IMRT 
on tissue constraints, TCP and NTCP and assess second cancer risk with 6MV 
and 15MV IMRT. The findings are summarised below.
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7.2 Summary of thesis findings by chapter
7,2.1 Image Guided Intensity Modulated Radiotherapy in patients 
receiving treatment to prostate only (Chapter 3)
In this study, the bladder and rectal volumes were overall smaller on mean 
CBCT compared to planning CT (40.6% and 6.7% respectively). This was 
followed by further reduction in bladder and rectal volumes on CBCT between 
first and final week (decrease by 15.8% and 14.3% respectively). In particular, 
the 10 patients with initial large rectal volume (>116.2cm^) had a significant 
decrease of 18.6% (p=0.006) in CBCT volume (94.6cm^).
There was a significantly lower prostate TCP calculated from CBCT in patients 
with a larger initial rectal volume.
For bladder and rectal DVHs, there were higher doses on CBCT and there were 
statistically significant differences between plans and CBCTs for V50 and V60 
bladder constraints, and between plans and CBCTs for all but one of the rectal 
constraints. The constraints were exceeded by the same few patients at each 
level, but the magnitude at which constraints were exceeded tended to be 
greater for the bladder.
There was no significant difference between prostate TCPs or bladder NTCPs 
on CT and CBCT. However, there were significantly higher rectal NTCPs 
calculated for CBCT compared to planning CT across all parameters.
The number of markers did not result in any significant differences in bladder or 
rectal constraints, nor on TCP or NTCPs on CBCT.
207
7.2.2 Effects of intrafraction changes on Image Guided Intensity 
Modulated Radiotherapy in patients receiving treatment to prostate 
only (Chapter 4)
The median time between pre and postRT CBCT was 12.7min (range 9.9- 
24.8min).
There was a statistically significant difference between preRT and postRT 
prostate and seminal vesicle TCPs (97.4 and 97.2% respectively) but this is 
likely to be clinically irrelevant.
The median intrafraction change in bladder volume on CBCT was an increase 
by 49.0cm^ (19%), and the median intrafraction rate of change in volume was 
3.9cm^/min.
As few as 74.2% of the bladder constraints were met on CBCT despite all 
constraints being achieved on plans. There was a significantly lower postRT 
bladder V50 and certain patients persistently failed to meet the desired 
constraints on CBCT.
The median intrafraction change in rectal volume was a decrease by 0.9cm^, 
and the median intrafraction rate of change in volume was -O.lcm^/min.
Between 41.9-71.0% of constraints were met on CBCT for rectal V30 and V40, 
though this increased to over 90% for V50 and above. There were significantly 
higher postRT rectal V30, V40, V50 and V60 compared to preRT parameters. 
There was no significant difference between bladder or rectal NTCPs on preRT 
and postRT CBCT.
7.2.3 Image Guided Intensity Modulated Radiotherapy in patients 
receiving treatment to prostate and nodes (Chapter 5)
The median CBCT bladder volume was 137 9cm^, which was 53.1% smaller
compared to planning CT. 50% (4/8) of the prostate and node patients had a
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median CBCT bladder volume <100cm^, whereas only 10% (2/20) of the 
prostate only patients had similarly small bladders. The median CBCT rectal 
volume was 62.4cm^, which was 7.3% larger compared to planning CT, the 
median CBCT bowel volume was 25.9% less than the planning CT volume. 
There was little difference between CBCT DVHs for prostate or pelvic nodes for 
the various matching scenarios.
The lowest OAR doses were on the plans, compared to all CBCT with various 
matching scenarios, but this was related to the plan calculation issue.
Although the bladder constraints were mostly fulfilled on the original plans, only 
about 50% of the online match CBCTs achieved the bladder constraints. Again, 
this appeared mainly due to certain patients having small CBCT bladder 
volumes. There was no significant difference between bladder doses for online 
CBCT bone match and the other matching scenarios.
There was lowest rectal dose on online CBCT bone match, then offline CBCT 
bone and offline kV markers, with highest dose for mean offline kV bone.
There was lowest bowel dose on offline kV markers and bone, with highest 
doses for online and offline CBCT bone match. There was lowest bowel dose 
on plan, followed by offline kV markers and bone, with highest doses for online 
and offline CBCT bone match.
Prostate TCP appeared to be higher for offline kV marker match (99.5%), with 
similar TCPs for the other matching scenarios (99.1%). In contrast, the nodal 
TCP was highest for online bone CBCT match. There was a significant 
difference between nodal TCP for online CBCT bone match and offline kV bone 
match (84.3% and 74.8% compared to 81.9% and 71.8% for clonal density of 
10®/cm^ and 10^/cm^ respectively).
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Bladder NTCPs tended to be lower with kV matching compared to CBCT 
matching. The rectal NTCPs tended to be higher with kV matching compared to 
CBCT matching. The highest NTCP was with offline kV bone match, followed by 
offline kV marker match, with both CBCT bone matching giving similar results. 
There were no significant differences on CBCT for bowel NTCP, though offline 
kV bone match had highest NTCP.
Overall, with CBCT matching, there tended to be a lower prostate TCP, higher 
nodal TCP, higher bladder NTCP, lower rectal NTCP and similar/equivocal 
bowel NTCP. Surprisingly, there was similar TCP/NTCP between kV bone and 
kV marker match.
7.2.4 Biophysical estimation of DNA damage and second cancer risk 
using gammaH2AX and TLDs in prostate cancer IMRT (Chapter 6)
The mean baseline level was 0.03 gammaH2AX foci/cell. There was a 
significant increase in gammaH2AX levels due to radiation in this study, with an 
approximately 2-3 fold increase from baseline levels in all cases and at all time 
points.
There was a trend towards failure to return to baseline levels at week 10 with 
15MV (p=0 110) suggesting possible incomplete recovery. However, there was 
no significant difference in age-specific risk, and significantly fewer MUs were 
required compared to 6MV.
There is no definite evidence of increased DNA damage or increased estimated 
second cancer risk with any particular group, which could potentially be 
reassuring to support the continued use of IMRT treating larger volumes.
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7.3 Final discussion and further developments
Since completion of the study, prostate IG-IMRT has become standard practice 
at SLCC. An online strategy is useful to overcome variation in bladder and 
rectal volume, as it appeared that variation in filling occurred despite a 
preparation protocol. This failure was also seen in published data(McNair, 
Wedlake et al. 2011). @
Further work would be required on matching and analysis of displacements for 
prostate and node patients, and modelling of various margins to determine the 
ideal matching target and margin as there is a lack of consensus in published 
data.
Further TCP and NTCP work could be carried out, for example, looking at 
alternative alpha/beta values, particularly for prostate because this has been 
quoted as between 1.12Gy to 8.3Gy(Bentzen and Ritter 2005). The Lyman- 
Kutcher-Burman (LKB) Model for NTCP calculations can be limited as a model 
because one of the parameters, n, which represents the magnitude of the 
volume effect, can have a large confidence interval when assessing 
rectum(Cheung, Tucker et al. 2004). Rectal dose-surface histograms (DSH) 
have been compared with dose-volume histograms to model late rectal toxicity. 
NTCP models based on DSHs were felt to be superior at predicting late 
toxicities compared to DVHs(Buettner, Gulliford et al. 2011), therefore this 
approach could be attempted in future.
Variations in shapes of contours can be assessed using the mean distance to 
conformity (MDC) which measures the average distance of all the points that 
deviate from the reference volume(Jena, Kirkby et al. 2010). As well as
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comparing interobserver variability as an educational tool, it could also be used 
to compare CBCTs throughout treatment.
Another limitation of the study was that there were patients in both IGRT and 
biological studies. It was not possible to restrict to one study due to insufficient 
throughput to allow adequate recruitment. Some patients may have received 
extra CBCT, and although the radiation dose is small, this may have diluted any 
effects due to varying energy.
There were multiple pairwise comparisons between groups in an attempt to 
detect differences. This increased the likelihood of a significant result being due 
to chance, in future, a Bonferroni correction could be used. The significance 
level is divided by the number of comparisons being made to generate a 
modified significance level which may reduce the likelihood of false positive 
results (type 1 error).
There were only small numbers of participants but this work could be expanded 
in future. Topics could include more detailed assessment of correlation between 
the following variables: acute and late toxicity, bladder and rectal volumes and 
cross sectional area, weight and BMI, TCP and .NTCP, PSA There could be 
increased CBCT planning, for example, adaptive treatment if patients were felt 
to be ‘at risk’ of undercoverage of PTV or overdosage of OAR(Xia, Qi et al. 
2010; Hatton, Greer et al. 2011) and there could also be modelling of alternative 
imaging protocols based on magnitude of initial displacements or bladder/rectal 
filling.
Regarding biological measurement, DNA damage could also be evaluated in
newer radiotherapy techniques such as rotational therapy or stereotactic
radiotherapy as well as assessing alternative fractionation schedules. Also, an
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automated method of counting biomarker of DNA damage could be explored in 
future.
7.4 Concluding remarks
The first part of this thesis concluded that prostate IG-IMRT with daily online kV 
matching to fiducial markers, and prostate and nodes IG-IMRT with daily online 
CBCT bone matching are both feasible. The second part concludes that there is 
no definite evidence of increased DNA damage or increased estimated second 
cancer risk with higher photon energies or larger treatment volume which could 
potentially be reassuring to support the continued use of IMRT for treatment of 
pelvic nodes.
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B IOCHEMICAL CONTROL IMPTOVBS OVERALL SURVIVAL. FOR  
INTERMEDIATE AND H IG H RISK PROSTATE CANCER PATIENTS 
W HO  HAVE AN ESTIMATED 10-YR SURVIVAL OF >« 50%
M. ÜU*. T. Picktes’ . M JoPres", M Ktiaira’ , W, Kwan', J. Monis'
* B.C. Ca ncer  Agencv • V ancouver Ce n tr e . Vancouver. BC. Canada 
® S j/ on  F ra s e r  U n ivers ity . Bumaiy. Canada 
® BC CANCER ActNCv - F ra s e r  V a lley  C e n tr e , Surrey, Canada
Purpose: To dendly patlen: groups, using estimated 10-yr survival (eCSlOy) 
and NCCN Risk Groups, who would have improvcmert in overtfl survival 
(OS) when prostale cancer Is biochemically conlroied.
Materials 1060 prostate career palients wJh >=4yr fotow up (rreiiBiT. 
l25mo; range: 51 176 iro} were included. Median age was 7 lyr (renge: 
46-86) and dsirlbuLons ol ww, mte'mcdiate and high nsk groups are 17%, 
38% and 46% respediv^y. 42% had hormonal Iherapy and aH had exter­
nal beam tfeafneni (medan dose: 66Gy; range: 50 72Gy). Cha'Iscr Inoex 
ot comorbidity (CCI) was obtained lor each pabert using their past metlical 
history and eC^iOy was calculated using age anc CCI (Hutchinson et al). 
Païehts are s;i>cSvided into 6 groups acooic&ng to I ne NCCN risk categories 
and eOSi Oy ol >= 50% and < 50%. OS was compared between aatie'ts w th 
and wHhout biochenvcal controiied dseaserbNED) in each grcif) Mult varl- 
atcana ysis was pertormed for OS.
Results: For higlt risk disease and eOSlOy pi <50%: the 10-yr OS was 
63% vs 65% tor patients with and wknout oNED respectvely {p»ns) While 
for eOSlOy of >=50%; She 10-yr OS was 86% %  vs 62%  ip= 0.002). For 
intermediate rîsk disease and eOSlOy <50%; the 10-yr OS was 69% vs 73% 
for paiienB w4tn and without bNED laspoctivoly (p=ns) While for eOSlOy of 
>»50%: the 10-yr OS was 95% %  vs 80% tp* 0  033) For tow risk osoaso 
and eCSiOy of <60%; the 10-yr OS was 79% vs 69% tot padenis with and 
wrJioui tiNED respectively. Whde toi eOSlOy of >=50% the i0-y? OS was 
86% v5 95%; p»n* tor the 2  abow  Risk factors alteclng OS aie. eOS" Oy ip= 
0 0034), bNEO (p = 00 2 l) enO risk groups ^>=0-0023).
Conclusions: For toteiiredlale risk arid Ngh risk, disease, ihe'e is surviva' 
advantage in bNED patients or y  when Ifieir cOS lOy is >= 50%, btA not when 
eOSlOy < 50%. Fdr low fiskcSsease. bhCD has no kTipaci on o w a *  survival, 
whether eOSlOy Is < or >= 50%.Retomnce:Hutchinson TA et e t Preoctma 
survival in adtdts with end-stagc renal disease: An age equivaerce inrtox. 
Arm Intern Med. 1962
1172 poster
in 3 palients and 5-10% in 1 patient. Fdr the remaining çratienl. ine tieaimertt- 
averaged R D 100% tVdturreTA; was 5.1%.
CBCT EVALUATION O F INTRAFRACTiON CHANGES IN RECTAL 
AND BLADDER VOLUME IN PROSTATE CANCER PATIENTS 
RECEIVING  IG IMRT
O  Chan*. E Adams', C Clark'*. K. Freeman', M D a t t» '. C- Jamieson'. 
M Hussein'*, T. Jordan", J. Mcney-Kyre’ , S. KnWtsar . R. Lafog*, S. 
Langley'', A. Nisrtjet*’ , M. T Guerreo Urba.ho'
' ROYA:. SJRPEY COUNTY H09P TAL. RadiofTeiBpy. GuidlO'd, United 
Kingdom
*  Royal Su r r s y  Co u n ty  Ho spital , Physics, Gu Idtord Uniied Kingdom
*  Royal S upb îv  Co u n ty  Ho spital , Uiotogy, Gu3dford United Kingdom
Purpose To evaluate the degree of tntra fraction changes In rectal and blad­
der vo'-mes during prostate Image Glided totensiiy Modulated Rediotneraf^ 
(IG-IMRT} using Cone Beam Confuted Tomography (CBCT) and its impact 
on actual dose received.
Materials: Nine patents with prcstale career treated widt IG tMRT With daily 
online matching to flducW markers on kV imaging were evaluated. Weekly 
pairs of CBGTs were otrtairted alter inftat patient sol up and immeckatety ai 
ter RT delivery and each im e  record^ ffladde- end rectum were outlined 
by a smgle observer on the 45 pairs ol CBCTs obtained and volumes cat- 
culatod. Pre-t eatment CBCTs were sh. tted to the online rratohed position 
and the plan was recalculated. Dose votome histograms fOVHs) were com­
pared to toose of the original iieatmenl plan on 29 C 8 C t pairs where plan 
recalculation was leaslbts.
Results: InirafracSon changes in bladder and rectum volumes are depicted 
in Table i . Across me patient population, median (range) rate oi toliafract on 
liftng for bladder volumes on week 1 was 5.Ccm",miin (t .6 - 10,6), on week 
4 was 35cm*/rnin (0 1 - 6,1) arrf on wcok 7 was 4.1cm^'min (2.1 ■ 7.5). For 
rectal volumes, tne media,*i j 'a T ^ )  intratractfon variaton on week 1 was - 
2.4cm" (-5.1 - 722 ). on week 4  was -0.7cm" {-i8 .2  - 6.1) and on week 7 
was 4.7cm" (-3.5 - 6.6). All dose conskaaiis for b adder and rectum were 
luifoled on the or ignal plans. Wtien pl»is were recalculated on CBCT, 68.5%  
and 69.4% of ail btedder and rectal constraints were mot across the paSent 
popuiatiOiT. In 6'29 troatrreni CBCT pa ts one or more badder conslte nts 
were exceeded This was exceected by 0  5% in 1 case, 5-iOA'» in 3  cases 
ana >10% ri 2 cases. Fur each patient, the average DVH ol ail the CBCTs 
was obla ned and the conslrairi exceeded on <y»y one ocstsion (Referees  
Dose - RD 68% by 103% ) In 17-29 treatment C8CT pairs cne or more 
rectal constraints were exceeded. This was exceeded by 0-5% to 11 cases, 
S-10% in4 cases end >10% m 2  cases. Theccnsiramts vrere exceeded on 5 
occasions on the averse  DVH. RD 41 -68% was exceeded l)y less than 5%
T##-# <*NWvf*e w
i
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Conclue Ion* Large inter and inlra-lract on changes In oiadder and rectal vol­
umes were (toserved to ai i patents despite otadder ftlli ng and recta errotying 
guidelines. Even widi onkne matching to the prostate, intor-f,-action va'iaJiors 
to volume had an *no»si cn the rectal dasa-volurre constratots in over SOT'i ol 
recta CBCT pairs, A reducton to margins and a d ^  ve radiotherapy [ART; 
may reduce thss impact.
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CHANG ING  PATTERNS O F PRACTICE FOR PROSTATE CANCER IN 
ITALY A SURVEY BY THE PROSTATE CANCER STUDY GRO UP O F  
THE ITALIAN RADIATION O NCOLOGY SOCIETY (A IRO)
S. ktegrini' .  L  Pegurri'*. G, Gitelti®. F. Munoz". R Paraia", R, BeliavUa*'.
A. Bonetla", M. Kremgli'', £ Cagna'®, F, Burkheila’ *, S Borghesi'", M. 
Srgnor"*. A DiMarco P, Berm ni'-. L, Llvl"'
* Bresc  A U n iv e r s ity , Radatioh Oncology. Bresca, Italy
" Specali CiViLi 0! B rescia. Radiat on Orcolcgy. Brescia, Italy 
" IVNEA HOSPITAL. Raciatkm Oncology, tvrea, Italy
* OSREOALE Mo-INcTTE U n ivers itv  OF TURIN, Radialfor Oncology, 
To-ino. Italy
^ A S O . O po ine  M a uriZ'ano  d i Torino  e IRCC di C an diOlO. Radatfon 
Oncology, Italy
® O spedalE Santa M ari*  della NliSERiconoiA. Radiation Oncology, 
Perugia, Italy
'  U n ive r s ity  of  P er jo ia , Perugia, Italy
*  IS t i t j t i  O sritaliepi Cr em o n a , Radiatior: Oncology, Brescia, Italy
** PiEwONTE O rie n ta le  U n ivers ity , Hadiaiton Oncology. Novara, haiy 
Cowo H o s p it a l , Radiabo-t Oncolo^. Como, Italy 
PoiiCLiNKto S. Of,SO;.* Malpighi, Academic RadW on Oncology 
Cteparlment, Bologna, Italy
’ '•* A r e zzo  Ho spital, Radiat on Oncology. Arezzo, Italy
"* AZiENoa O s p Univ . S.M. MiSERicOP.Oi* UDINE. Department of
Radiation Oncology Lidme, Italy
*" M.antua hOPsiTAi. Hadialioo Oncotcgy. Mantua, Italy
PoLicuNiCQ CM HAooena , Ceoarimeni of Racial on Orcciogy. Mocena, 
Italy
'*  UNIVERSITY OF FLORENCE. RacNotion OncQtogy. Arenzo. Italy
Purpose This rétrospective study describes the Patte-ne cl Practices for 
prostate cancer and the resuhs obta ned to 14 liaRan Radiation Oncology 
Centers 1999 through 2003. in comparison with a previous survey covering 
tne perioC 1980-1996 (and m particular wkn the data avaiaxe for the 1005 
pts accrued du-mg the period 1995 1998) (1)
I4aterisla Clincal and tho-aoeutc teatures of 2923 patients (pis) accrued 
1999 20C3 were analyzed Cause specilio (CS) and overai surviva) (OS) tig-
Chan O, Adams E, Clark C, Dabbs M, Jamieson C, Hussein M, Laing R, 
Langley S, Nisbet A, Guerrero-Urbano T. (2010)
Impact of intrafraction motion on tumour control probability and bladder and 
rectal normal tissue complication probablility values in patients receiving image- 
guided intensity modulated radiotherapy (IG-IMRT) for prostate cancer.
Int J Radiat Oncol Biol Phys 78(3) Supplement 8363-364. 
Purpose/Objective(s):
To evaluate the impact on TCP and rectal NTCP of intrafraction motion during 
prostate Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) using 
Cone Beam Computed Tomography (CBCT).
Materials/Methods:
Nine patients treated with IG-IMRT with daily online matching to fiducial 
markers on kV imaging were evaluated. CBCTs were scheduled after initial 
patient set up and immediately after RT delivery on a weekly basis. Prostate 
and seminal vesicles (SV), bladder and rectum were outlined by a single 
observer on the 30 CBCT pairs obtained and volumes calculated. Pre-treatment 
CBCTs were shifted to the online matched/treatment delivered position. Plan 
recalculation was feasible on 29 CBCT pairs and dose volume histograms were 
obtained. All plans were calculated for a dose of 74Gy in 37 fractions. A 
radiobiological software package, Bibsuite, was used to estimate TCP and 
rectal NTCP with the following parameters:
Prostate tumour: clonogen density = 107/cm3,; a/(3= 1.5Gy.
Rectal grade>2 RTOG: n = 0.08, m = 0.14, TD50 = 78Gy, a/(3= 3Gy.
Rectal G>2 CTCAE v3.0: n = 0.08, m = 0.108, TD50 = 78.4Gy, 0/(3= 3Gy.
228
Combined G>2 rectal toxicity from meta-analysis of 4 papers examining G>2 
RTOG, CTCAE v3.0, bleeding and modified scale: n = 0.09, m = 0.13, TD50 = 
76.9Gy, 0/(3= 3Gy.
Median (range) values are reported.
Results:
Across the patient population, median (range) volume on planning CT for 
prostate and SV was 60.4cm^ (38.5-94.7), 303.3cm^ (203.8-524.9) for bladder 
and 80.8cm^ (68.6-125.0) for rectum. Median time between pre and post IG- 
IMRT CBCT was 12.7 mins (9.9-24.8). Median intrafraction change in volume 
and rate of change were, respectively, 51.3cm^ (6.4-134.5) and 4.2cm^/min 
(0.5-13.6) for bladder and 4.2cm^ (-35.2-40.2) and 0.3cm3/min (-2.2-3.4) for 
rectum. Median intrafraction change in prostate volume was -0.7cm^ (-6.3-3.4) 
and -2.3cm^ (-8.8-4.4) for prostate and SV. Median TCP on planned volumes 
was 98.5% (97.5-99.3%). Pre and post IG-IMRT median TCPs were 98.9% 
(98.0-99.4) and 98.9% (95.6-99.5) respectively. For RTOG ^2 late rectal 
toxicity, predicted NTCP on planned volumes was 2.9% (0-4.0), with pre and 
post IG-IMRT NTCPs being 2.9% (0.5-14.3) and 3.2% (0.6-17.4) respectively. 
CTCAEv3.0 >2 rectal predicted NTCP was 0.6% (0-1.0), with pre and post 
values being 0.7% (0-7.7) and 0.8% (0-10.4) respectively. Finally, for combined 
G>2 rectal toxicity, predicted NTCP on planned volumes was 1.9% (0-2.9), with 
pre and post IG-IMRT NTCPs being 2.0% (0.3-12.7) and 2.2% (0.3-16.0) 
respectively.
Conclusions:
With an online matching protocol to prostate fiducial markers, the impact of
intrafraction motion on TCP and late rectal toxicity NTCP values appears small.
229
Although a trend towards higher late rectal NTCP is observed, this is unlikely to 
have a significant clinical impact.
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(actors of 6 MV small fields i)  Beam profiles of cobalt 60 narrow fields and IK) 6 
MV intensSy modulated ratfioiherapy (IMRT) segments.Tt» two-dimensional 
RF of a PTW 300131C was obtained ty MC simulation of ttie absortDed dose 
to cavity air when Die 1C was scanned by a 0.6 x 0.6 mm* cross section par­
allel pendl beam. In tfiese simulations the 1C laid horizontally in a water tank 
at 1 cm depth. Two pendl Iteam spectra ware considered i) A monoenergetic 
1 ss MeV beam and ii) that obtained for a 0.5 x 0.5 cm' field delivered by a 6 
MV Siemens PRIMUS.FIuence cfistributions tor small fields ranging between 
0.5 X 0.5 and 10 X 10 cm* and deihrered by a 6 MV Siemens PRIMUS were 
obtained by MC smulation.Fluenoe distributions tor 1.4 x 1.4 and 3 x 3  cm* 
fields and delivered ty  a MLC-equipped AECL Theratron Cobalt 60 imitwere 
determined by diode measurements.Ruence distritxrtions lor 6 MV IMRTcün- 
ictd segments were obtained tiy radiochromtc film dosimetry measurements 
and Treatment Planning System (TPS) calculations. For each of tho cases 
studied, ttie results of the 1C direct measurement were compared with ttie 
correspondtog obtained ty  the OS method.
Results; For aB Of ttie cases studied, the agreement befiveen ttie 1C dsect 
measurement arto the 10 caCuiated response was excellent Ttie relative 
deviation between both responses was below 0.8% in the cases of e MV 
small field output (ardors (as it can be seen in figure 1) and crAalt 60 narrow 
beam profiles. In the case of IMRT segments ttie relative deviation was below 
1%.
!
I
M b f» m m* M t
Figure 1. Comparison between (greet measurement (full squares) and calcu­
lated response of output laraors (void s()uares) lor a PTW 30013 tC. 
Conchjsions: This method could be implemented m TPS in order to perform 
anexperimental IMRT treatment verificaion with in-phantom ioniz^on cham­
ber measurements. The miss-response of the 1C (toe to ttie non-referenoe 
contfitions could tie corrected by this method rather than employing MC de­
rived oonection factors. Ttiis method can be considered as an alternative to 
the plan class associated correction factors proposed in Alfonso et al Med 
Phys 35 (11) 2008 as part of an IAEA work group on non-standard field 
dosimotry.
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CHARACTERIZATION OF THE TEMPERATURE. POLARIZATION. 
AND ION RECOMBINATION FOR THE MICROLION LIQUID IONIZA­
TION CHAMBER
A. Gutierrez*. S. Stathakis*, N. Papanikotaou'^
’ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER/CaNCER T h ERAPY AND
R esea r c h  C en te r . Department of Radiation Oncokw. San Antonio. USA 
® C a n c e r  T h er a py , San Antonia TX. USA
Purpose: To stue  ^the temperature, polarization and general recombinatton 
effects ol ttie PTW miaoLlon ionization chamber.
Materials; Measurements were perfomned on a Clinac 2300C 80MLC linear 
aooelerator. The MP30CS water phantom (PTW. Hicksville. NY) which mte 
pates the detector posSioning TRUFIX was used during all measurements. 
The temperature dependence of the ionization chamber was done by vary- 
tog the water temperature in two degree steps from the reference of 29S°K 
down to 286°K and up to 3 0 f  K. Five conseciklve measurements with a 6MV 
photon beam and two different polarizing voltages (400V and 800V) were ac­
quired at each temperature increment. The polarization effect was performed 
ty irradiating the microUon with a 9 MeV electron beam as a function of 
depth and tor two dSferent polarization voltages (400(80(W). The general re­
combination effect was done tor pulse and continuous beam. In the first case, 
the pulse repetition frequency (PRF) of the linear accelerator was set at 30 
pulsesfsec for an 18MV beam and 50 pulses/Sec for a 6MV beam and a pulse 
length of 3.7 us m both cases. Tfvee different doses per pulse were used in 
each case. For the 6 MV beam, the thiee doses per pulse were; 0.023. 
0.0175 and 0.012 cGy/tmn. while tor the IB MV beam the doses per pulse 
were 0.046. .035 and .023 c%/min. Ftve consecuthe measurements were
acquired varying the polarization voltage from 400V to 800V in 50V steps. An 
lr-192 source was used during the continuous beam experiment. The source 
had a dose rate of 5.98 cGy/min at 10 cm with a varying pofarizaticn voltage 
ranging from 400 to 800 V in 50 V steps.
Results; The rmcroUon chamber demonstrreed a linear relationship (slope = 
0.2%/°K) as a function of temperature for both tfie 400 and soov polareation 
voltages. The polarization effect study showed a polarization < i.o% for both 
polarization voltages with a stem effect of 3% tor the 400V and .8% for the 
800V. In the general, recombination effect demonsfiated a linear relationship 
at polarization voltages higher than 600 V and a dropping curve with voltages 
lower than 600 V in both delivered modes; pulse arid continuous beam.
Conclusions The ihicroLkin ionizafion (diamber demonstrated a linear de­
pendence with increase temperature which is consistent with the theoretical 
model based on the Onsager theory. The polarization effect study showed 
percem differences of less than i.D% in txith polarization voltages and the 
general recontotntkion effect showed sitrelar response to previously putilished 
data on the isooctane liquid used in differeni geometries.
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BIOPHYSICAL ESTIMATION OF DNA DAMAGE AND SECOND 
CANCER RISK USING GAMMA H2AX AND TLDS IN PROSTATE 
CANCER IMRT
O. Chan' .  M. Hussein*, M. Worku", R. Latog', T. dordan*. H. Pandha*, R. 
Morgan*, S. Short", A. Nisbet*, T. Guerrero Uitano'
* St  Lu k e 's Ca n c er  C e n tr e , IToyal S u r r ey  C o u n ty  Ho spita l . 
Guildford. United Krngttom
*  T h e  Royal S u rrey  Co u n t y  H ospital NHS Fo undation  T r u s t , 
Department of Medical Pfysics. Guildford. United Kingdom
" UCL Ca n c er  In s t it u t e .  London, United Ktegdom
*  Un iv e r s it y  o f  S u r r e y . Ftos%raduate Medical School, Guildford. United 
Kingdom
Purpose; IMFTT is reported to be associated with a higfier risk of second 
cancer compared to conformai FIT. ft can potentiagy double the risir due to 
the increased volume of normal tissue receiving low doses and increased 
scatter radiation and le a k ^  from longer beam on times.This risk is poten- 
tiaiv higher n  patieras treated with Ngher ener^ beams, generally used to 
treat deep seated tumours.Phosphorylated H2AX (gamma H2AX) is an early 
cellular response to DNA dpubile strand break formation and can b» used to 
quantify radiation induced DNA damage.lt ooukt potentially be used as a sur­
rogate marker for second mat'iyiarKy as some stucfies have suMested friat 
levels increase (nearly with radiation dose.The aim is to evaluate DNA dam­
age and dosimetric parameters with changes in beam energy and treated 
volume.
Materials 20 patients with prostate cancer were treated with IMF(T, with 
5 patiente per groi^: Prostate (74Gy '37F-6MV, 57-60Qy/i 9-20F-6MV. 57- 
6i>Gyrt9-20F-i5MV). Prostate and nodes (74<^,'37F-6MV).Pre- and 30 min­
utes post-irradiation venous samples were taken to assess DNA damage at 
planning CT, F i, F2. midway and end of RT. plus at week lO.ClWcal IMRT 
plans were deliwred to a phantom conttening tiiermoluminescent dosime- 
ters.Organ e<|uivalent (toses and effective dose were calculated using bssue 
weighting factors from international Commission cxi (Radiological (Yotection 
i03.Tfie effective dose was used to estimate the theoretical age-corrected 
lifetime risk of second cancer.
Results; At least 3(X) cells were counted from each of (tie 169 sam- 
ples.Actoss as patients, ttie mean baseline gamma H2AX level was 0.033 
(SD^.012) and recovery at 10 weeks was obaerved. with mean 0.037
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(SD=0.014). p=0.50S. V/hen analysed tor each group, there was a trend to­
wards incomplète recovety in the 15MV group (p=0.li3).Comparlsons wore 
made between the standard 74Gy prostate only group and the 3 other groups 
for mean difference tietween post- and pre-irradiation levels. There was no 
signllicant difference tretweon the groups at æy time point There m ^  be 
a trend towards mcreased difference at the end of RT in prost^ and nodes 
compared to74Gy prostate only (0.048 compared to 0.032. p= 0.153).Similar 
compwison was made for effective dose and it was found to be signifi­
cantly higher for prostate and nodes (p:^0.04l) and slightly lower for 15MV 
(p=0.07i). However, this tSd not translate to a difference in age-corrected 
risk.
Table showing number of gamma H2AX foci/cell a t 
baseline, week 10 and difference between post- and 
pre-irradiation for 5 time points (CT, F I, F2, midway, 
end). Effective Dose and Age Corrected Lifetime Risk 
for each group.
Prostate
Prostate
and
nodes
74Gy 57-$OGs ' 57-COG; 
«MV CMV I5MV
74Gs
6MV
Baseline gamma 
H2AX level (foci/ 
cell), mean. 527
0.035 a030 I 0.026 0.040 
fit» / ûfil?
Week. 10 gamma 
H2AX level (focil 
cell), mean. 527
0.030 0.033 0.038 0.048
aot^  aot?
CT 0.027 0.046 . 0.031 0.077
am  a m  am  aata
post- and 
pre
irradiation
gamma
H2AX
level
(focMcell). 
mean, S tf
FI 0.034 0.047 0.040 0.032
aaaa aais aoM a m
F2 0,040 0.027 0,034 0,023
aa»» aata aa/^  aasa
fVHd 0031 0.028 0.042 0.043
aasa aa^ aau aax>
End 0.032 0.033 0.038 0.048
AfW aaia a m  aar?
Effective 
Dose(Sv). mean. 
527
2.430 2373 1.458 3.850
tasa uaa a m  a m
Afo-coneoted
lifetime risk (X). 
mean. 55£7
1.634 1 ^  I.OK 3 J«
tjoa a m  a m  tssa
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DEVELOPMENT OF AN A-SI EPID BASED SYSTEM FOR «MACHINE. 
IMRT AND VMAT QUALITY ASSURANCE
L. A. Vazquez-Quino* , X  Chen’, M. Fitzpatrick’ . C. Shi’ , P. Mavroidis*, H. 
Alkhatib", D. MihaiDdis*, N. Papanikolaou’
’ CTRC @ UT HSC AT Sa n  A n to n io . San Antoniq USA
*  KAROLINSKA iNSTrrUTET AND STOCKHOLM UNtVERSITY, StOCkhOlm, 
Sweden
® So u t h  Ca r o lin a  O n c o l o g y  A s s o c ., Columbia. USA
*  C h a r le s to n  R adsation T her a p y  Co n s . Charleston. USA
Purpose: The mcreasing prevalence of amorphous-sSicon (a-Si) electronic 
portal knagng devices (EPID) for in-line verification Imaging, has led to 
heightened interest in applying EPID based dosimetry to machine and pa­
tient quality assurance (QA). As such, EPID dosimetry offers the potential to 
riH a useful role when verifying intensity modulated radiotherapy (IMRT) and 
volumetric arc therapy (Vk(AT) troatroerS plans. The purpose of the present 
study is to validate die development of æ  in-house software using an EPID 
measured team duenoe for IMFTT and VMAT QA.
Materials: EPID images are acquired by direct^ irradiating an aSlOOO EPiD 
in the following two acquiâtion confiions: 1) Using an integrated image ac­
quisition mode, for a 6 MV beam. 600 MUTnin dose rate with an IMRT plan 
and; 2) Using a continuous image acx i^sitton mode, for a 6 MV beam. 600 
MU/fnin dose rate with a VMAT plan, signal intensity of the EPID images ate 
corwerted to a planar dose map using a calibrated linear signal to-dose rela- 
tionshp. Using an m house QA software system we analyze the EPID4>ased 
fluence images. Fdr routine machine QA. recommendations by TG-40 and 
TG-4S AAPM reports are implemented to evaluate beam flatnessr'symmetry. 
perform dynamic MLC validation and perform a Wiston-Lutz isocenfer test 
For IMFTT and VMAT QA. the fluence maps are reconstructed from the EPID- 
measured fluence and serve as input to tfie treatment plan ^stem. The treat­
ment planning system is then used for dose calculation and trial comparison 
between the measurement and tfie plan.
Results; EPID-measured machine OA restdts are comparaibie to film mea­
surements for the Winston-Lutz isooenter tesL beam flatness and symme­
try along widi checks of dynamic MLC treatmeM profiles. Figure 1 shows 
the comparison of the cafoulated cfose using EPID-measured fluence to the 
framed dose lor IMRT and VMAT. Tfie EF1D based IMFTT and VMAT QA 
method was atiie to verify tfie treatment plan and demonstrates a good plan- 
versus-QA comparson with a gamma analysis (3% maxmium dose. 3 mm 
distance to agreement) resulting in over eg % of pointe wih a gamma <i as 
shown in figure 1. Ffoint dose between EPID and Ion chamber measurements 
for IMFTT plans were on average witfiin 2% for 20 plans <Â different treatment 
sites.
Conclusions; Gamma HaAX is potential^ a promising biofogical dosimetry 
marker to add to physical piarameters used to provide estimates of second 
cancer risk with IMRT There is a trend towards mcomplele recovety at week 10 with 1SMV. but with possibly Inver effective dose .This could be due to 
impvoved dose at depth with 15MV. as well as pcssfoie Ifoiïations of tfie small 
study number. I^ ra to ry  techruque and pfiantcm measure me nts.lncreased 
numbers are required to draw further txmdusfons.
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